A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
Phase: PHASE2
Conditions: Hepatitis C Virus Infection
Sponsor: Gilead Sciences

Study Title: 
Sponsor: 
IND No.: 
EudraCT Number: 
Indication: 
Protocol ID: 
Gilead Sciences 
Medical Monitor and 
Study Director: 
Protocol Version/Date: 
(rJ GILEAU 
CLINICAL STUDY PROTOCOL 
A Phase 2, Open-Label, Multicenter, Multi-coh01i Study to 
Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed 
Dose Combination+/- Ribavirin in Adolescents and Children with 
Chronic HCV-Infection 
Gilead Sciences, Inc. 
333 Lakeside Drive 
Foster City, CA 94404, USA 
115268 
2014-003578-17 
Hepatitis C Vims Infection 
GS-US-337-1116 
Name: 
Benedetta Massetto, MD 
rpo 
rpo 
I"'U 
Telephone: 
Fax: 
E-mail: 
Original: 
10 July 2014 
Amendment 1.0: 08 October 2014 
Amendment 2.0: 08 December 2014 
Amendment 2.1: 09 Janmuy 2015 (United Kingdom Only) 
Amendment 2.2: 01 April 2015 (United Kingdom Only) 
Amendment 3.0: 28 May 2015 
Amendment 4.0: 15 March 2016 
Amendment 5.0: 04 November 2016 
Amendment 6.0: 08 Jlme 2017 
CONFIDENTIALITY STATEMENT 
The inf01mation contained in this document, pmiicularly unpublished data, is the prope1iy or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by you, your staff, and an applicable Institutional 
Review Bom·d or Independent Ethics Committee. The infonnation is only to be used by you in 
connection with authorized clinical studies of the investigational dmg described in the protocol. 
You will not disclose any of the infonnation to others without written authorization from 
Gilead Sciences, Inc., except to the extent necessa1y to obtain infonned consent from those 
persons to whom the dmg may be administered. 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 2
08 June 2017
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................................................2
LIST OF IN-TEXT TABLES........................................................................................................................................5
LIST OF IN-TEXT FIGURES ......................................................................................................................................5
PROTOCOL SYNOPSIS ..............................................................................................................................................6
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS....................................................................19
1.
INTRODUCTION ..............................................................................................................................................22
1.1.
Background ............................................................................................................................................22
1.2.
Ledipasvir/Sofosbuvir Fixed-Dose Combination...................................................................................23
1.2.1.
Summary of Additional Clinical Experience with Ledipasvir/Sofosbuvir 
Fixed-Dose Combination .....................................................................................................23
1.3.
Ribavirin (RBV).....................................................................................................................................30
1.4.
Rationale for the Current Study .............................................................................................................30
1.5.
Rationale for Dose Selection of LDV/SOF FDC ...................................................................................31
1.6.
Overall Risk/Benefit Assessment...........................................................................................................34
2.
OBJECTIVES.....................................................................................................................................................35
3.
STUDY DESIGN................................................................................................................................................36
3.1.
Treatment Plan and Regimen .................................................................................................................36
3.1.1.
PK Lead-in Phase.................................................................................................................36
3.1.2.
Treatment Phase ...................................................................................................................37
3.2.
Visit Schedule ........................................................................................................................................39
3.2.1.
PK Lead-in ...........................................................................................................................39
3.2.2.
Treatment Phase ...................................................................................................................40
3.3.
Virologic Response-Based Stopping Criteria.........................................................................................40
3.4.
Treatment Discontinuations Criteria ......................................................................................................41
3.5.
Discontinuations.....................................................................................................................................41
3.6.
Optional Intensive Pharmacokinetics Substudy.....................................................................................41
3.7.
Pharmacogenomics Substudy.................................................................................................................41
3.8.
Long-Term Follow-Up...........................................................................................................................42
3.9.
Breakthrough Futility Assessment .........................................................................................................42
3.10.
Reconsent...............................................................................................................................................42
4.
SUBJECT POPULATION..................................................................................................................................43
4.1.
Number of Subjects and Subject Selection ............................................................................................43
4.2.
Inclusion Criteria....................................................................................................................................43
4.3.
Exclusion Criteria...................................................................................................................................44
5.
INVESTIGATIONAL MEDICINAL PRODUCTS ...........................................................................................46
5.1.
Randomization and Blinding..................................................................................................................46
5.2.
Ledipasvir/Sofosbuvir Fixed-Dose Combination...................................................................................46
5.2.1.
Description and Handling.....................................................................................................46
5.2.2.
Storage and Handling...........................................................................................................48
5.2.3.
Dosage and Administration of LDV/SOF FDC ...................................................................48
5.3.
Ribavirin (GT-3 Subjects Only).............................................................................................................49
5.3.1.
Description and Handling of RBV .......................................................................................49
5.3.2.
Dosage and Administration of RBV (GT-3 Subjects Only).................................................50
5.4.
Co-administration of LDV/SOF FDC and RBV (GT-3 Subjects Only).................................................50
5.5.
Study Drug Compliance.........................................................................................................................51

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 3
08 June 2017
5.6.
Prior and Concomitant Medications.......................................................................................................51
6.
STUDY PROCEDURES ....................................................................................................................................53
6.1.
Subject Enrollment.................................................................................................................................53
6.2.
Screening Assessments ..........................................................................................................................53
6.2.1.
Screening Visit (Day –28 to Day 0) .....................................................................................53
6.3.
PK Lead-in: Treatment Assessments .....................................................................................................55
6.3.1.
Day 1 ....................................................................................................................................55
6.3.2.
Day 3 ....................................................................................................................................56
6.3.3.
Day 10 – Intensive PK..........................................................................................................56
6.4.
Treatment Phase: Treatment Assessments .............................................................................................58
6.4.1.
Day 1 ....................................................................................................................................58
6.4.2.
Weeks 1 and 2 (± 3 days) .....................................................................................................60
6.4.3.
Weeks 4 and 8 (± 3 days) .....................................................................................................60
6.4.4.
Week 12 (± 3 days) - Subjects on 12 Week Treatment Regimen Only................................61
6.4.5.
Week 12 (± 3 days) - Subjects on 24 Week Treatment Regimen Only................................62
6.4.6.
Week 16 and 20 (± 3 days) – Subjects on 24 Week Treatment Regimen 
Only......................................................................................................................................63
6.4.7.
Week 24 (± 3 days) – Subjects on 24 Week Treatment Regimen Only ...............................63
6.4.8.
Optional Intensive Pharmacokinetics (PK) Substudy...........................................................64
6.4.9.
Unscheduled Visit/Early Termination Visit .........................................................................66
6.5.
Post-Treatment Assessments..................................................................................................................67
6.5.1.
4-Week Post-Treatment Visit (± 5 days)..............................................................................67
6.5.2.
12-Week Post-Treatment Visit (± 5 days)............................................................................68
6.5.3.
24-Week Post-Treatment Visit (± 5 days)............................................................................69
6.6.
Procedures and Specifications................................................................................................................69
6.6.1.
Clinical Laboratory Analytes ...............................................................................................69
6.6.2.
Medical History....................................................................................................................70
6.6.3.
Complete Physical Examination...........................................................................................70
6.6.4.
Tanner Pubertal Stage Assessment.......................................................................................70
6.6.5.
Height & Weight Measurement............................................................................................71
6.6.6.
Bone Age Assessment..........................................................................................................71
6.6.7.
Acceptability Assessment.....................................................................................................71
6.6.8.
Vital Signs............................................................................................................................71
6.6.9.
Estimated Glomerular Filtration Rate (GFR) .......................................................................71
6.6.10.
Viral Sequencing (Archive)..................................................................................................72
6.6.11.
Pregnancy Testing................................................................................................................72
6.6.12.
Quality of Life Survey (PedsQL™) .....................................................................................72
7.
TOXICITY MANAGEMENT............................................................................................................................73
7.1.
Modification of Dose/Schedule Due to Toxicity....................................................................................73
7.2.
Subject Stopping Rules for LDV/SOF FDC and RBV...........................................................................73
8.
ADVERSE EVENTS MANAGEMENT ............................................................................................................74
8.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events.................................74
8.1.1.
Adverse Events.....................................................................................................................74
8.1.2.
Serious Adverse Events........................................................................................................74
8.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events .........................................................................75
8.2.
Assessment of Adverse Events and Serious Adverse Events.................................................................75
8.2.1.
Assessment of Causality for Study Drug and Procedures ....................................................75
8.2.2.
Assessment of Severity ........................................................................................................76
8.3.
Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead or CRO .........................................................................................................76

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 4
08 June 2017
8.4.
Gilead Reporting Requirements.............................................................................................................78
8.5.
Special Situations Reports......................................................................................................................78
8.5.1.
Definitions of Special Situations..........................................................................................78
8.5.2.
Instructions for Reporting Special Situations.......................................................................79
9.
STATISTICAL CONSIDERATIONS................................................................................................................81
9.1.
Analysis Objectives and Endpoints........................................................................................................81
9.1.1.
Analysis Objectives..............................................................................................................81
9.1.2.
Primary Endpoints................................................................................................................82
9.1.3.
Secondary Endpoints............................................................................................................82
9.2.
Analysis Conventions.............................................................................................................................82
9.2.1.
Analysis Sets ........................................................................................................................82
9.2.2.
Data Handling Conventions .................................................................................................83
9.2.3.
Interim Analysis ...................................................................................................................84
9.3.
Demographic Data and Baseline Characteristics ...................................................................................84
9.4.
Pharmacokinetic Analysis......................................................................................................................85
9.5.
Safety Analysis.......................................................................................................................................86
9.5.1.
Extent of Exposure...............................................................................................................86
9.5.2.
Adverse Events.....................................................................................................................87
9.5.3.
Laboratory Evaluations ........................................................................................................88
9.5.4.
Other Safety Evaluations......................................................................................................88
9.6.
Efficacy Analysis ...................................................................................................................................88
9.6.1.
Key Efficacy Analysis..........................................................................................................88
9.6.2.
Secondary Efficacy Analysis................................................................................................88
9.6.3.
Subgroup Analysis ...............................................................................................................89
9.7.
Quality of Life Analysis.........................................................................................................................89
9.8.
Acceptability ..........................................................................................................................................89
9.9.
Data Monitoring Committee ..................................................................................................................89
9.10.
Sample Size............................................................................................................................................90
10.
RESPONSIBILITIES..........................................................................................................................................91
10.1.
Investigator Responsibilities ..................................................................................................................91
10.1.1.
Good Clinical Practice..........................................................................................................91
10.1.2.
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Approval...............................................................................................................................91
10.1.3.
Informed Consent/Assent.....................................................................................................92
10.1.4.
Confidentiality......................................................................................................................92
10.1.5.
Study Files and Retention of Records ..................................................................................92
10.1.6.
Case Report Forms...............................................................................................................94
10.1.7.
Drug Accountability.............................................................................................................94
10.1.8.
Inspections............................................................................................................................94
10.1.9.
Protocol Compliance............................................................................................................94
10.2.
Sponsor Responsibilities ........................................................................................................................95
10.2.1.
Protocol Modifications.........................................................................................................95
10.2.2.
Study Report and Publications .............................................................................................95
10.3.
Joint Investigator/Sponsor Responsibilities ...........................................................................................95
10.3.1.
Access to Information for Monitoring..................................................................................95
10.3.2.
Access to Information for Auditing or Inspections ..............................................................96
10.3.3.
Study Discontinuation..........................................................................................................96
11.
REFERENCES ...................................................................................................................................................97
12.
APPENDICES ..................................................................................................................................................100

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 5
08 June 2017
Appendix 1.
Investigator Signature Page..................................................................................................101
Appendix 2.
Study Procedures Table........................................................................................................102
Appendix 3.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities.............108
Appendix 4.
Tanner Stages* .....................................................................................................................130
Appendix 5.
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements.................................................................................................131
LIST OF IN-TEXT TABLES
Table 1-1.
Statistical Comparison of Pharmacokinetic Parameters for Formulation Comparison 
- Test versus Reference Treatments (Primary PK analysis Set) .............................................26
Table 1-2.
Statistical Comparison of Pharmacokinetic Parameters for Food Effect Comparison 
- Test versus Reference Treatments (Primary PK analysis Set) .............................................27
Table 1-3.
Steady-state PK and Statistical Comparisons of LDV, SOF and GS-331007 PK in 
Adolescent Subjects (PK Lead-in) and Adult Subjects (Phase 2/3 Population PK 
Analysis).................................................................................................................................29
Table 1-4.
Steady-state PK and Statistical Comparisons of LDV, SOF and GS-331007 PK in 
Pediatric Cohort 2 Subjects (6 to <12 years old; PK Lead-in) and Adult Subjects 
(Phase 2/3 Population PK Analysis).......................................................................................29
Table 3-1.
Subject Enrollment by HCV Genotype, Country, and Treatment Duration ...........................38
Table 5-1.
Disallowed and Concomitant Medications to be Used with Caution .....................................52
Table 7-1.
RBV Dose Reduction Guidelines...........................................................................................73
Table 9-1.
GS-331007, SOF, and LDV PK Parameters after Once-Daily Administration of 
LDV/SOF FDC in HCV-Infected Adults Subjects (Population PK Analysis from 
Phase 2 and 3 Studies)............................................................................................................86
LIST OF IN-TEXT FIGURES
Figure 1-1.
Predicted LDV, SOF, and GS-331007 AUCtau following administration of 
LDV/SOF FDC 45 mg/ 200 mg or LDV/SOF FDC 33.75 mg/ 150 mg (3 to < 6 
years of age) ...........................................................................................................................33
Figure 3-1.
PK Lead-in Phase Study Schema ...........................................................................................37

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 6
08 June 2017
PROTOCOL SYNOPSIS
Gilead Sciences, Inc. 
333 Lakeside Drive
Foster City, CA 94404, USA
Study Title: 
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to 
Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed 
Dose Combination +/- Ribavirin in Adolescents and Children with 
Chronic HCV Infection
IND Number:
EudraCT Number:
115268
2014-003578-17
Study Centers:
Approximately 30 sites in the United States, Europe, Australia, and 
New Zealand
Number of Subjects:
Approximately 220 subjects
Target Population:
Adolescents and children (aged 3 to < 18 years) chronic hepatitis C 
virus (HCV) infection
Treatment Duration:
PK Lead-in – 10 days
Treatment Phase – 12 or 24 weeks
Objectives:
The primary objective of the PK Lead-in Phase of this study is:

To evaluate the steady state pharmacokinetics (PK) and confirm 
the dose of LDV/SOF FDC in chronic HCV-infected pediatric 
subjects
The secondary objective of the PK Lead-in Phase of this study is:

To evaluate the safety, tolerability, and antiviral activity of 
10 days of dosing of LDV/SOF FDC in chronic HCV infected 
pediatric subjects
The primary objective of the Treatment Phase of this study is:

To evaluate the safety and tolerability of LDV/SOF FDC +/- RBV 
for 12 or 24 weeks in chronic HCV -infected pediatric subjects. 

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
Study Design: 
CONFIDENTIAL 
Final 
Amendment 6.0 
The seconda!y objectives of the Treatment Phase ofthis study are: 
• 
To detennine the antiviral efficacy of 12 or 24 weeks of 
LDV/SOF FDC +/- RBV u·eatment in chronic HCV infected 
subjects (including the impact of HCV genotype, IL28B 
genotype, and prior u·eatment experience), as assessed by the 
prop01iion of subjects with sustained virological response (SVR) 
12 weeks after completion ofu·eatment (SVR12) 
• 
To determine the antiviral efficacy of 12 or 24 weeks of 
LDV/SOF FDC +/- RBV u·eatment in chronic HCV -infected 
subjects, as assessed by the prop01iion of subjects with SVR 4 and 
24 weeks after completion ofu·eatment (SVR4 and SVR24) 
• 
To evaluate the kinetics of circulating HCV RNA during 
u·eatment and after completion of u·eatment 
• 
To evaluate acceptability assessed by swallowability of tablets 
and palatability of granules 
• 
To evaluate the emergence of viral resistance to LDV and SOF 
during u·eatlnent and after completion of u·eatment 
• 
To evaluate the effect of growth and development on pediau·ic 
subjects during and after u·eatment 
The explorat01y objective of this study is: 
• 
PD 
Open-label, multi-coh01i, two-patt study evaluating the PK, safety, 
and antiviral activity ofLDV/SOF FDC +/- RBV in chronic 
HCV -infected pediau·ic subjects. 
The study commenced with GT-1 , -3 and -4 HCV-infected pediau·ic 
subjects. Subjects with GT-5 and -6 are cunently eligible for 
inclusion into actively emolling groups/coh01is following the 
demonsu·ation ofbenefit:risk in the adult population. Subjects with 
GT-2 will be included once adult data m·e available, if appropriate. 
Page7 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 8
08 June 2017
PK Lead-in Phase: PK Lead-in will evaluate and/or confirm age 
appropriate LDV/SOF FDC doses by analyzing PK, safety, and 
antiviral activity of LDV/SOF FDC through 10 days of dosing for 
each of the three cohorts. Children aged 3 to < 6, children aged 
6 to < 12 years, and adolescents aged 12 to < 18 years with evidence 
of chronic HCV and HCV RNA ≥1000 IU/mL at study entry will be 
evaluated. Subjects must be treatment naïve without history of 
cirrhosis to participate in the PK Lead-in Phase.
Three cohorts of at least 10 subjects each will be sequentially 
enrolled: 

Cohort 1: 12 to < 18 years old, weighing ≥ 45kg

Cohort 2: 6 to < 12 years old, weighing ≥ 17 kg and < 45 kg

Cohort 3: 3 to < 6 years old 
At least 4 subjects weighing ≥ 17 kg 
At least 4 subjects weighing < 17 kg
The study will start with Cohort 1. Subjects will receive LDV/SOF 
FDC (90 mg/ 400 mg fixed dose combination tablet or 
4 x 22.5 mg/ 100 mg based on LDV/SOF FDC swallowability 
assessment) for 10 days with intensive PK conducted on Day 10.
Once Cohort 1 data is analyzed and a Cohort 2 dose is determined, 
Cohort 2 will open for screening. Cohort 2 subjects will receive 
45 mg/ 200 mg LDV/SOF FDC (2 × 22.5 mg/ 100 mg tablets) for 
10 days with intensive PK conducted on Day 10. Cohort 3 subjects 
will receive LDV/SOF FDC oral granules formulation; subjects 
weighing ≥17 kg will receive 45 mg/ 200 mg LDV/SOF FDC
(4 × 11.25 mg/ 50 mg packets) and subjects weighing <17 kg will 
receive 33.75 mg/ 150 mg LDV/SOF FDC (3 × 11.25 mg/ 50 mg 
packets) for 10 days with intensive PK conducted on Day 10. 
PK Lead-in subjects in each cohort (Cohorts 1, 2 and 3) will 
immediately enroll in the Treatment Phase as they complete Day 10
of the PK Lead-in Phase. They will continue dosing with LDV/SOF 
FDC with no interruption of study drug administration. Subjects 
rolling over from the PK Lead-in will not be required to perform 
Treatment Phase Screening, Day 1, or Week 1 visits in the Treatment 
Phase. 
Following completion of study treatment in the PK Lead-in of each 
Cohort, intensive PK and safety results of study treatment will be 
reviewed to confirm the appropriateness of the evaluated LDV/SOF 
FDC dose for the Treatment Phase of that Cohort as well as to 
determine the age-appropriate dose to be evaluated in the PK Lead-in 
of the next Cohort.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 9
08 June 2017
Treatment Phase: Treatment Phase will be initiated sequentially by 
cohort after confirmation of age-appropriate LDV/SOF FDC dosage 
levels. Subjects who participate in PK Lead-in Phase will 
immediately rollover into Treatment Phase, with no interruption of 
study drug administration, until the appropriateness of the dose is 
confirmed by PK and safety data from the PK Lead-In Phase. These 
subjects will start at the Week 2 visit of the Treatment Phase. 
Additional subjects will be enrolled in the Treatment Phase after 
completion of each Cohort and upon confirmation of the appropriate 
dose.
Children aged 3 to < 12 years and adolescents aged 12 to < 18 years 
with chronic HCV infection and a HCV RNA ≥1000 IU/mL at study 
entry (those who were dosed in the PK Lead-in Phase will have met 
these criteria prior to enrollment) will be evaluated. The study 
commenced with GT-1, -3 and -4 HCV-infected pediatric subjects. 
Subjects with GT-5 and -6 are currently eligible for inclusion into 
actively enrolling groups/cohorts following the demonstration of 
benefit:risk in the adult population. Subjects with GT-2 will be 
included once adult data are available, if appropriate.
Subjects enrolled in the study will receive the following regimen:

United Kingdom:
GT-1, GT-4, GT-5, and GT-6 treatment-naïve with or without 
cirrhosis: LDV/SOF FDC for 12 weeks
GT-1, GT-4, GT-5, and GT-6 treatment-experienced without 
cirrhosis: LDV/SOF FDC for 12 weeks
GT-1, GT-4, GT-5, and GT-6 treatment-experienced with 
cirrhosis: LDV/SOF FDC for 24 weeks
GT-3 treatment-experienced with or without cirrhosis: 
LDV/SOF FDC + RBV for 24 weeks

United States/Australia/New Zealand:
GT-1 treatment-naïve with or without cirrhosis: LDV/SOF 
FDC for 12 weeks
GT-1 treatment-experienced without cirrhosis: LDV/SOF 
FDC for 12 weeks
GT-1 treatment-experienced with cirrhosis: LDV/SOF FDC 
for 24 weeks
GT-4, GT-5, and GT-6 treatment-naïve or 
treatment-experienced with or without cirrhosis: LDV/SOF 
FDC for 12 weeks

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
Substudies and 
Long-Te1m 
Follow-Up Study: 
CONFIDENTIAL 
Final 
Amendment 6.0 
The study will enroll both treatment-naive and treatment-experienced 
pediatric subjects, with up to 40 subjects allowed to be treatment 
experienced. Approximately 220 subjects, including subjects that 
prui icipated in the PK Lead-in Phase, will be enrolled in the 
Treatment Phase as follows: 
• 
Group 1: Approximately 100 adolescent subjects (12 to < 18 yeru·s 
of age) 
• 
Group 2: Approximately 120 pediatric subjects (3 to < 12 yeru·s of 
age) 
The following defmitions will be used for treatment-experienced 
subjects: 
• 
Interferon intolerant: Subject who discontinued therapy 
(:::; 12 weeks total) due to:=::: 1 adverse event 
• 
Interferon non-responder: Subject who did not achieve 
undetectable HCV RNA levels while on treatment 
• 
Relapse/breakthrough: Subject who achieved undetectable HCV 
RNA dming treatment or within 4 weeks of the end of treatment 
but did not achieve a sustained virologic response (SVR) 
The study schedule contains the following visits: Screening, Day 1, 
Weeks 1, 2, 4, 8, and 12 (and Weeks 16, 20, and 24 for subjects 
requiring 24 weeks of treatment) dm'ing the treatment phase followed 
by post-treatment visits 4, 12, and 24 weeks after discontinuation of 
therapy. 
All subjects who do not attain SVR or have viral relapse will be 
encomaged to discuss treatment with standard-of-care (SOC) therapy 
with their healthcru·e provider. 
Optional Intensive Pharmacokinetics (PK) Substudy: 
PD 
Pharmacogenomics (PG) Substudy 
PD 
Page 10 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 11
08 June 2017
Long-Term Follow-up
Subjects who attain SVR24 or those who do not attain SVR24 and do 
not initiate other experimental or approved anti-HCV therapy will be 
followed every 6 months for the first 2 years followed by every 
12 months for assessments of growth, quality of life, and long-term 
viral suppression (if applicable) in a separate protocol 
(GS-US-334-1113). This follow-up will continue for 5 years.
Diagnosis and Main 
Eligibility Criteria: 
Chronic HCV-infected, treatment-naïve and treatment experienced
(up to 40 subjects); male and female subjects aged 3 to < 18 as 
determined at Day 1. The study commenced with GT-1, -3, and -4
HCV -infected pediatric subjects. Subjects with GT-5 and -6 are 
currently eligible for inclusion into actively enrolling groups/cohorts 
following the demonstration of benefit:risk in the adult population. 
Subjects with GT-2 will be included once adult data are available, if 
appropriate. 
Inclusion Criteria:

Chronic HCV infection documented by either:
A) positive anti-HCV antibody test or positive HCV RNA or 
positive HCV genotyping test at least 6 months prior to the 
Day 1 visit, or
B) liver biopsy performed prior to the Day 1 visit with evidence 
of chronic HCV- infection

HCV RNA ≥ 1000 IU/mL at Screening 

PK Lead-in Only: subjects in Cohort 1 (age 12 to < 18 years of 
age) must weigh ≥ 45 kg

PK Lead-in Only: subjects in Cohort 2 (age 6 to < 12 years of 
age) must weigh ≥ 17 kg and < 45 kg

Females of childbearing potential (as defined in Appendix 5) must 
have a negative pregnancy test at Screening and Day 1.

Hematologic or biochemical parameters at screening within the 
protocol-specified requirements
Exclusion Criteria:

HIV, acute hepatitis A virus (HAV) or chronic HBV infection

History of or current decompensated liver disease

Hepatocellular carcinoma or other malignancy (with exception of 
certain resolved skin cancers)

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 12
08 June 2017

Chronic liver disease of a non-HCV etiology 
(e.g., hemochromatosis, Wilson’s disease, alpha-1 antitrypsin 
deficiency)

Systemic corticosteroid use for > 2 weeks (pulmonary/nasal 
administration is permitted)

Active or recent history (≤ 1 year) of drug or alcohol abuse

History or current evidence of any condition, therapy, laboratory
abnormality or other circumstance that might confound the results 
of the study, or interfere with the subject’s participation for the 
full duration of the study, such that it is not in the best interest of 
the subject to participate.

Sexually active subjects who are not willing to use 2 forms of an 
effective method of contraception, as referenced in Appendix 5
See Sections 4.2 and 4.3 of the protocol for full eligibility criteria.
Study Procedures/
Frequency:
Screening assessments will be completed within 28 days of the Day 1 
visit. 
Screening assessments will include: informed consent, medical 
history (including parental height, if available), complete physical 
examination, vital signs (including body height and weight), 
concomitant medications, LDV/SOF FDC Swallowability 
Assessment, as applicable (may be performed at screening up to 
Day 1), hematology, safety laboratory tests, coagulation tests, HCV 
RNA, serum β-human chorionic gonadotropin (hCG - females of 
childbearing potential only), urinalysis, urine drug screen, IL28B 
genotyping, serology (HIV, HAV, HCV, and HBV, HCV 
genotyping), HbA1c, thyroid stimulating hormone (TSH), alpha 
fetoprotein, alpha-1 anti-trypsin.
For subjects continuing from PK Lead-in into the Treatment Phase, a 
screening visit for the Treatment Phase will not be required.
PK Lead-in Phase: 
Study Visits will occur at Day 1, Day 3, and Day 10.
On-Treatment assessments include physical examination, Tanner 
Pubertal Stage Assessment (Day 1 only), vital signs (including body 
height and weight), bone age assessment (Day 1 only), adverse events 
(AEs), concomitant medications, pregnancy prevention counseling 
(Day 1 only; all subjects ≥ 12 years of age and subjects 
< 12 years of age at the discretion of the Investigator based on 
subject’s pubertal status), quality of life survey (Day 1 only), safety 
laboratory tests, HCV RNA, viral sequencing sampling and 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 13
08 June 2017
urinalysis. Coagulation testing and urine pregnancy tests (females of 
child bearing potential only) will be performed at Day 1 and Day 10 
only. LDV/SOF FDC swallowability assessment as applicable with 
placebo will be performed (if not performed at Screening) on Day 1 
to assess a subject’s ability to swallow the 90 mg/ 400 mg or 22.5 mg/ 
100 mg tablet, as applicable (only subjects administered LDV/SOF 
FDC in tablet form). 
Subjects (at least 10 subjects per cohort) enrolled in the PK Lead-in 
Phase will participate in an intensive PK evaluation on Day 10. 
Following completion of the Day 10 intensive PK visit, subjects will 
then return for scheduled study visits outlined in the Treatment Phase 
and will continue dosing with LDV/SOF FDC with no interruption of 
study drug administration. Subjects will be administered a dosing 
diary with instructions. 
Treatment Phase: 
Study visits will occur at Day 1, and at the end of Weeks 1, 2, 4, 8, 
and 12 (and Weeks 16, 20, and 24 for subjects requiring 24 weeks of 
treatment). All Treatment Phase subjects will then return for 
follow-up visits at 4, 12, and 24 weeks after discontinuation of 
therapy. 
On-treatment assessments will include physical examination, vital 
signs (including body height and weight), AEs, concomitant 
medications, pregnancy prevention counseling (all subjects 
≥12 years of age and subjects < 12 years of age at the discretion of 
the Investigator based on subject’s pubertal status), safety laboratory
tests, coagulation tests, HCV RNA, HBV DNA for HBcAb positive 
subjects, viral sequencing, urine pregnancy tests (females of 
childbearing potential only), a quality of life survey, and urinalysis. 
Tanner Pubertal Stage assessment will be performed at Day 1 and end 
of treatment visits; parental heights will be recorded at Day 1 as 
available. The Bone Age Assessment will be performed at the Day 1 
visit. LDV/SOF FDC swallowability assessment as applicable will be 
performed (if not performed at Screening) on Day 1 to assess a 
subject’s ability to swallow a placebo to match the 90 mg/ 400 mg or 
22.5 mg/ 100 mg LDV/SOF FDC tablet, as applicable (only subjects 
administered LDV/SOF FDC in tablet form). For subjects continuing 
from the PK Lead-in, the screening, Day 1, and Week 1 visits of the 
Treatment Phase will not be required. Samples for viral RNA 
sequencing/phenotyping will be collected at Day 1 and every visit 
thereafter. Palatability of LDV/SOF FDC oral granules will be 
assessed at Day 1 in subjects from 3 to <6 years of age, as applicable. 

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
CONFIDENTIAL 
PD 
Final 
Amendment 6.0 
For all subjects in the Treatment Group 2, the following single PK 
sampling timepoints will be collected as applicable: 
• 
For subjects receiving 12 weeks of treatment: a PK sample will be 
collected at any time point at the following visits: Weeks 1, 2, 12 
and Unscheduled or Early T ennination. 
• 
For subjects receiving 24 weeks of treatment: a PK sample will be 
collected at any time point at the following visits: Weeks 1, 2, 12, 
16, 20, 24 and Unscheduled or Early Tennination. 
Post-treatment assessments will include vital signs (including body 
weight and height), symptom-directed physical examination, AEs 
(only SAEs will be captured at post-treatment Week 12 and 
post-treatment Week 24), concomitant medications (only 
post-treatment Week 4), safety laborat01y tests, HCV RNA, HBV 
DNA for HBcAb positive subjects, Tanner Pube1ial Stage assessment 
(only post-treatment Week 12 and post-treatment Week 24), Bone 
Age Assessment (only post-treatment Week 24) and urine pregnancy 
tests (as defmed in Appendix 5). 
PD 
Page 14 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 15
08 June 2017
Test Product, Dose, 
and Mode of 
Administration:
PK Lead-in: 
(Cohort 1) LDV/SOF FDC is manufactured as a tablet, consisting of 
400 mg SOF and 90 mg LDV, for oral administration. LDV/SOF 
FDC tablets will be administered once daily. Subjects unable to 
swallow the LDV/SOF FDC 90 mg/ 400 mg adult tablet (as 
determined by LDV/SOF FDC Swallowability Assessment at 
Screening or at Day 1) will be re-assigned to 4 × 22.5 mg/ 100 mg 
LDV/SOF FDC tablets daily.
(Cohort 2) LDV/SOF FDC 45 mg/ 200 mg (2 × 22.5 mg/ 100 mg) 
will be administered once daily.
(Cohort 3) LDV/SOF FDC oral granules will be administered once 
daily for 10 days. Subjects who weigh ≥17kg will receive 45 mg/ 
200 mg LDV/SOF FDC (4 × 11.25 mg/ 50 mg packets) and subjects 
who weigh <17kg will receive 33.75 mg/ 150 mg LDV/SOF FDC 
(3 × 11.25 mg/ 50 mg packets).
Intensive PK and safety results from the PK Lead-in of each Cohort 
will be reviewed to confirm the appropriateness of the evaluated 
LDV/SOF FDC dose for the Treatment Phase of that Cohort as well 
as to determine the age-appropriate dose to be evaluated in the PK 
Lead-in of the next Cohort.
Treatment Phase: 
Subjects who participated in PK Lead-in of each Cohort will continue 
in the Treatment Phase with no interruption of study drug 
administration until the appropriateness of the dose is confirmed by 
PK and safety data from the PK-Lead-in. Additional subjects will be 
enrolled in the Treatment Phase of each Cohort upon confirmation of 
the appropriateness of the dose.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 16
08 June 2017
RBV Weight-Based Dosing (GT-3 Subjects only):
The RBV dose is:
Body Weight kg
(lbs.)
RBV Daily 
Dose
RBV Number of Capsules
<47 (<103)
15 mg/kg/day
Use Oral Solution. Divided dose in the 
morning and evening.
47-49 (103-108)
600 mg/day
1 × 200-mg capsules A.M.
2 × 200-mg capsules P.M.
50-65 (110 – 143)
800 mg/day
2 × 200-mg capsules A.M.
2 × 200-mg capsules P.M.
66-80 (145 – 176)
1000 mg/day
2 × 200-mg capsules A.M.
3 × 200-mg capsules P.M.
81-105 (178-231)
1200 mg/day
3 × 200-mg capsules A.M.
3 × 200-mg capsules P.M.
>105 (>231)
1400 mg/day
3 × 200-mg capsules A.M.
4 × 200-mg capsules P.M.
*
Note: Subjects with a body weight greater than or equal to 47 kg may utilize the RBV 
oral solution if necessary.
The morning dose of RBV will be taken with food and a weight 
and/or age-appropriate dose of LDV/SOF FDC. The evening dose of 
RBV will be taken with food.
Reference Therapy:
None
Evaluation Criteria:
Safety:
AEs, laboratory tests, physical examinations, and vital sign 
measurements will be collected throughout the study. 
Efficacy:
Efficacy will be evaluated using scheduled assessments of HCV RNA 
performed using COBAS® AmpliPrep/COBAS® TaqMan® HCV 
Test.
PK:
For subjects in the PK Lead-in, the steady-state PK of LDV, SOF,
and its major metabolites (GS-331007 and GS-566500) will be 
assessed at Day 10. For Cohorts 1 and 2, plasma samples will be 
collected for PK analyses following dosing of study drug on Day 10
at the following time points: 0 (predose), 0.5, 1, 2, 3, 4, 5, 8, and 
12 hours postdose (with predose also serving as t= 24). For Cohort 3, 
plasma samples for PK analyses will be collected at the following 
time points: 0 (predose), 0.5, 2, 4, 8, and 12 hours postdose (with 
predose also serving as t = 24).

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
Statistical Methods: 
CONFIDENTIAL 
Final 
Amendment 6.0 
Plasma PK parameters such as Cmax, Tmax, Clast, Tlast, Ctau, AUCtau, and 
t112 will be estimated. 
PD 
For Treatment Group 2 subjects, a PK blood sample will be collected 
at all visits while on u·eatment: a PK sample will be collected between 
15 minutes to 4 hours post-dose at Weeks 4 and 8 as applicable. A PK 
sample will be collected at any timepoint at all remaining visits, as 
applicable. The PK of GS-331 007, SOF and LDV will be assessed. 
The effect of age and LDV/SOF FDC dose on PK (GS-331007, SOF, 
and LDV) will be explored. 
For the PK Lead-in, plasma PK parameters Cmax, Tmax, Clast, Tlast, Ctau, 
AUCtau, AUClast, and t112 will be estimated. The PK parameters will be 
summarized by cohort. The effect of age and LDV/SOF FDC dose on 
PK (GS-331007, SOF, and LDV) will be explored. 
For the Treatment Phase, the primruy safety endpoint is any AE 
leading to pennanent discontinuation of study. The key efficacy 
endpoint is SVR12 in all emolled and u·eated subjects. Point estimate 
of SVR12 rate and its 95% confidence interval will be provided for 
each age group. 
Acceptability of the study u·eatments will be summru·ized using 
descriptive statistics by assessing swallowability of tablets and 
palatability of granules as applicable. Clinically relevant subgroup 
analysis on SVR12 may be conducted as appropriate (i.e., assuming 
that adequate numbers of patients in the subsets are available for 
analysis). 
All continuous endpoints will be summarized using an 8-number 
surmnruy (n, mean, standru·d deviation, median, Q1, Q3, minimum, 
and maximum). All categorical endpoints will be sUIIllnru·ized by 
number and percentage of subjects who meet the endpoint definition. 
Safety endpoints will be analyzed by the number and percent of 
subjects with events or abn01m alities for categorical values or 
8-number summruy (n, mean, standru·d deviation, median, Q1, Q3, 
minimum, maximum) for continuous data. 
Page 17 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 18
08 June 2017
With approximately 100 subjects enrolled into 12 to <18 years 
(Group 1) of the Treatment Phase, a two-sided 95.0% confidence 
interval of the SVR12 rate will extend at most 5.9% in both directions 
from the observed SVR12 rate, assuming the expected SVR12 rate is 
90%.
With approximately 120 subjects enrolled into the 3 to < 12 years 
(Group 2) of the Treatment Phase, a two-sided 95.0% confidence 
interval of the SVR12 rate will extend at most 5.4% in both directions 
from the observed SVR12 rate, assuming the expected SVR12 rate is 
90%.
This study will be conducted in accordance with the guidelines of Good Clinical Practices 
(GCPs) including archiving of essential documents.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 19
08 June 2017
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C 
degrees Celsius
F
degrees Fahrenheit
AE
adverse event
ALT
alanine aminotransferase (also SGPT)
ANC
absolute neutrophil count
APTT
activated partial thromboplastin time
AST
aspartate aminotransferase (also SGOT)
AUC
area under the curve
AUCtau
area under the plasma concentration versus time curve over the dosing interval (tau)
BLQ
below the lower limit of quantification
BMI
body mass index
CK
creatine kinase
Cmax
the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
Ctau
observed drug concentration at the end of the dosing interval (tau)
CRF
case report form(s)
CRO
Contract (or clinical) research organization 
DAA
Direct acting antiviral
dL
Deciliter
DNA
deoxyribonucleic acid
DMC
Data Monitoring Committee
DSPH
Drug Safety and Public Health
ECG
Electrocardiogram
eCRF
Electronic case report form(s)
EMA
European Medicines Agency
ESA
Erythropoiesis stimulating agent
ESPGHAN
European Society for Paediatric Gastroenterology
EU
European Union
FAS
full analysis set
FDA
(United States) Food and Drug Administration
FDC
Fixed-Dose Combination
FEV1
forced expiratory volume in one second
GCP
Good Clinical Practice (Guidelines)
GCSF
Granulocyte colony stimulating factor
GFR
glomerular filtration rate
GGT
gamma glutamyl transferase
GSI
Gilead Sciences, Inc.
GT
Genotype (viral)

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 20
08 June 2017
GSI
Gilead Sciences, Inc.
GT
Genotype (viral)
HAV
Hepatitis A Virus
Hb
Hemoglobin
HbA1c
Hemoglobin A1c
HBsAg
Hepatitis B surface antigen
HBsAb
Hepatitis B surface antibody
HBcAb
Hepatitis B core antibody
HBV
Hepatitis B virus
HCV
Hepatitis C virus
HDPE
high-density polyethylene
HIV
Human Immunodeficiency Virus
HLGT
High-Level Group Term
HLT
High-Level Term
ICH
International Conference on Harmonisation
IEC
independent ethics committee
IL28B
IL28B gene
IND
Investigational New Drug (Application)
IRB
institutional review board
IUD
intrauterine device
IWRS
interactive web response system
kg
Kilogram
L
Liter
LDV
Ledipasvir
LLN
lower limit of the normal range
LLOQ
Lower limit of quantification
LLT
Lower-Level Term 
MedDRA
Medical Dictionary for Regulatory Activities
Mg
Milligram
MH
Mantel-Haenszel
mL
Milliliter
Min
Minute
mmHg
millimeters mercury
NS (3/4A/5A/5B)
Non-structural Protein
PBMC
peripheral blood mononuclear cell(s)
PEG
peginterferon alfa-2a
P-gp
P-glycoprotein
PI
Protease inhibitor
PK
Pharmacokinetic
QD
once daily (use only in tables)

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 21
08 June 2017
RBC
Red blood cell count
RBV
ribavirin
RNA
ribonucleic acid
SADR
Serious adverse drug reaction
SAE
serious adverse event
SD
Standard deviation
SOC
Standard-of-Care
SOF
Sofosbuvir
SOP
Standard operating procedure
SUSAR
Suspected Unexpected Serious Adverse Reaction
SVR
Sustained Virologic Response
tmax
The time (observed time point) of Cmax
TSH
Thyroid stimulating hormone
t½
An estimate of the terminal elimination half-life of the drug in serum/plasma/PBMC, 
calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz)
ULN
upper limit of the normal range
US
United States
WBC
white blood cell count

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 22
08 June 2017
1.
INTRODUCTION
1.1.
Background
Hepatitis C virus (HCV) is responsible for a large proportion of chronic liver disease worldwide 
and accounts for 70% of cases of chronic hepatitis in industrialized countries. The global 
prevalence of chronic hepatitis C is estimated to average 3% {Esteban 2008}. 
The natural history of chronic HCV-infection in children differs from that in adults since 
HCV-infection in children is relatively benign. Most children chronically infected with HCV are 
asymptomatic or have mild nonspecific symptoms. Clinical symptoms are present in 
approximately 20% of children in the first 4 years of life, with hepatomegaly being the most 
frequent sign (10%). Many, but not all, perinatally infected children will have intermittently or 
persistently abnormal alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 
levels, particularly in the first 2 years of life. In children with vertical HCV-infection who have 
undergone liver biopsy, the histological spectrum is usually mild, although severe liver disease is 
encountered {Mohan 2010}. Despite the overall more favorable prognosis compared to adults, 
approximately 4% to 6% of children with chronic HCV-infection have evidence of advanced 
fibrosis or cirrhosis and some children eventually require liver transplantation for end-stage liver 
disease as a consequence of HCV-infection {Hu 2010}.
The goal of HCV treatment in both pediatric and adult populations is eradication of the virus, 
thereby preventing hepatic inflammation, hepatic fibrosis, cirrhosis, and liver failure resulting in 
either death or need for liver transplantation. This goal, however, is limited by the nature of the 
disease and the fact that not all patients are suitable candidates for currently approved treatments. 
In addition, pediatric treatment is controversial as the current treatment options are limited and 
severe side effects and tolerability can significantly limit or preclude their use. Despite 
well-established guidelines for the treatment of HCV in adults, there is no universal consensus 
on when or if to treat chronic HCV-infection in children. In 2010, the European Society for 
Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) issued guidance for clinical 
trial development for chronic HCV-infection in children {Wirth 2010}. In the guideline, the 
ESPGHAN suggested that the primary goal of treatment in children is to eradicate the infection 
to prevent late complications. Hence, the goal is not the treatment of an ongoing liver disease, 
but rather the prevention of a future one.
PEG and weight-based RBV are currently considered the SOC for the treatment of 
HCV-infection in children. Current recommendations are that patients with GT-2 or GT-3 be 
treated with PEG+RBV for 24 weeks and those with GT-1 or GT-4 should receive 48 weeks of 
therapy. Successful treatment of GT-1, however, has proved very difficult to achieve in spite of 
additional therapy or increased duration of treatment. A number of pediatric studies have 
reported that despite 48 weeks of treatment, sustained virologic response (SVR24) was observed 
in only 36% to 53% of subjects with GT-1, while response rates were > 80% in subjects with 
GT-2 or GT-3 {Wirth 2012}. Safety and efficacy data in pediatric patients with GT-5 or GT-6 
are limited.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 23
08 June 2017
Most children treated with PEG+RBV experience at least 1 adverse event due to treatment 
{Wirth 2012}. Although most of these events are mild to moderate in severity, many of them 
result in dose reductions of 1 or both of the drugs. The most common adverse events have 
consisted of influenza-like illness (91%), headache (62%), and injection site reactions (45%), 
often leading to poor compliance and/or discontinuation from treatment.
Additionally, the concern for growth and development in this age group and the role that both 
PEG and RBV potentially play in reducing growth rates has initiated significant debate among 
pediatric hepatologists as to whether these treatments should even be considered in the pediatric 
population {Serranti 2011}. Many pediatricians currently advocate delay of treatment past 
adolescence or even into adulthood when options with DAAs are possible {Serranti 2011}. 
Unfortunately, in the 25% of pediatric patients who do meet the criteria for treatment (elevated 
transaminases and viral loads), the option of PEG+RBV therapy remains inadequate in regard to 
both efficacy in GT-1 and safety due to the many risks associated with this treatment.
1.2.
Ledipasvir/Sofosbuvir Fixed-Dose Combination
Ledipasvir/Sofosbuvir fixed-dose combination (LDV/SOF FDC) combines two HCV specific 
direct acting antiviral (DAA) agents into a single tablet for the treatment of chronic 
HCV-infection. SOF is a nucleotide analog that is a potent and selective inhibitor of 
NS5B-directed HCV replication with demonstrated activity against GT 1-6 HCV-infection. 
Ledipasvir (LDV) is a novel HCV NS5A inhibitor that has demonstrated potent anti-HCV 
activity, with the highest activity against GT-1 HCV-infection. 
Harvoni® (LDV/SOF FDC) is approved in the United States (US) by the Food and Drug 
Administration (FDA) and in the European Union by the European Medicines Agency (EMA) 
for treatment of GT-1, GT-4, GT-5, and GT-6 HCV infection in both treatment-naïve and 
treatment-experienced adult patients with or without cirrhosis. Additionally, LDV/SOF FDC + 
RBV is approved for treatment of GT-3 HCV infection in treatment-experienced adult patients 
with or without cirrhosis. The recommended treatment regimens depend on HCV genotype, 
presence or absence of cirrhosis, and prior treatment experience. 
1.2.1.
Summary of Additional Clinical Experience with Ledipasvir/Sofosbuvir 
Fixed-Dose Combination
The LDV/SOF FDC phase 3 program consisted of 3 clinical studies: GS-US-337-0102 {Afdhal 
2014b}, GS-US-337-0109 {Afdhal 2014a}, and GS-US-337-0108 {Kowdley 2014}. Studies 
GS-US-337-0102 and GS-US-337-0109 evaluated treatment with LDV/SOF FDC ± RBV for 
12 or 24 weeks in treatment-naïve and treatment-experienced subjects, respectively, infected 
with GT-1 HCV. Both studies enrolled up to 20% of HCV-infected subjects who had 
documented compensated cirrhosis. GS-US-337-0108 evaluated LDV/SOF FDC ± RBV 
treatment for 8 weeks and LDV/SOF FDC treatment for 12 weeks in non-cirrhotic 
treatment-naïve subjects with GT-1 HCV-infection. Across these 3 clinical studies, LDV/SOF 
FDC demonstrated a high degree of efficacy (> 93%) for treatment-naïve and treatment
experienced subjects with GT-1 HCV-infection in subjects with and without cirrhosis and
achieved their primary efficacy endpoints {Afdhal 2014a, Afdhal 2014b, Kowdley 2014}. 
Additionally, treatment with LDV/SOF FDC ± RBV was safe and well tolerated in the Phase 3 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 24
08 June 2017
studies {Afdhal 2014a, Afdhal 2014b, Kowdley 2014}. The inclusion of RBV to the treatment 
regimen was associated with an increase in the total incidence of adverse events and in graded 
laboratory abnormalities of anemia and increased bilirubin. 
LDV/SOF FDC indication in GT-3 HCV infection is supported by the Phase 2 Study 
GS-US-337-0122 (ELECTRON-2). In this Phase 2 open-label study, the safety and efficacy of 
LDV/SOF FDC were evaluated with or without RBV in 51 treatment-naïve patients with GT-3 
HCV infection, with or without cirrhosis. Subjects were treated with LDV/SOF FDC (n = 25) or 
LDV/SOF FDC + RBV (n = 26) for 12 weeks. SVR12 rates were 64% (16/25) and 100% (26/26) 
in the LDV/SOF FDC and LDV/SOF FDC + RBV treatment groups, respectively. The relative 
efficacy of a 12-week regimen consisting of LDV/SOF FDC + RBV, compared to a 24-week 
regimen of SOF + RBV has not been investigated. Therefore, 24 weeks of therapy is advised in 
all treatment-experienced GT-3 patients and those treatment-naïve GT-3 patients with cirrhosis 
to maximize therapeutic benefit to achieve SVR.
Both nonclinical and clinical data support the inclusion of GT-4 HCV-infected subjects in the 
Study GS-US-337-1116. LDV displays potent antiviral activity against GT-4. In the replicon 
system the EC50 value of LDV for GT-4d HCV was 0.60 nM and 0.39 nM for GT-4a HCV. For 
reference, the EC50 values of LDV for GT-1a and GT-1b is 0.031 nM and 0.004 nM, 
respectively.
In the Phase 3 Study GS-US-337-0102 (ION-1), 2 subjects with GT-4d HCV infection were 
inadvertently randomized in violation of the protocol inclusion/exclusion criteria. Both subjects 
achieved SVR12. Subject 
 was treated for 12 weeks with LDV/SOF FDC and 
Subject 
 was treated for 24 weeks with LDV/SOF FDC + RBV.
Data from Study GS-US-337-1119 support the inclusion of GT-4 as well as GT-5 HCV-infected 
subjects within the current study. Study GS-US-337-1119 was a European study that investigated
the efficacy and safety of LDV/SOF FDC in treatment-naive and treatment-experienced subjects 
with chronic GT-4 or GT-5 HCV infection. A total of 44 subjects with GT-4 HCV infection, of 
whom 10 (23%) had cirrhosis and 22 (50%) were treatment experienced, were enrolled to 
receive LDV/SOF FDC for 12 weeks. SVR12 was achieved by 41 (93%) of the GT-4 HCV
infection subjects including 21 (96%) who were treatment-naïve and 20 (91%) who were 
treatment-experienced subjects. In addition, a total of 41 subjects with GT-5 HCV infection were 
enrolled, of whom 9 (22%) had cirrhosis and 20 (49%) were treatment-experienced, and received 
LDV/SOF FDC for 12 weeks. SVR12 was achieved by 39 (95%) including 19 (95%) who were 
treatment-experienced and 8 (89%) with cirrhosis.
In addition, data are available from the NIAID/NIH collaborative Study CO-US-337-0117. In 
this study, 21 subjects with GT-4 HCV infection received 12 weeks of LDV/SOF FDC 
treatment. SVR12 was achieved by 20 of 21 subjects including 6 subjects with cirrhosis.
Inclusion of subjects with GT-6 HCV in the current study is supported by data from the 
ELECTRON-2 study (GS-US-337-0122). In ELECTRON-2, treatment-naïve or 
treatment-experienced adult subjects with GT-6 HCV infection with or without cirrhosis (n = 25) 
received LDV/SOF FDC for 12 weeks. In this study, 96% (24/25) of patients achieved SVR12.
PPD
PPD

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
1.2.1.1. 
GS-US-337-2091 
Final 
Amendment 6.0 
Study GS-US-337-2091 was a single dose, randomized, 3-period crossover Phase 1 study in 
healthy adult subjects conducted to evaluate relative bioavailability and the effect of food on 
LDV/SOF FDC oral granules. Subjects were administered the following treatments in a 
randomized order with a 9 day washout between doses: 1 x 90 mg/ 400 mg LDV/SOF FDC 
tablet (adult fonnulation) in the fasted state (Treatment A), 90 mg/ 400 mg LDV/SOF FDC oral 
granules (8 x 11.25 mg/ 50 mg packets) in a fasted state (Treatment B), and 90 mg/ 400 mg 
LDV /SOF oral granules (8 x 11.25 mg/ 50 mg packets) after a standardized high-fat meal 
(Treatment C). F01iy-two healthy subjects were emolled and completed all u·eatments. Overall, 
both LDV/SOF FDC f01mulations were well tolerated. No subjects experienced a serious 
adverse event (SAE) or a Grade 3/4 u·eatment emergent adverse event (AE), and no subjects 
required u·eatment discontinuation for an AE. Grade 3/4laboratOiy abn01m alities were seen in 
1 subject who had a u·ansient Grade 4 lipase elevation (481 UIL) prior to the 3rd dose, followed 
by progressive decrease through 3 weeks after the dose. The subject was asymptomatic and had a 
medical hist01y notable for isolated lipase elevation. 
In accordance with the FDA and EU guidance for Bioavailability and Bioequivalence studies the 
primaty PK analysis set consisted of subjects with pre-dose concenu·ations < 5% of Cmax for each 
period (Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs 
or INDs - General Considerations [FDA], Guideline on the Investigation of Bioequivalence EU] 
{Emopean Medicines Agency (EMEA) 2010, U.S. Depm·tment of Health and Human Services 
2014}). A sensitivity analysis including PK data from all subjects was also conducted. 
1.2.1.1.1. 
GS-US-337-2091 F01mulation Comparison 
Statistical compat·isons of the primaty PK paratneters AUCinf, AUC1ast> Cmax for LDV, and 
GS-331 007 (the primruy circulating metabolite of SOF) are presented below following 
adminisu·ation of90 mg/ 400 mg LDV/SOF FDC oral granules (8 x 11.25 mg/ 50 mg) fasted 
(Treatment B; Test) relative to 90 rng/ 400 mg LDV/SOF FDC tablets (1 x 90 mg/ 400 mg). 
fasted Treatment A; Reference . PO 
CONFIDENTIAL 
Page 25 
08 Jnne 2017 

LDVISOFFDC 
Protocol GS-US-337-1116 
Final 
Gilead Sciences, Inc. 
Amendment 6.0 
Table 1-1. 
Statistical Comparison of Pharmacokinetic Parameters for 
Formulation Comparison- Test versus Reference Treatments 
(Primary PK analysis Set) 
Mean (%CV) 
% GLSM Ratio (90% CI) 
LDV/SOF 
LDV/SOF FDC 
FDC Tablet 
Oral Granules 
LDV /SOF FDC Oral Granules 
90 mg/400 mg 
Sx 11.25 mg/50 mg 
VS 
PK Parameter 
(Reference) 
(Test) 
LDV/SOF FDC Tablet 
LDV (N=42 reference/N=39 test) 
AUC~as~ (h*ng/mL) 
7362.3 (48.3) 
6242.5 (40.7) 
87.76 (77.94, 98.82) 
AUCinf (h *ng/mL) 
8467.5 (54.4) 
7088.4 (46.3) 
88.36 (78.43, 99.54) 
Cmax (ng/mL) 
261.3 (43.5) 
214.8 (38.2) 
84.59 (74.69, 95.81) 
GS-331007 (N=42 reference/N=42 test) 
AUC~as~ (h*ng/mL) 
11146.3 (26.9) 
11525.8 (26.3) 
103.14 (96.71, 110.00) 
AUCinf (h *ng/mL) 
11720.0 (26.1) 
12095.0 (24.4) 
103.64 (98.48, 109.07) 
Cmax (ng/mL) 
833.9 (23.6) 
951.9 (27.0) 
112.81 (104.12, 122.22) 
SOF (N=42 reference/N=42 test) 
AUC~as~ (h*ng/mL) 
1559.8 (40.5) 
1676.9 (43.7) 
102.13 (87.16, 119.67) 
AUCinf (h *ng/mL) 
1580.8 (40.2) 
1684.1 (43.5) 
101.60 (86.67, 119.10) 
Cmax (ng/mL) 
1221.0 (38.5) 
1266.7 (46.6) 
95.98 (78.00, 118.11) 
GS-566500 (N=42 reference/N=42 test) 
AUC~as~ (h*ng/mL) 
1846.6 (31.4) 
1952.9 (33.5) 
100.59 (88.89, 113.83) 
AUCinf (h *ng/mL) 
1894.9 (30.8) 
2009.7 (33.0) 
101.37 (90.17, 113.96) 
Cmax (ng/mL) 
475.1 (33.9) 
511.3 (34.9) 
103.04 (91.06, 116.60) 
* 
Primary PK analysis set excluded subjects with pre-dose concentrations> 5% of Cmax for each period 
Data from the primruy analysis demonstrated modestly lower LDV exposure (~ 1 2%) in the 
LDV /SOF FDC oral granules as compru·ed with the LDV /SOF FDC tablet, with the lower 
bounds of the 90% CI being approximately 75-78%. A slightly larger (20%) reduction in LDV 
was observed using sensitivity analysis that included data from all subjects. These modest 
decreases in exposure are not considered to be clinically relevant based on the established 
exposure/efficacy relationship for LDV and LDV/SOF. 
GS-331007 exposure in the LDV/SOF FDC oral granules was bioequivalent to the LDV/SOF 
FDC tablets. PO 
CONFIDENTIAL 
Page 26 
08 June 2017 

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
1.2.1.1.2. 
GS-US-337-2091 - Food Effect Evaluation 
Final 
Amendment 6.0 
Statistical comparisons of the primmy PK parameters AUCinf and AUC1ast for LDV, and 
GS-331 007 (the primmy circulating metabolite of SOF) are presented below following 
administration ofLDV/SOF oral granules (8 x 11.25 mg/ 50 mg packets in fed state 
Treatment C; Test relative to a fasted state Treatment B; Reference . PD 
Table 1-2. 
Statistical Comparison of Pharmacokinetic Parameters for Food 
Effect Comparison - Test versus Reference Treatments 
(Primary PK analysis Set) 
Mean (OfoCV) 
OfoGLSM Ratio (90% CI) 
LDV/SOF FDC 
LDV/SOFFDC 
LDV/SOFFDC 
Oral Granules 
Oral Granules 
Oral Granules + 
High-Fat Meal 
Fasted 
High-Fat Meal 
VS 
PK Parameter 
(Reference) 
(Test) 
Fasted 
LDV(N=39 reference/N=40 test) 
AUC~as~ (h*ng/mL) 
6242.5 (40.7) 
5149.6 (26.2) 
87.62 (79.65, 96.39) 
AUCinf (h *ng/mL) 
7088.4 (46.3) 
5748.3 (29.0) 
87.06 (78.95, 96.00) 
Cmax (ng/mL) 
214.8 (38.2) 
159.8 (28.9) 
78.15 (71.26, 85.71) 
GS-331007 (N=42 reference/N=42 test) 
AUC~as~ (h*ng/mL) 
11525.8 (26.3) 
11653.6 (18.9) 
103.12 (97.61, 108.94) 
AUCinf (h *ng/mL) 
12095.0 (24.4) 
12220.6 (18.3) 
102.26 (98.18, 106.52) 
cmax (ng/mL) 
951.9 (27.0) 
583.1 (24.2) 
62.01 (56.90, 67.59) 
SOF (N=42 reference/N=42 test) 
AUC1as1 (h*ng/mL) 
1676.9 (43.7) 
2577.2 (33.1) 
166.11 (145.00, 190.30) 
AUCinf (h *ng/mL) 
1684. 1 (43.5) 
2597.7 (32.9) 
166.18 (145.56, 189.71) 
Cmax (ng/mL) 
1266.7 (46.6) 
1236.3 (49.0) 
100.32 (84.83, 118.65) 
GS-566500 (N=42 reference/N=42 test) 
AUC~as~ (h*ng/mL) 
1952.9 (33.5) 
2931.7 (19.1) 
163.23 (144.62, 184.23) 
AUCinf (h *ng/mL) 
2009.7 (33.0) 
2988.8 (18.7) 
160.65 (143.40, 179.99) 
Cmax (ng/mL) 
511.3 (34. 9) 
593.9 (31.0) 
122.12 (108.28, 137.73) 
* 
Primary PK analysis set excluded subjects with pre-dose concentrations > 5% of Cmax for each period 
CONFIDENTIAL 
Page 27 
08 Jnne 2017 

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
Final 
Amendment 6.0 
With regards to food effect, the primruy and sensitivity analyses demonsu·ated that the 
prespecified equivalence criteria for LDV (70-143%) and GS-331007 (80-125%) AUC!ast and 
AUCinrafter adminisu·ation ofLDV/SOF FDC oral granules with a high-fat/hi h-calorie meal 
comj)ru·ed with fasted adminisu·ation were met. PD 
1.2.1.2. 
GS-US-337-1116 
Preliminruy data are available for the cunent study in adolescent subjects Coh01i 1 
(12 to < 18 yeru·s of age; N=10) and pediau·ic subjects Cohort 2 (6 to <12 yeru·s of age; N=12) 
who emolled in the PK Lead-in Phase and received an adult clinical dose ofLDV/SOF FDC 90 
mg/ 400 mg or a reduced dose ofLDV/SOF FDC 45 mg/200 mg, respectively. Of note, 2 out of 
12 subjects (subject PO 
and PPD 
in Coh01i 2 enoneously received a dose of 90 mg/ 
400 mg LDV/SOF FDC during the PK Lead-in Phase: Subjecg~;D received 90 mg/ 400 mg 
from Day 1 through Day 10 and Subject PD 
received 90 m 
400 mg from Day 1 through 
Day 4 followed by the con ect dose of 45 mg/ 200 mg for the remainder of the PK Lead-in Phase 
(Day 5 through Day 10). 
Evaluation ofPK in Coh01i 2 subjects was conducted using data from all12 subjects; observed 
LDV, SOF, and GS-331007 (primruy SOF metabolite) exposures on Day 10 were used for 
Subject PD 
and exposures were scaled to 45 mg/ 200 mg for SubjectPPD 
(Table 1-4). Mean 
exposures ofLDV, SOF, and GS-331007 in Coh01i 1 and 2 subjects were comparable to 
observed exposures in the adult subjects in the Phase 2/3 LDV/SOF FDC clinical progrrun; 
thereby confirming the appropriateness of the adult dose (90 mg/ 400 mg) in the adolescent 
population (12 to < 18 yeru·s of age) and 45 mg/ 200 mg in pediau·ic patients (6 to < 12 yeru·s of 
age) Table 1-3 and Table 1-4. The appropriateness of the 90 mg/ 400 mg LDV/SOF FDC dose in 
adolescents and 45 mg/ 200 mg LDV /SOF FDC dose in the pediau·ic patients is fmiher 
supported by available safety and efficacy data in the treatment phases of the study. 
CONFIDENTIAL 
Page 28 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 29
08 June 2017
Table 1-3.
Steady-state PK and Statistical Comparisons of LDV, SOF and 
GS-331007 PK in Adolescent Subjects (PK Lead-in) and Adult 
Subjects (Phase 2/3 Population PK Analysis)
Mean (%CV)
Adolescents (N=10)
Phase 2/3 (N=2113)
GMR% (90% CI)
LDV
AUCtau (ng*hr/ml)
10200 (50.9)
8530 (60.8)
127 (94.9, 170)
Cmax (ng/ml)
564 (41.2)
364 (51.4)
162 (125, 209)
Ctau (ng/ml)
319 (71.5)
247 (59.2)
128 (95.2, 172)
SOF*
AUCtau (ng*hr/ml)
2180 (26.6)
1380 (34.0)
160 (138, 185)
Cmax (ng/ml)
1140 (57.2)
659 (34.0)
156 (127, 190)
GS-331007
AUCtau (ng*hr/ml)
12700 (13.7)
12500 (29.2)
105 (90.6, 122)
Cmax (ng/ml)
1010 (21.5)
736 (28.2)
139 (120, 161)
Data reported to 3 significant figures; *N=1542
Table 1-4.
Steady-state PK and Statistical Comparisons of LDV, SOF and 
GS-331007 PK in Pediatric Cohort 2 Subjects (6 to <12 years old; PK 
Lead-in) and Adult Subjects (Phase 2/3 Population PK Analysis)
Mean (%CV)
Pediatrics (N=12)**
Phase 2/3 (N=2113)
GMR% (90% CI)
LDV
AUCtau (ng*hr/ml)
7520 (58.0)
8530 (60.8)
86.9 (66.5, 114)
Cmax (ng/ml)
432 (51.3)
364 (51.4)
116 (92.1, 147)
Ctau (ng/ml)
248 (67.5)
247 (59.2)
91.1 (69.5, 120)
SOF*
AUCtau (ng*hr/ml)
1600 (29.7)
1380 (34.0)
116 (101, 133)
Cmax (ng/ml)
906 (36.0)
659 (34.0)
139 (116, 167)
GS-331007
AUCtau (ng*hr/ml)
8140 (31.6)
12500 (29.2)
65.2 (56.9, 74.7)
Cmax (ng/ml)
772 (24.4)
736 (28.2)
106 (92.8, 122)
Data reported to 3 significant figures; *N=1542 (Phase 2/3), ** Similar results were observed following exclusion of subjects 
 and 
 who received LDV/SOF 90 mg/400 mg during the PK-Lead-in
PPD
PPD

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 30
08 June 2017
Please refer to the Investigator’s Brochure (IB) for additional information on the LDV/SOF FDC 
including:

In Vitro Anti-Hepatitis C Virus Activity

Nonclinical Pharmacokinetics and In Vitro Metabolism

Nonclinical Pharmacology and Toxicology

Clinical Experience
1.3.
Ribavirin (RBV)
Ribavirin is a guanosine analogue that inhibits the in vitro replication of a wide range of RNA 
and DNA viruses {Roche Laboratories Inc. 2010, Roche Products Limited 2010}. Ribavirin 
monotherapy has little or no effect on the replication of HCV but can result in normalization of 
serum ALT activity and improvement in liver histology. When combined with interferon or PEG 
therapy, RBV decreases substantially the relapse rate seen after cessation of interferon therapy 
{McHutchison 1998, Poynard 1998}.
Ribavirin is a known teratogen (FDA category X). Furthermore, RBV is known to accumulate 
intracellularly where it is cleared slowly, and is also excreted in semen. Therefore, extreme care 
must be taken to avoid pregnancy during RBV therapy and for up to 7 months following 
completion of treatment. A comprehensive review of RBV is contained in the package 
insert/SmPC.
1.4.
Rationale for the Current Study
This clinical study is designed to evaluate the efficacy, pharmacokinetics, and safety of treatment 
with LDV/SOF FDC +/- RBV for adolescents and children with chronic HCV-infection. 
Currently PEG and weight-based RBV are considered the SOC for the treatment of 
HCV-infection in children. Therefore, there is a need for new treatments for HCV in the 
pediatric population that combine potent and sustained efficacy with improved tolerability and 
safety. The primary aim for new treatments of pediatric patients with HCV is to eliminate the 
need to use PEG. In this way, pediatric patients would be able to avoid the necessity of weekly 
injections which can be traumatic and burdensome, and significantly reduce the serious adverse 
events seen with PEG administration. The secondary aim is to eliminate RBV and the adverse 
events seen with its administration within HCV infected subjects.
Harvoni® (LDV/SOF FDC) is approved in the US and EU for the treatment of adults with 
chronic HCV infection. LDV/SOF FDC +/- RBV would provide an all-oral, IFN-free regimen 
with a shorter treatment duration (12 or 24 weeks of LDV/SOF FDC +/- RBV treatment versus 
standard-of-care 24 to 48 weeks of treatment) for GT-1, -3, -4, -5, and -6 HCV infected patients
and would offer another important option in the treatment of HCV infection in the pediatric 
population.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 31
08 June 2017
In vitro viral replicon assay has data demonstrating LDV has potent, antiviral activity against all 
HCV genotypes. In the LDV/SOF FDC phase 3 program, LDV/SOF FDC without RBV has been 
shown to have good efficacy and safety in adults infected with GT-1 HCV infection. In the 
GS-US-337-0102 (ION-1), GS-US-337-1119, and CO-US-337-0117 studies, LDV/SOF FDC 
without RBV has been shown to have good efficacy and safety in adults infected with GT-4
HCV-infection. In study GS-US-337-0122, a phase 2 open-label study of GT-3 treatment-naïve
adult subjects with and without cirrhosis, LDV/SOF FDC for 12 weeks resulted in an SVR12 of 
64% whereas LDV/SOF + RBV for 12 weeks resulted in an SVR of 100% {Gane 2014}. The 
clinical data to support the use of Harvoni® in patients infected with HCV GT-3 are limited. As a 
result, the current study includes a 24-week RBV treatment regimen for only 
treatment-experienced pediatric subjects with GT-3 HCV-infection.
Considering that SOF has pan-genotypic activity and LDV has in vitro, picomolar to nanomolar 
antiviral activity against certain subtypes within GT 4-6 and sub-micromolar antiviral activity 
against certain subtypes within GT-2, studies in patients with GT-5 and GT-6 HCV have been 
completed and used to support treatment recommendations for the use of LDV/SOF FDC in 
adults infected with GT-5 and GT-6 HCV in both the US and EU. In studies GS-US-337-1119 
and GS-US-337-0122, LDV/SOF FDC for 12 weeks resulted in SVR12 rates of 93% and 96% in 
GT-5 and GT-6 HCV, respectively. Based on these clinical data pediatric subjects with GT-5 and 
GT-6 infection are eligible for enrollment into this clinical study.
If emerging LDV/SOF FDC data in GT-2 HCV infected subjects support treatment in adults,
pediatric subjects with GT-2, will be enrolled in the current study. Of note, there is an ongoing 
study enrolling GT-2 (and GT-3) pediatric patients, GS-US-334-1112, for treatment with 
SOF + RBV for 12 and 24 weeks, respectively.
1.5.
Rationale for Dose Selection of LDV/SOF FDC
Ledipasvir /Sofosbuvir (90 mg/ 400 mg) fixed-dose combination tablet +/- RBV has 
demonstrated favorable safety and efficacy profiles in over 3000 HCV-infected subjects across 
different patient populations in Phase 2 and 3 clinical trials. These doses represent the marketed 
dose of a ledipasvir/sofosbuvir fixed-dose combination tablet for the treatment of HCV-infection
in adults.
Selection of doses of LDV/SOF FDC +/- RBV for adolescents and younger age groups will 
target systemic exposures similar to those observed in adults at the proposed marketed dose. 
LDV and SOF are substrates for efflux drug transporters P-glycoprotein (P-gp) and breast cancer 
resistance protein (BCRP). LDV is also a subject to slow oxidative metabolism via an unknown 
mechanism. SOF is extensively metabolized to the pharmacologically active nucleoside analog 
phosphate. The activation pathway involves hydrolysis by intestinal and hepatically expressed 
carboxylesterase (CES1) and Cathepsin A (CatA) enzymes {Yang 2009, Zhu 2009}. SOF is also 
converted to GS-331007, an inactive circulating metabolite, which is eliminated renally by active 
tubular secretion and glomerular filtration. Available data suggest comparable hepatic expression 
of CES1 in adolescents and adults with modestly decreased expression in children. However, 
little is known about the developmental regulation of Pgp, CES, and CatA. When adjusted for 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 32
08 June 2017
BSA, the processes of active secretion and glomerular filtration approximate adult activity by 
6 to 12 months of age {Kearns 2003}. 
The adult clinical dose of LDV/SOF FDC (90 mg/ 400 mg) was evaluated in adolescent subjects 
(12 to <18 years old) while a lower LDV/SOF FDC (45 mg/ 200 mg) is being evaluated in 
children (6 to <12 years old), respectively. The appropriateness of these doses are supported by 
data from the Cohort 1 and Cohort 2 PK Lead-in Phase which demonstrated comparable LDV, 
SOF, and GS-331007 exposures in adolescent subjects who received LDV/SOF FDC (90 mg/
400 mg) or children who received LDV/SOF FDC (45 mg/ 200 mg) compared to adult subjects 
in Phase 2/3 population PK analyses.
In Cohort 3 (3 to < 6 years of age), a dose of LDV/SOF FDC (45 mg/ 200 mg) administered as 
granules is proposed for evaluation in children weighing ≥ 17 kg, whereas a lower LDV/SOF
FDC granules dose (33.75 mg/ 150 mg) is proposed for evaluation in children weighing < 17 kg. 
These proposed doses are supported by scaling of adult exposures based on correlations between 
body weight and clearance capacity (liver volume/size for LDV and SOF, and renal capacity for 
GS-331007) for the expected body weight range in children (3 to < 6 years of age), and the 
results of the relative bioavailability Phase 1 evaluation of LDV/SOF FDC oral granules 
(GS-US-337-2091), as presented in Figure 1-1 {Fanta 2007, Kearns 2003}. Based on this scaling 
approach, doses of LDV/SOF FDC oral granules (45 mg/ 200 mg) in children ≥17 kg and 
LDV/SOF FDC granules (33.75 mg/ 150 mg) in children < 17 kg are expected to achieve mean 
systemic exposures of LDV, SOF, and GS-331007 within the range of those observed in the 
Phase 2/3 population (Figure 1-1). Safety and PK data in children (3 to < 6 years of age) who 
enroll in the PK-Lead-in Phase will be evaluated to confirm the appropriateness of the dose for 
this age group.

LDVISOFFDC 
Protocol GS-US-337-1116 
Final 
Gilead Sciences, Inc. 
Amendment 6.0 
Figure 1-1. 
Predicted LDV, SOF, and GS-331007 AUCtau following 
administration ofLDV/SOF FDC 45 mg/ 200 mg or LDV/SOF FDC 
33.75 mg/ 150 mg (3 to< 6 years of age) 
~ 
Cl> 
iii 
u 
~ 
-!!!.e 
"1:: 
S.c: 
g •CI 
<(.S 
u. 
0 
5000 
150 mg SOF 
Predicted SOF exposure 
200 mg SOF 
(<17kg) 
(~17kg) 
•••••••••·t•·•••••••••••••••••••••••••••••••••••••••••• max 
I 
I 
95th%ile 
Q3 
median 
C/) 
1000 
Q1 
5th%ile 
500 
min 
20000 
10 12 14 161718 20 22 24 26 28 30 32 34 36 38 40 42 44 
weight (kg) 
o 
5th percentile 
o 
01 "' median 
v 
03 o 
95th percentile 
150 mg SOF 
Predicted GS-331007 exposure 
200 mg SOF 
• (-:=-J ?. ~9) .•................. ,(;::::,1.~ l<W •..•.........••.••• max 
95th %ile 
"=- 10000 
~ E 
Oo:: 
Q3 
median 
Q1 
::I.e 
<( • 
,... Cl 
o.S 
0 
5th %ile 
5000 
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • 
nlin 
10 12 14 161718 20 22 24 26 28 30 32 34 36 38 40 42 44 
weight (kg) 
o 
5th percentile 
o 
Q1 
6 
median 
v 
03 o 
95th percentile 
r-O-o 
~::r 
CJ)A> 
Olll 
"TIC!> 
CD~ 
0-o 
3 0 
ce-o 
-
c: 
~­
oA> 
oe. 
3 g 
cc 
CONFIDENTIAL 
Page 33 
08 Jtme 2017 

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
1.6. 
50000 
:0 '* 
10000 
(J ~ 
~"E 
:>1:: 
S.r:. 
gc, 
<.s 
Ei 
..J 
1000 
Predicted LDV exposure 
33.75 mg LDV 
45 mg LDV 
(<1 7 kg) 
(?!:17 kg) 
................ "'!"····· .•..........................................•............... 
10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 
weight (kg) 
o 
5th percentile 
o 
Q1 
" 
Q2 
v 
Q3 
<> 
95th percentile 
Overall Risk/Benefit Assessment 
max 
95th %lie 
Q3 
Q2 
Q1 
5th %lie 
min 
Final 
Amendment 6.0 
r-
O-o 
~:r 
C/)1» 
o"' 
.,co 
~~ 
CD W 
0"'0 
3 0 
(Q"O 
-
c 
..,._ 
Ol» 
0~ 
3 g 
e 
Although the majority of pediatric patients infected with HCV exhibit minimal hepatic sequelae 
despite active viral replication and inflammation, a subset of children and adolescents will 
require treatment. Studies suggest that 3 major categories of disease can occur within 10 years 
after putative HCV exposure: (1) undetectable viremia and n01mal ALT, (2) persistent yet 
uncomplicated mild liver disease, and (3) progression to end-stage liver disease {Bortolotti 
2008}. It is the last two groups of children in whom therapy may be indicated to prevent 
end-stage disease, either during childhood/adolescence or in early adulthood. 
Given that the cmTent SOC for the treatment of children infected with HCV is PEG and RBV 
and these regimens are long in duration, relatively toxic, and not well tolerated, there continues 
to be a need for new treatments for HCV that combine potent and sustained efficacy with 
improved tolerability and safety. 
The combination ofLDV plus SOF is anticipated to offer greater antiviral efficacy which could 
result in a sho1ter treatment duration and/or lead to a regimen without RBV or interferon. These 
in tum could result in reduction in adverse events. LDV /SOF FDC could also potentially be of 
benefit in patients who have failed prior treatment with SOF+/-RBV+/- PEG. 
If high rates of SVR can be obtained with sh01t, well-tolerated regimens, the anticipated 
improvements in safety and tolerability would offer a favorable risk-benefit dete1mination for 
individuals with chronic HCV-infection. 
CONFIDENTIAL 
Page 34 
08 Jtme 2017 

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
2. 
OBJECTIVES 
The prima1y objective of the PK Lead-in Phase of this study is: 
Final 
Amendment 6.0 
• 
To evaluate the steady state phrumacokinetics (PK) and confmn the dose ofLDV/SOF FDC 
in chronic HCV-infected pediatric subjects 
The secondruy objective of the PK Lead-in Phase of this study is: 
• 
To evaluate the safety, tolerability, and antiviral activity of 10 days of dosing ofLDV/SOF 
FDC in chronic HCV -infected pediatric subjects 
The primary objective of the Treatment Phase of this study is: 
• 
To evaluate the safety and tolerability ofLDV/SOF FDC +/- RBV for 12 or 24 weeks in 
chronic HCV -infected pediatric subjects 
The secondruy objectives of the Treatment Phase of this study ru·e: 
• 
To dete1mine the antiviral efficacy of 12 or 24 weeks ofLDV/SOF FDC +/- RBV treatment 
in chronic HCV-infected subjects (including the impact of HCV genotype, IL28B genotype, 
and prior treatment experience), as assessed by the prop01iion of subjects with SVR 
12 weeks after completion of treatment (SVR12) 
• 
To dete1mine the antiviral efficacy of 12 or 24 weeks ofLDV/SOF FDC +/- RBV treatment 
in chronic HCV-infected subjects, as assessed by the proportion of subjects with SVR 4 and 
24 weeks after completion of treatment (SVR4 and SVR24) 
• 
To evaluate the kinetics of circulating HCV RNA during treatment and after completion of 
treatment 
• 
To evaluate the emergence of viral resistance to LDV and SOF during treatment and after 
completion of treatment 
• 
To evaluate acceptability 
• 
assessed by swallowability of tablets and palatability of granules. 
• 
To evaluate the effect of growth and development on pediatric subjects during and after 
treatment 
The explorat01y objective of this study is: 
• 
PD 
CONFIDENTIAL 
Page 35 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 36
08 June 2017
3.
STUDY DESIGN
3.1.
Treatment Plan and Regimen
This is an open-label, multi-cohort, two-part study evaluating the PK, safety, and antiviral 
activity of LDV/SOF FDC +/- RBV in chronic HCV-infected pediatric subjects.
3.1.1.
PK Lead-in Phase
The PK Lead-in Phase will evaluate and/or confirm the age appropriate LDV/SOF FDC dose by 
analyzing PK, safety, and antiviral activity of LDV/SOF FDC through 10 days of dosing for each 
cohort. Children aged 3 to < 6 years, children aged 6 to < 12 years, and adolescents 
aged 12 to < 18 years with chronic HCV-infection and a HCV RNA ≥1000 IU/mL at study entry 
will be evaluated. Subjects must be treatment naïve without history of cirrhosis to participate in 
the PK Lead-in Phase. Three cohorts of at least 10 subjects each will be sequentially enrolled: 

Cohort 1: 12 to < 18 years old, weighing ≥45kg

Cohort 2: 6 to < 12 years old, weighing ≥ 17 kg and < 45 kg

Cohort 3: 3 to < 6 years old 
At least 4 subjects weighing ≥ 17 kg 
At least 4 subjects weighing < 17 kg
The study will start with Cohort 1. Subjects will receive LDV/SOF FDC (90 mg/ 400 mg 
adult tablet or 4 × 22.5 mg/100 mg tablets if determined necessary based on LDV/SOF FDC
swallowability assessment) for 10 days with intensive PK conducted on Day 10. 
Cohort 2: Subjects will receive LDV/SOF FDC 45 mg/ 200 mg (2 × 22.5 mg/ 100 mg tablets) for 
10 days with intensive PK conducted on Day 10.
Cohort 3: Subjects will receive LDV/SOF FDC oral granules; subjects weighing ≥17 kg will 
receive LDV/SOF FDC 45 mg/ 200 mg (4 × 11.25 mg/ 50 mg packets) and subjects weighing 
<17 kg will receive LDV/SOF FDC 33.75 mg/ 150 mg (3 × 11.25 mg/ 50 mg packets) for 
10 days with intensive PK assessments conducted on Day 10.
Subjects enrolled in the PK Lead-in Phase of each cohort (Cohorts 1, 2, and 3) will immediately 
enroll in the Treatment Phase as they complete Day 10 of PK Lead-in Phase. They will continue 
dosing with LDV/SOF FDC with no interruption of study drug administration. Subjects rolling 
over from the PK Lead-in Phase will not be required to perform the screening, Day 1, or Week 1 
visit of the Treatment Phase.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 37
08 June 2017
Figure 3-1.
PK Lead-in Phase Study Schema
3.1.2.
Treatment Phase
The Treatment Phase will be initiated sequentially by age group as defined in Cohort 1, 2, and 3 
of the PK Lead-in. Subjects who participated in PK Lead-in phase will immediately rollover into 
Treatment Phase with no interruption of study drug administration until the appropriateness of 
the dose has been confirmed by PK and safety results from the PK Lead-in. The first visit in the 
Treatment Phase for these subjects will be the Week 2 visit. Additional subjects will be enrolled 
in the Treatment Phase of each Cohort upon confirmation of the appropriateness of the dose from 
the PK Lead-in.
Children aged 3 to < 12 years (Group 2) and adolescents aged 12 to < 18 years (Group 1) with 
chronic HCV-infection and a HCV RNA ≥1000 IU/mL at study entry (those who were dosed in 
the PK Lead-in phase will have met this criteria prior to enrollment) will be evaluated.
Subjects enrolled in the Treatment Phase will receive the following regimen:
a) United Kingdom:

GT-1, GT-4, GT-5, & GT-6 treatment-naïve subjects with or without cirrhosis: LDV/SOF 
FDC for 12 weeks

GT-1, GT-4, GT-5, & GT-6 treatment-experienced subjects without cirrhosis: LDV/SOF 
FDC for 12 weeks

GT-1, GT-4, GT-5, & GT-6 treatment-experienced subjects with cirrhosis: LDV/SOF 
FDC for 24 weeks

GT-3 treatment-experienced subjects with or without cirrhosis: LDV/SOF FDC + RBV 
for 24 weeks

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 38
08 June 2017
b) United States/Australia/New Zealand:

GT-1 treatment-naïve subjects with or without cirrhosis: LDV/SOF FDC for 12 weeks

GT-1 treatment-experienced subjects without cirrhosis: LDV/SOF FDC for 12 weeks

GT-1 treatment-experienced subjects with cirrhosis: LDV/SOF FDC for 24 weeks

GT-4, GT-5, & GT-6 treatment-naïve or treatment-experienced subjects with or without 
cirrhosis: LDV/SOF FDC for 12 weeks
Table 3-1.
Subject Enrollment by HCV Genotype, Country, and Treatment 
Duration
GT-1
GT-3
GT-4, GT-5, & GT-6
Cirrhotic or 
Non-cirrhotic 
Subjects 
(TN)
Non-cirrhotic 
Subjects 
(TE)
Cirrhotic 
Subjects 
(TE)
Non-cirrhotic 
or Cirrhotic 
Subjects 
(TE)
Cirrhotic or 
Non-cirrhotic 
Subjects 
(TN)
Non-cirrhotic 
Subjects 
(TE)
Cirrhotic 
Subjects 
(TE)
United 
States
12 Weeks of 
treatment with 
LDV/SOF 
FDC
12 Weeks of 
treatment with 
LDV/SOF 
FDC
24 Weeks 
of treatment 
with 
LDV/SOF 
FDC
N/A
12 Weeks of 
treatment with 
LDV/SOF 
FDC
12 Weeks of 
treatment with 
LDV/SOF 
FDC
12 Weeks 
of treatment 
with 
LDV/SOF 
FDC
Australia
12 Weeks of 
treatment with 
LDV/SOF 
FDC
12 Weeks of 
treatment with 
LDV/SOF 
FDC
24 Weeks 
of treatment 
with 
LDV/SOF 
FDC
N/A
12 Weeks of 
treatment with 
LDV/SOF 
FDC
12 Weeks of 
treatment with 
LDV/SOF 
FDC
12 Weeks 
of treatment 
with 
LDV/SOF 
FDC
New 
Zealand
12 Weeks of 
treatment with 
LDV/SOF 
FDC
12 Weeks of 
treatment with 
LDV/SOF 
FDC
24 Weeks 
of treatment 
with 
LDV/SOF 
FDC
N/A
12 Weeks of 
treatment with 
LDV/SOF 
FDC
12 Weeks of 
treatment with 
LDV/SOF 
FDC
12 Weeks 
of treatment 
with 
LDV/SOF 
FDC
United 
Kingdom
12 Weeks of 
treatment with 
LDV/SOF 
FDC
12 Weeks of 
treatment with 
LDV/SOF 
FDC
24 Weeks 
of treatment 
with 
LDV/SOF 
FDC
24 Weeks of 
treatment with 
LDV/SOF 
FDC + RBV
12 Weeks of 
treatment with 
LDV/SOF 
FDC
12 Weeks of 
treatment with 
LDV/SOF 
FDC
24 Weeks 
of treatment 
with 
LDV/SOF 
FDC
TN = Treatment Naïve, TE = Treatment Experienced, N/A = Not Applicable
Subjects with GT -1, -3, and -4 were enrolled initially. GT-5 and GT-6 subjects will be included 
in those groups/cohorts actively enrolling subjects given confirmation of benefit:risk in adult 
patients has been obtained. If emerging LDV/SOF FDC data in GT-2 support treatment in adults,
pediatric subjects with GT-2 will be subsequently enrolled. 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 39
08 June 2017
The study will enroll both treatment naïve and treatment experienced pediatric subjects with up 
to 40 subjects allowed to be treatment experienced. Approximately 220 subjects, including 
subjects from the PK Lead-in Phase, will be enrolled in the Treatment Phase as follows:

Group 1: Approximately 100 adolescent subjects (12 to < 18 years of age)

Group 2: Approximately 120 pediatric subjects (3 to < 12 years of age)
The following definitions will be used for treatment experienced subjects:

Interferon intolerant: Subject who discontinued therapy (≤ 12 weeks total) due to ≥1 adverse 
event

Interferon non-responder: Subject who did not achieve undetectable HCV RNA levels while 
on treatment

Relapse/breakthrough: Subject who achieved undetectable HCV RNA during treatment or 
within 4 weeks of the end of treatment but did not achieve a sustained virologic response 
(SVR)
All subjects who do not attain SVR or have viral relapse will be encouraged to discuss treatment 
with SOC therapy with their healthcare provider.
3.2.
Visit Schedule
3.2.1.
PK Lead-in
Screening assessments will be completed within 28 days of the Day 1 visit. 
Study Visits will occur at Screening, Day 1, Day 3, and Day 10.
Subjects (at least 10 subjects per cohort) enrolled in the PK Lead-in Phase will participate in an 
intensive PK evaluation on Day 10. Subjects will be administered a dosing diary with 
instructions. 
Following completion of the Day 10 intensive PK visit, subjects will then return for scheduled 
study visits outlined in the Treatment Phase and continue dosing with LDV/SOF FDC with no 
interruption of study drug administration. Subjects rolling over from the PK Lead-in Phase will 
not be required to perform the screening, Day 1, or Week 1 visits of the Treatment Phase.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 40
08 June 2017
3.2.2.
Treatment Phase
Screening assessments will be completed within 28 days of the Day 1 visit. Subjects continuing 
from the PK Lead-in Phase will not be required to complete Screening, Day 1, and Week 1 visits 
of the Treatment Phase.

Subjects requiring 12 weeks of treatment: Study visits will occur at Screening, Day 1, and 
the end of weeks 1, 2, 4, 8, and 12.

Subjects requiring 24 weeks of treatment: Study visits will occur at Screening, Day 1, and 
the end of weeks 1, 2, 4, 8, 12, 16, 20, and 24.
All subjects will then return for follow-up visits at 4, 12, and 24 weeks after discontinuation of
therapy.
The total time to complete all study visits is approximately 40 or 52 weeks including:

28 day (4 week) screening period

12 or 24 week treatment period

24 week post-treatment period
The assessments performed at each visit are described in Section 6.
3.3.
Virologic Response-Based Stopping Criteria
HCV RNA will be unblinded to the Investigator and Sponsor.
The following on-treatment virologic response-based treatment stopping criteria will be utilized:

Confirmed HCV RNA ≥LLOQ after 2 consecutive HCV RNA <LLOQ

Confirmed >1 log10 increase from nadir 

HCV RNA ≥LLOQ through 8 weeks of treatment
Confirmation should be performed as soon as possible but within 2 weeks after determination of 
initial observation. Subjects that meet the virologic response-based stopping criteria above will 
be notified of their eligibility to participate in the Long-Term Follow-Up Study 
(GS-US-334-1113).

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
3.4. 
Treatment Discontinuations Criteria 
Final 
Amendment 6.0 
The Medical Monitor should be consulted prior to subject discontinuation when medically 
feasible. Study medication must be discontinued in the following instances: 
• 
Unacceptable toxicity (as defmed in Section 7) or toxicity that, in the judgment of the 
investigator, compromises the ability to continue study-specific procedures or is considered 
to not be in the subject's best interest. 
• 
Pregnancy of female subject or female partner of male subject. 
• 
Efficacy failure as defmed in Section 3.3. 
• 
Significant protocol violation including non-compliance with study assessments. 
• 
Subject request to discontinue for any reason; it is imp01tant to detennine whether the 
withdrawal of consent is primarily due to an AE, lack of efficacy, or other reason. 
• 
Discontinuation of the study at the request of Gilead, regulat01y agency, or an Institutional 
Review Board (IRB)/Independent Ethics Committee (IEC). 
3.5. 
Discontinuations 
Subjects discontinuing treatment prior to completion of the assigned dosing period should 
complete an Early Tennination visit as described in the Section 6.4.9. 
Subjects who pennanently discontinue the study dmg for any reason including safety and/or 
tolerability concems prior to completion of the assigned dosing period will be followed 
according to the post-u·eatment study assessments described in Section 6.5. 
3.6. 
Optional Intensive Pharmacokinetics Substudy 
PD 
3.7. 
Pharmacogenomics Substudy 
CONFIDENTIAL 
Page41 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 42
08 June 2017
3.8.
Long-Term Follow-Up
All subjects (those who do or do not attain SVR24) who do not initiate other experimental or 
approved anti-HCV therapy will be followed every 6 months for the first 2 years followed by 
every 12 months for assessments of growth, quality of life, and long-term viral suppression (if 
applicable) in a separate protocol (GS-US-334-1113). This follow-up study will continue for 5 
years.
3.9.
Breakthrough Futility Assessment
A futility assessment will be performed after the first 10 subjects complete Week 8 on study or 
have viral breakthrough at or prior to Week 8. If 3 or more of the first 10 subjects enrolled have 
viral breakthrough at or prior to Week 8 or are non-responders (HCV RNA > LLOQ through 
8 weeks of treatment) then further enrollment of subjects will be suspended. Virologic 
breakthrough is defined as confirmed HCV RNA > LLOQ while on treatment after 
two consecutive visits with HCV RNA < LLOQ.
If a holding rule has been met and following an internal safety review it is deemed appropriate to 
restart enrollment, a request to restart enrollment with pertinent data will be submitted to the 
appropriate regulatory agencies. Enrollment will only resume after review by the appropriate 
regulatory agencies. Any subject on treatment when a holding rule has been met will be allowed 
to continue to treatment.
Subjects with known or suspected study drug non-adherence will not be considered to meet the 
definition of virologic breakthrough, relapse, or non-responder. 
3.10.
Reconsent
When a subject reaches the age of consent in their country/region, they will be invited to consent 
as an adult to allow them to continue participating in the clinical trial.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 43
08 June 2017
4.
SUBJECT POPULATION
4.1.
Number of Subjects and Subject Selection
Approximately 220 subjects will be enrolled in this study.
In order to manage the total study enrollment, Gilead Sciences, Inc. at its sole discretion, may 
suspend screening and/or discontinue the enrollment at any site at any time (upon written notice 
to the site). Discontinuation of the enrollment phase may result in the immediate ineligibility of 
all subjects screened but not yet enrolled, regardless of the progress or outcome of the screening 
assessments performed.
4.2.
Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for participation in this 
study.
1) Parent or legal guardian able to provide written informed consent prior to any screening 
evaluations and willing to comply with study requirements. Subjects will provide assent if 
possible.
2) 3 years to < 18 years of age as determined at Day 1 (consent of parent or legal guardian 
required)
3) PK Lead-in phase only: subjects in Cohort 1 (age 12 to <18 years of age) must weigh 45 kg
4) PK Lead-in phase only: subjects in Cohort 2 (age 6 to <12 years of age) must weigh 17 kg
and < 45 kg
5) PK Lead-in phase only: all subjects must be treatment naïve: no prior exposure to any IFN, 
RBV, or other approved or experimental HCV-specific DAA agent
6) Treatment experienced subjects: prior treatment failure to a regimen including interferon 
either with or without RBV that was completed at least 8 weeks prior to Day 1.
i)
Interferon intolerant: Subject who discontinued therapy (≤ 12 weeks total) due to 
≥1 adverse event
ii) Interferon non-responder: Subject who did not achieve undetectable HCV RNA levels 
while on treatment
iii) Relapse/breakthrough: Subject who achieved undetectable HCV RNA during treatment 
or within 4 weeks of the end of treatment but did not achieve a sustained virologic 
response (SVR)

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 44
08 June 2017
7) Chronic HCV-infection documented by either:
a) a positive anti-HCV antibody test or positive HCV RNA or positive HCV genotyping test 
at least 6 months prior to the Day 1 visit, or
b) a liver biopsy performed prior to the Day 1 visit with evidence of chronic HCV-infection
8) Infection with HCV as determined at Screening:
a) United Kingdom Only: As of Protocol Amendment 4.0, the study is enrolling GT-1, -3, 
-4, -5, and -6 HCV-infected pediatric subjects and will subsequently enroll subjects with 
GT-2 once adult data is available, if appropriate.
b) United States/ Australia/ New Zealand Only: As of Protocol Amendment 4.0, the study is 
enrolling GT-1, -4, -5, and -6 HCV-infected pediatric subjects and will subsequently 
enroll subjects with GT-2 once adult data is available, if appropriate.
9) HCV RNA ≥1000 IU/mL at Screening
10) Adequate hematologic function (absolute neutrophil count 1,500/mm3; 
hemoglobin 11 g/dL or 12 g/dL for GT-3 males only).
11) Negative serum -HCG pregnancy test (for females of childbearing potential only, as defined 
in Appendix 5)
12) Subject able to provide written assent, if they have the ability to read and write, as 
determined by IRB/IEC/local requirements and Investigator’s discretion
4.3.
Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.
1) Pregnant or lactating subjects
2) Sexually-active males or females of childbearing potential who are not willing to use an 
effective method of contraception during the study (see Appendix 5 for further details)
3) Treatment-naïve subjects with GT-3 HCV infection as determined at Screening. Treatment 
naïve is define by no prior exposure to any IFN, RBV, or other approved or experimental 
HCV-specific DAA agent
4) Decompensated liver disease defined as INR 1.2 ULN, platelets 50,000/mm3, serum 
albumin 3.5 g/dL, or prior history of clinical hepatic decompensation (e.g., ascites, 
jaundice, encephalopathy, variceal hemorrhage)
5) Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson’s disease, 
alpha-1 antitrypsin deficiency)

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 45
08 June 2017
6) -fetoprotein 50 ng/mL
7) Serum creatinine > 1.5 mg/dL
8) Estimated glomerular filtration rate 90 mL/min/1.73m2, as calculated by the Schwartz 
Formula
9) Evidence of hepatocellular carcinoma (HCC) or other malignancy (with the exception of 
certain resolved skin cancers)
10) Co-infection with HIV, acute HAV, or HBV (i.e. Hepatitis B Surface Ag positive at 
screening)
11) Significant cardiovascular, pulmonary, or neurological disease
12) Evidence of a gastrointestinal malabsorption syndrome that may interfere with absorption of 
orally administered medications
13) History of solid organ or bone marrow transplantation
14) Chronic daily non-steroidal anti-inflammatory drug therapy
15) Systemic corticosteroid use for > 2 weeks (pulmonary/nasal administration is permitted)
16) Investigational agents taken within the past 28 days (except with the expressed approval of 
the Sponsor)
17) Clinically-relevant alcohol or drug abuse within 12 months of screening. A positive drug 
screen will exclude subjects unless it can be explained by a prescribed medication; the 
diagnosis and prescription must be approved by the investigator
18) Known hypersensitivity to the study drug, the metabolites, or formulation excipients
19) Any other condition (including alcohol or substance abuse) or prior therapy that, in the 
opinion of the Investigator, would make the subject unsuitable for the study or unable to 
comply with dosing requirements
20) Use of any prohibited concomitant medications as described in Section 5.6
21) PK Lead-in phase only: subjects with history of cirrhosis (as determined by liver biopsy)
22) Psychiatric hospitalization, suicide attempt, and/or a period of disability as a result of their 
psychiatric illness within the last 5 years. Subjects with psychiatric illness (without the prior 
mentioned conditions) that is well-controlled on a stable treatment regimen for at least 
12 months prior to enrollment or has not required medication in the last 12 months may be 
included.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 46
08 June 2017
5.
INVESTIGATIONAL MEDICINAL PRODUCTS
5.1.
Randomization and Blinding
Not applicable.
5.2.
Ledipasvir/Sofosbuvir Fixed-Dose Combination
5.2.1.
Description and Handling 
5.2.1.1.
Formulations
5.2.1.1.1.
LDV/SOF FDC 90 mg/ 400 mg tablets
LDV/SOF FDC 90 mg/400 mg tablets are orange, diamond-shaped, film-coated tablets 
containing 90 mg of LDV and 400 mg of SOF. The tablets are debossed with “GSI” on one side 
and “7985” on the other side. The LDV/SOF FDC tablets contain the following inactive 
ingredients: lactose monohydrate, copovidone, microcrystalline cellulose, croscarmellose 
sodium, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, titanium dioxide, talc, 
polyethylene glycol, FD&C yellow # 6 /sunset yellow FCF aluminum lake.
Placebo to match LDV/SOF FDC 90 mg/ 400 mg tablets for the Swallowability Assessment are 
orange, diamond-shaped, film-coated tablets debossed with “GSI” on one side and “7985” on the 
other side. The tablets contain lactose monohydrate, copovidone, microcrystalline cellulose, 
croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, talc, 
polyethylene glycol, FD&C yellow # 6 /sunset yellow FCF aluminum lake.
5.2.1.1.2.
LDV/SOF FDC 22.5 mg/ 100 mg tablets 
Age-appropriate formulations of LDV/SOF FDC have been developed for subjects who are 
unable to swallow the LDV/SOF FDC 90 mg/ 400 mg tablets which include a lower dose 
strength tablet (LDV/SOF FDC 22.5 mg/100 mg) formulation. LDV/SOF FDC lower dose 
strength tablets are round, plain-faced, white film-coated tablets containing 22.5 mg of LDV and 
100 mg of SOF. The LDV/SOF FDC lower dose strength tablets contain the following inactive 
ingredients: lactose monohydrate, copovidone, microcrystalline cellulose, croscarmellose 
sodium, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, titanium dioxide, talc,
and polyethylene glycol.
Placebo to match LDV/SOF FDC 22.5 mg/ 100 mg tablets for the Swallowability Assessment 
are round, plain-faced, white film-coated tablets. The placebo tablets contain the following 
inactive ingredients: lactose monohydrate, copovidone, microcrystalline cellulose, 
croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, talc and 
polyethylene glycol.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 47
08 June 2017
5.2.1.1.3.
LDV/SOF FDC Oral Granules
The LDV/SOF FDC oral granules 11.25 mg/ 50 mg are orange, round, film-coated granules. The 
LDV/SOF FDC oral granules contain the following inactive ingredients: lactose monohydrate, 
copovidone, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, 
magnesium stearate, hypromellose, talc, polyethylene glycol, titanium dioxide, iron oxide 
yellow, iron oxide red, and amino methacrylate copolymer.
5.2.1.2.
Packaging and Labeling
5.2.1.2.1.
LDV/SOF FDC 90 mg/ 400 mg tablets
LDV/ SOF FDC 90 mg/ 400 mg tablets are packaged in white, high density polyethylene 
(HDPE) bottles. Each bottle contains 28 or 30 tablets, a silica gel desiccant, and polyester 
packing material. Each bottle is enclosed with a white, continuous thread, child resistant screw 
cap with an induction-sealed, aluminum faced liner.
Placebo tablets to match LDV/SOF FDC 90 mg/ 400 mg tablets for the Swallowability 
Assessment are packaged in white, high density polyethylene (HDPE) bottles. Each bottle 
contains 30 tablets, a silica gel desiccant and polyester packing material. Each bottle is enclosed 
with a white, continuous thread, child resistant screw cap with an induction-sealed, aluminum 
faced liner.
5.2.1.2.2.
LDV/SOF FDC 22.5 mg/ 100 mg tablets
LDV/SOF FDC 22.5 mg/ 100 mg tablets are packaged in white, high density polyethylene 
(HDPE) bottles. Each bottle contains 30 tablets, a silica gel desiccant, and polyester packing 
material. Each bottle is enclosed with a white, continuous thread, child resistant screw cap with 
an induction-sealed, aluminum faced liner.
Placebo tablets to match LDV/SOF FDC 22.5 mg/ 100 mg tablets for Swallowability Assessment 
are packaged in white, high density polyethylene (HDPE) bottles. Each bottle contains 30 tablets, 
a silica gel desiccant and polyester packing material. Each bottle is enclosed with a white, 
continuous thread, child resistant screw cap with an induction-sealed, aluminum faced liner.
5.2.1.2.3.
LDV/SOF FDC oral granules
The LDV/SOF FDC 11.25 mg/ 50 mg oral granules are packaged in aluminum foil packets. A 
prespecified number of packets will be packaged into cartons for dispensation to subjects at 
clinical sites.
All LDV/SOF FDC tablets, oral granules, and placebo to match LDV/SOF FDC bottles to be 
distributed in the US, EU, and the rest of the countries shall be labeled to meet all applicable 
requirements of the US Food and Drug Administration (FDA), Annex 13 of Good Manufacturing 
Practices: Manufacture of investigational medicinal products (February 2010), and/or other local 
regulations as applicable.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 48
08 June 2017
5.2.2.
Storage and Handling
LDV/ SOF FDC 90 mg/ 400 mg tablets, 22.5 mg/ 100 mg tablets, and 11.25 mg/ 50 mg packets
should be stored at controlled room temperature until required for administration. Controlled 
room temperature is defined as 25 °C (77 °F); excursions are permitted between 15 °C and 30 °C 
(59 °F to 86 °F).
Placebo to match LDV/SOF FDC tablets, 90 mg/ 400 mg, and 22.5 mg/ 100 mg, for the 
Swallowability Assessment should be stored at controlled room temperature until required for 
administration. Controlled room temperature is defined as 25 °C (77 °F); excursions are 
permitted between 15 °C and 30 °C (59 °F to 86 °F). 
All drug products should be stored in a securely locked area, accessible only to authorized site 
personnel. To ensure the stability of the Investigational Medicinal Product (IMP) and to ensure 
proper product identification, the drug product should not be stored in a container other than the 
container in which they are supplied. Consideration should be given to handling, preparation, and 
disposal through measures that minimize drug contact with the body. Appropriate precautions 
should be followed to avoid direct eye contact or exposure through inhalation when handling 
LDV/SOF FDC.
Sufficient quantities of LDV/SOF FDC tablets, oral granule packets, and placebo tablets will be 
shipped to the investigator or qualified designee from Gilead Sciences (or its designee).
5.2.3.
Dosage and Administration of LDV/SOF FDC
PK Lead-in Phase: 
Cohort 1: LDV/SOF FDC 90 mg/ 400 mg tablets will be administered once daily with or without 
food. Subjects determined unable to swallow the placebo to match the 90 mg/ 400 mg LDV/SOF 
FDC tablet (via LDV/SOF FDC Placebo Swallowability Assessment at Screening up to Day 1) 
will be re-assigned to 4 × 22.5 mg/ 100 mg tablets daily. Subjects who weigh < 45 kg will be 
excluded.
Cohort 2: LDV/SOF FDC 2 × 22.5 mg/ 100 mg tablets will be administered once daily with or 
without food. Subjects must weigh ≥ 17 kg and < 45 kg.
Cohort 3: LDV/SOF FDC oral granules 45 mg/ 200 mg (4 × 11.25 mg/ 50 mg packets) will be 
administered once daily with or without food for subjects weighing ≥17kg. LDV/SOF FDC oral
granules 33.75 mg/ 150 mg (3 x 11.25 mg/ 50 mg packets) will be administered once daily with 
or without food for subjects weighing <17 kg.
Intensive PK and safety results from the PK Lead-in Phase of each cohort will be reviewed to 
confirm the appropriateness of the evaluated LDV/SOF FDC dose for the Treatment Phase of 
that cohort as well as to determine the age-appropriate dose to be evaluated in the PK Lead-in
phase of the next cohort.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 49
08 June 2017
Treatment Phase: Subjects who participated in the PK Lead-in Phase of each cohort will continue 
in the Treatment Phase with no interruption of study drug administration until the 
appropriateness of the dose is confirmed by PK and safety data from the PK-Lead-in Phase. 
Additional subjects will be enrolled in the Treatment Phase of each cohort upon confirmation of 
the appropriateness of the dose. 
Subjects should be instructed that if vomiting occurs within 5 hours of dosing an additional tablet 
should be taken. If vomiting occurs more than 5 hours after dosing, no further dose is needed.
If a dose is missed and it is within 18 hours of the normal time, subjects should be instructed to 
take the tablet as soon as possible and then subjects should take the next dose at the usual time. If 
it is after 18 hours then subjects should be instructed to wait and take the next dose at the usual 
time. Subjects should be instructed not to take a double dose.
5.3.
Ribavirin (GT-3 Subjects Only)
5.3.1.
Description and Handling of RBV
5.3.1.1.
Formulation
REBETOL capsules consist of a white powder in a white, opaque, gelatin capsule. Each capsule 
contains 200 mg ribavirin and the inactive ingredients microcrystalline cellulose, lactose 
monohydrate (40 mg), croscarmellose sodium, and magnesium stearate. The capsule shell 
contains gelatin, titanium dioxide. The capsule shell imprint contains shellac, propylene glycol, 
ammonium hydroxide, coloring agent (E 132).The hard capsule is imprinted with blue ink.
REBETOL RBV Oral Solution 40 mg per mL is a clear, colorless to pale or light yellow bubble 
gum-flavored liquid. In addition to the active ingredient, RBV oral solution contains the 
following inactive ingredients: sucrose, glycerin, sorbitol, propylene glycol, sodium citrate, citric 
acid, sodium benzoate, natural and artificial flavor for bubble gum #15864, and water.
5.3.1.2.
Packaging and Labeling
The RBV capsules are packaged in blisters. Each blister card contains 20 capsules and seven 
cards (140 capsules) per carton.
The RBV oral solution is packaged in 4-oz amber glass bottles (100 mL/bottle) with 
child-resistant closures.
RBV capsules and oral solution to be distributed to centers in the US, EU and the rest of the 
countries shall be labeled to meet all applicable requirements of the US Food and Drug 
Administration (FDA) and Annex 13 of Good Manufacturing Practices: Manufacture of 
investigational medicinal products (February 2010) and/or other local regulations as applicable.
5.3.1.3.
Storage and Handling
RBV capsules should not be stored above 30C (86 F).
RBV oral solution should not be stored above 30°C (86°F).

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 50
08 June 2017
5.3.2.
Dosage and Administration of RBV (GT-3 Subjects Only)
RBV dose will be administered by weight as follows:
Body Weight kg (lbs.)
RBV Daily Dose
RBV Number of Capsules
<47 (<103)
15 mg/kg/day
Use Oral Solution. Divided dose in the morning and evening.
47-49 (103-108)
600 mg/day
1 × 200-mg capsules A.M.
2 × 200-mg capsules P.M.
50-65  (110 – 143)
800 mg/day
2 × 200-mg capsules A.M.
2 × 200-mg capsules P.M.
66-80 (145 – 176)
1000 mg/day
2 × 200-mg capsules A.M.
3 × 200-mg capsules P.M.
81-105 (178-231)
1200 mg/day
3 × 200-mg capsules A.M.
3 × 200-mg capsules P.M.
>105 (>231)
1400 mg/day
3 × 200-mg capsules A.M.
4 × 200-mg capsules P.M.
*
Note: Subjects with a body weight greater than or equal to 47 kg may utilize the RBV oral solution if necessary.
The morning dose of RBV will be taken with food and LDV/SOF FDC. The evening dose of 
RBV will be taken with food.
RBV will be supplied by Gilead Sciences for all subjects.
5.4.
Co-administration of LDV/SOF FDC and RBV (GT-3 Subjects Only)
In the Treatment Phase of the study, each subject will be given instructions to maintain 
approximately the same daily dosing interval between study drug doses.
For morning doses, subjects will be instructed to take study drugs as follows:

LDV/SOF FDC

Weight-based RBV (as per Section 5.3.2).
For evening doses, subjects will be instructed to take study drug as follows:

Weight-based RBV (as per Section 5.3.2).
If a subject forgets to take the study medication at the correct time, it may be taken later in the 
day; however, no more than the protocol specified dose of LDV/SOF FDC should be taken on 
any calendar day. The subject should resume the standing dosing schedule on the next day. Study 
medications should not be cut or split. 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 51
08 June 2017
5.5.
Study Drug Compliance
Subjects will be instructed to return any unused LDV/SOF FDC and/or RBV in the original 
container on Day 3 (PK Lead-in), Day 10 (PK Lead-in), and/or at study treatment visits every 
4 weeks (Treatment Phase). 
Returned medication will be reconciled by the investigator in order to monitor the subject’s 
compliance with the medication regimen.
5.6.
Prior and Concomitant Medications
Concomitant medications taken within 30 days prior to screening, up to and including 30 days 
after the last dose of study drug, need to be recorded in the source documents and electronic case 
report form(s) (eCRFs).
The following medications are prohibited during the screening period and for a minimum of 
28 days prior to the Day 1 visit through the end of treatment:

Hematologic stimulating agents (e.g., erythropoiesis-stimulating agents (ESAs); granulocyte 
colony stimulating factor (GCSF); thrombopoietin (TPO) mimetics)

Chronic use of systemic immunosuppressants including, but not limited to, corticosteroids 
(prednisone equivalent of > 10 mg/day for > 2 weeks), azathioprine, or monoclonal 
antibodies (e.g., infliximab)

Investigational agents or devices for any indication

Drugs disallowed per prescribing information of REBETOL® for GT-3 subjects only
Concomitant use of certain medications or herbal/natural supplements (inhibitors or inducers of 
drug transporters i.e., P-gp) with study drug(s) may result in PK interactions resulting in 
increases or decreases in exposure of study drug(s). Examples of representative medications 
which are prohibited from 21 days prior to Day 1 through the end of treatment are listed 
below (Table 5-1). In addition, the use of amiodarone is prohibited from 60 days prior to 
Baseline/Day 1 through the end of treatment.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 52
08 June 2017
Table 5-1.
Disallowed and Concomitant Medications to be Used with Caution
Drug Class
Agents Disallowed
Use with Caution
Acid Reducing Agentsa
Proton- Pump Inhibitors, H2-Receptor 
Antagonists, Antacids
Anticonvulsantsc
Phenobarbital, Phenytoin, Carbamazepine, 
Oxcarbazepine
Antimycobacterialsc
Rifabutin, Rifapentine, Rifampin
Cardiac Medications
Amiodaronee
Digoxinb, Dabigatranb
Herbal/Natural 
Supplementsc
St. John’s Wort, Echinacea, Milk thistle 
(i.e., silymarin), Chinese herb sho-saiko-to 
(or Xiao-Shai-Hu-Tang)
HMG-CoA Reductase 
Inhibitorsd
Rosuvastatin
Atorvastatin, Simvastatin, Pravastatin, 
Pitavastatin, Fluvastatin, Lovastatin
a
It is recommended to separate antacid and LDV/SOF FDC administration by 4 hours. H2-receptor antagonists may be 
administered simultaneously with or staggered from LDV/SOF FDC at a dose that does not exceed doses comparable to
famotidine 40 mg twice daily. Proton-pump inhibitor doses comparable to omeprazole 20 mg can be administered 
simultaneously with LDV/SOF FDC or up to 2 hours after taking LDV/SOF FDC. Proton-pump inhibitors should not be 
taken before LDV/SOF FDC. 
b
May result in an increase in the concentration of study drug and/or concomitant medications. Co-administration of 
LDV/SOF FDC with digoxin or dabigatran may increase the concentration of digoxin or dabigatran. Caution is warranted 
and therapeutic concentration monitoring of digoxin or clinical monitoring of dabigatran is recommended when 
co-administered with LDV/SOF FDC. 
c
May result in a decrease in the concentrations of study drug.
d
Use with study drug may result in an increase in the concentration of the HMG-CoA Reductase Inhibitors. Monitor for signs 
and symptoms of muscle weakness or myopathy, including rhabdomyolysis.
e
May result in symptomatic bradycardia. Mechanism is not currently known. The use of amiodarone is prohibited from 
60 days prior to Baseline/Day 1 through the end of treatment.
Medications for disease conditions excluded from the protocol (e.g., active cancer, 
transplantation) are not listed under this Concomitant Medication section and are disallowed in 
the study.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 53
08 June 2017
6.
STUDY PROCEDURES
All subjects will complete screening, on-treatment, and post-treatment assessments. Screening 
assessments will be completed within 28 days of the Day 1 visit. The end of study will occur at 
the 24-week Post-Treatment visit. The schedule of assessments is described below. 
Information on the specific laboratory parameters to be measured and clinical assessments to be 
performed are provided in Section 6.6.
6.1.
Subject Enrollment 
Each candidate’s parent or legal guardian must sign an Informed Consent Form prior to the
conduct of any screening procedures. Each study candidate who has the ability to read and write
must sign an Assent Form, as required by IRB/IEC/local requirements, prior to the conduct of 
any study procedures. Screening evaluations will be used to determine the eligibility of each 
candidate for study enrollment. Candidates who fail to meet eligibility criteria by screening 
evaluations may be re-screened once ≥ 30 days after the initial screen if there is a reasonable 
expectation that the candidate will be eligible after repeat screening.
6.2.
Screening Assessments
6.2.1.
Screening Visit (Day –28 to Day 0)
Subjects will complete all screening assessments within 28 days of the Day 1 visit. The screening 
window can be extended to 42 days for subjects requiring additional HCV GT testing or for 
extenuating circumstances.
The following procedures will be performed and documented:

Written informed consent from parent or legal guardian and assent from subject, if applicable 
(see above)

Medical history, including:
Hepatitis C history
Hepatitis C treatment history
Family history (including height of parents, if known)
Liver biopsy results (if available)

Complete physical examination 

Vital signs (temperature, blood pressure, pulse, respiratory rate) and body weight and height

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 54
08 June 2017

Obtain blood samples for tests as listed in Section 6.6.1:
Hematology
Chemistry
Coagulation tests
HCV RNA
Determination of HCV viral GT and subtype
HCV antibody, HIV 1/2 antibody, HBV surface antigen (HBsAg), HBV surface antibody 
(HBsAb), HBV core antibody (HBcAb), and HAV antibody
HbA1c
TSH
IL28B
Serum -hCG pregnancy test for females of childbearing potential only
Alpha fetoprotein (AFP)
Alpha-1 anti-trypsin (ATT)

Obtain urine sample for:
Urinalysis
Urine Drug Screen

Review of concomitant medications

Ask subject and/or parent/legal guardian if the subject is able to swallow and tolerate taking 
pills.

Review of all inclusion and exclusion criteria

Perform LDV/SOF FDC swallowability assessment, as applicable 
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic for the Day 1 visit assessments.

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
6.3. 
PK Lead-in: Treatment Assessments 
6.3.1. 
Day l 
Final 
Amendment 6.0 
After confnmation of eligibility has been evaluated, the following tests and procedmes must be 
completed prior to emollment and dosing/dispensing on Day 1: 
• 
Perf01m complete physical examination 
• 
Tanner Pubertal Stage Assessment 
• 
Vital signs, including body weight and height measmements 
• 
A single X-ray of the left wrist, hand, and fingers for Bone Age Assessment 
• 
Assessment of AEs and concomitant medications 
• 
Pregnancy prevention counseling including partner pregnancy prevention for male 
pruiicipants (all subj ects ~ 12 yeru·s of age and subjects < 12 yeru·s of age at the discretion of 
the Investigator based on subject's pube1ial status) 
• 
Obtain blood samples for: 
-
Hematology 
-
Chemistiy 
-
Coagulation tests 
-
HCVRNA 
-
Viral sequencing (ru·chive) 
-
HBV DNA testing for subjects HBcAb positive at Screening 
_ 
PD 
• 
Obtain mine samples for the following procedmes: 
-
Urinalysis 
-
~-hCG pregnancy test for females of childberu·ing potential only 
• 
Subject completes quality of life smvey: Subject is to review questionnaire with a 
pru·ent/guru·dian and write/mru·k answers directly onto the questionnaire. 
CONFIDENTIAL 
Page 55 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 56
08 June 2017
6.3.1.1.
Drug Administration

Dispense study drug(s) as directed by the IWRS

Instruct the subject on the packaging, storage and administration of study drug

Perform LDV/SOF FDC swallowability assessment (for subjects administered LDV/SOF 
FDC in tablet form only if not previously completed at screening). Observe the subject taking 
the first dose of study drug (with or without food) and record the time of first dose

Subjects will be administered a dosing diary with instructions.
6.3.2.
Day 3
The following procedures/assessments are to be completed on Day 3:

Perform a symptom-directed physical examination as needed

Vital signs, including body weight and height

Assessment of AEs and concomitant medications

Review medication compliance with subject and/or subject’s parent/guardian

Obtain blood samples for:
Hematology
Chemistry
HCV RNA
Viral sequencing (archive)

Review subject dosing diary
6.3.3.
Day 10 – Intensive PK
The Day 10 Intensive PK visit should occur on the protocol-specified visit date based on the 
Day 1 visit. For the purposes of scheduling, the Day 10 Intensive PK visit may 
be performed within +3 days of the protocol-specified visit date (subjects will continue 
daily dosing through the Intensive PK Visit).
Subjects should come in a fasted state for the Day 10 Intensive PK visit (i.e., no food or drink 
except water at least 8 hours prior to the Day 10 Intensive PK visit). Subjects and/or 
parents/guardians should be instructed that the Day 10 dose of LDV/SOF FDC must not be taken 
until the evaluations listed below are completed. 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 57
08 June 2017
If the subject has already dosed prior to the Day 10 clinic visit or is not in a fasted state, the 
Day 10 intensive PK assessments must not be completed. The subject and/or parents/guardians 
should be instructed to return in a fasted state within 3 days (Days 11, 12, or 13) for the intensive 
PK visit. 
If dosing non-compliance is identified as per subject dosing diary and study drug count on or 
prior to the Day 10 visit, the Day 10 intensive PK assessments must not be completed. The 
subject and/or parents/guardians should be counseled regarding proper dosing and be scheduled 
to return for the Day 10 intensive PK visit no sooner than 3 days following compliant dosing and 
no later than Day 14 (i.e., return on Day 13 or Day 14). If dosing non-compliance is due to an 
AE, consultation with the Gilead Medical Monitor is required regarding the potential of 
rescheduling the Day 10 intensive PK visit.
In both scenarios described above, the subject and/or parents/guardians should be reminded not 
to take the LDV/SOF FDC prior to arriving at the clinic on the day of the re-scheduled intensive 
PK visit. All Day 10 intensive PK assessments listed below should be completed when the 
subject returns.
The following evaluations are to be completed at the Day 10 Intensive PK visit:

Perform a symptom-directed physical examination 

Vital signs, including body weight and height

Assessment of AEs and concomitant medications

Perform study drug accountability 

Review Subject Dosing Diary

Review medication compliance with subject and/or parent/guardian.

Obtain urine samples for the following procedures:
Urinalysis
Urine pregnancy test (females of childbearing potential only). If the urine pregnancy test 
is positive, the Intensive PK sampling will not be completed. The positive result will be 
confirmed with a serum pregnancy test. 

Obtain blood samples for the following laboratory analyses:
Hematology 
Chemistry 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 58
08 June 2017
Coagulation tests
HCV RNA
Viral sequencing (archive)

Perform intensive PK sampling: 
Blood samples will be collected at 0 (predose, ≤30 minutes prior to dosing). After 
collection of the predose sample, subjects will be provided a standardized meal. Within 
5 minutes after consuming the standardized meal, subjects will be dosed with 
LDV/SOF FDC per dosing requirements.
Post-dose blood samples will be collected as follows: 
■
For Cohorts 1 and 2: 0.5, 1, 2, 3, 4, 5, 8, and 12 hours post-dose (with predose also 
serving as t= 24).
■
For Cohort 3 only: 0.5, 2, 4, 8, and 12 hours post-dose (with predose also serving as 
t = 24).
Subjects will be restricted from food intake until after collection of the 4-hour post dose 
blood sample, except for subjects in Cohort 3. Please also refer to the PK manual for 
details about standardized meals and PK sample processing instructions.
After completing the Day 10 intensive PK visit subjects will then continue to the Week 2 visit in 
Treatment Phase (described in Section 6.4.2) with no interruption in dosing.
6.4.
Treatment Phase: Treatment Assessments 
6.4.1.
Day 1
After confirmation of eligibility has been evaluated, the following tests and procedures must be 
completed prior to enrollment and dosing/dispensing on Day 1:

Perform complete physical examination

Tanner Pubertal Stage Assessment

Vital signs, including body weight and height measurements 

A single X-ray of the left wrist, hand, and fingers for Bone Age Assessment

Review of AEs and concomitant medications

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
Final 
Amendment 6.0 
• 
Pregnancy prevention counseling including partner pregnancy prevention for male 
pmiicipants (all subj ects ~ 12 years of age and subjects < 12 yem·s of age at the discretion of 
the Investigator based on subject's pubertal status). 
• 
Obtain blood samples for: 
-
Hematology 
-
Chemistiy 
-
Coagulation tests 
-
HCVRNA 
-
Viral sequencing (m·chive) 
-
HBV DNA testing for subjects HBcAb positive at Screening 
_ 
PD 
• 
Obtain urine sample for: 
-
Urinalysis 
-
~ -hCG pregnancy test for females of childbem·ing potential only 
• 
Subject completes quality of life survey: Subject is to review questionnaire with a 
parent/guardian and write/mm·k answers directly onto the questionnaire 
• 
Perf01m LDV/SOF FDC swallowability assessment (for subjects administered 
LDV /SOF FDC in tablet f01m only if not previously completed at screening) 
• 
Perf01m LDV/SOF FDC oral granules palatability assessment, for Treatinent Group 2 
subjects from 3 to < 6 years of age, as applicable. 
6.4.1.1. 
Dmg Adminisu·ation 
• 
Dispense study dmg as directed by the IWRS 
• 
GT-3 subjects only: Instiuct the subject on the appropriate RBV dose after weight-based 
dosage is calculated using Day 1 weight 
• 
Instiuct the subject on the packaging, storage, and adminisu·ation of study dmg 
• 
Observe the subject taking the first dose of study dmg (with or without food) and record the 
time of fust dose 
CONFIDENTIAL 
Page 59 
08 Jnne 2017 

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
6.4.2. 
Weeks 1 and 2 (± 3 days) 
Final 
Amendment 6.0 
Subjects who patticipated in the PK Lead-in phase will strut study visits in the Treatment Phase 
at Week 2. The following procedures/assessments are to be completed at these visits: 
• 
Vital signs, including body weight and height measurements 
• 
Perf01m symptom-directed physical examination 
• 
Assessment of AEs and concomitant medications 
• 
Obtain blood samples for: 
-
Hematology 
-
Chemistiy 
-
Coagulation tests 
-
HCVRNA 
-
Viral sequencing (m·chive) 
-
Single PK collected at any time point 
6.4.3. 
Weeks 4 and 8 (± 3 days) 
• 
PD 
• Vital signs, including body weight and height measurements 
• Perf01m symptom-directed physical examination 
• Assessment of AEs and concomitant medications 
• Obtain blood samples for 
-
Hematology 
-
Chemistiy 
-
Coagulation tests 
-
HCVRNA 
CONFIDENTIAL 
Page 60 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 61
08 June 2017
Viral sequencing (archive)
A single PK sample will be collected between 15 minutes to 4 hours post-dose, as 
applicable 
HBV DNA testing for subjects HBcAb positive at Screening

Obtain urine sample for:
-hCG pregnancy test for females of childbearing potential only

Review medication compliance with subject and/or parent/guardian (subject should return all 
study drug at these visits)

Dispense study drug as directed by the IWRS
6.4.4.
Week 12 (± 3 days) - Subjects on 12 Week Treatment Regimen Only

Perform complete physical examination

Tanner Pubertal Staging Assessment

Vital signs, including body weight and height measurements

Assessment of AEs and concomitant medications

Pregnancy prevention counseling including partner pregnancy prevention for male 
participants (all subjects ≥ 12 years of age and subjects < 12 years of age at the discretion of 
the Investigator based on subject’s pubertal status)

Obtain blood samples for:
Hematology
Chemistry
Coagulation tests
HCV RNA
Viral sequencing (archive)
TSH
Single PK collected at any time point

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 62
08 June 2017
HBV DNA testing for subjects HBcAb positive at Screening

Obtain urine sample for:
-hCG pregnancy test for females of childbearing potential only

Subject completes quality of life survey: Subject is to review questionnaire with a
parent/guardian and write/mark answers directly onto the questionnaire.

Review medication compliance with subject and/or parent/guardian.

Subjects should return all bottles of study drug at the Week 12 Visit
6.4.5.
Week 12 (± 3 days) - Subjects on 24 Week Treatment Regimen Only

Perform symptom-directed physical examination

Vital signs, including body weight and height measurements

Assessment of AEs and concomitant medications

Obtain blood samples for:
Hematology
Chemistry
Coagulation tests
HCV RNA
Viral sequencing (archive)
Single PK collected at any time point
HBV DNA testing for subjects HBcAb positive at Screening

Obtain urine sample for:
-hCG pregnancy test for females of childbearing potential only

Review medication compliance with subject and/or parent/guardian (subject should return all 
study drug at these visits)

Dispense study drug as directed by the IWRS

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 63
08 June 2017
6.4.6.
Week 16 and 20 (± 3 days) – Subjects on 24 Week Treatment Regimen Only

Vital signs, including body weight and height measurements 

Perform symptom-directed physical examination

Assessment of AEs and concomitant medications

Obtain blood samples for
Hematology
Chemistry
Coagulation tests
HCV RNA
Viral sequencing (archive)
Single PK collected at any time point
HBV DNA testing for subjects HBcAb positive at Screening

Obtain urine sample for:
-hCG pregnancy test for females of childbearing potential only

Review medication compliance with subject and/or parent/guardian (subject should return all 
study drug at these visits)

Dispense study drug as directed by the IWRS
6.4.7.
Week 24 (± 3 days) – Subjects on 24 Week Treatment Regimen Only

Perform complete physical examination

Tanner Staging Assessment

Vital signs, including body weight and height measurements

Assessment of AEs and concomitant medications

Pregnancy prevention counseling including partner pregnancy prevention for male 
participants (Subjects 12 to < 18 years of age and subjects < 12 years of age at the discretion 
of the Investigator based on subject’s pubertal status)

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
• 
Obtain blood samples for: 
-
Hematology 
-
Chemistiy 
-
Coagulation tests 
-
HCVRNA 
-
Viral sequencing (archive) 
-TSH 
-
Single PK collected at any time point 
-
HBV DNA testing for subjects HBcAb positive at Screening 
• 
Obtain urine sample for: 
-
~-hCG pregnancy test for females of childbearing potential only 
Final 
Amendment 6.0 
• 
Subject completes quality of life survey: Subject is to review questionnaire with a 
parent/guardian and write/mark answers directly onto the questionnaire 
• 
Review medication compliance with subject and/or parent/guardian. 
• 
Subjects should retum all bottles and blister cards (if applicable) of study dmg at the 
Week 24 Visit 
6.4.8. 
Optional Intensive Pharmacokinetics (PK) Substudy 
PPD 
I 
I 
CONFIDENTIAL 
Page 64 
08 Jnne 2017 

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
PD 
I 
I 
I 
I 
I 
I 
I 
I ·-
• 
·-
·-
• ·-
• 
CONFIDENTIAL 
Page 65 
Final 
Amendment 6.0 
08 Jnne 2017 

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
• PD 
I 
I 
I 
6.4.9. 
Unscheduled Visit/Early Termination Visit 
Final 
Amendment 6.0 
A subject should attend an unscheduled visit if requested by the sponsor or the investigator. The 
assessments are at the investigator's discretion. 
The Sponsor/CRO should be inf01med when a subject comes off u·eatment due to an adverse 
event. If a subject discontinues u·eatment then the assessments outlined below should be 
perfonned. 
• 
Perf01m complete physical examination 
• 
Tanner Pube1ial Stage Assessment 
• 
Vital signs, including body weight and height measurements 
• 
Assessment of AEs and concomitant medications 
• 
Pregnancy prevention counseling including partner pregnancy prevention for male 
pruiicipants (all subj ects ~ 12 yeru·s of age and subjects < 12 yeru·s of age at the discretion of 
the Investigator based on subject's pube1ial status) 
• 
Obtain blood srunples for: 
-
Hematology 
-
Chemistry 
-
Coagulation tests 
CONFIDENTIAL 
Page 66 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 67
08 June 2017
HCV RNA
Viral sequencing (archive)
TSH
Single PK collected at any time
HBV DNA testing for subjects HBcAb positive at Screening

Obtain urine sample for:
-hCG pregnancy test for females of childbearing potential only

Subject completes quality of life survey: Subject is to review questionnaire with a
parent/guardian and write/mark answers directly onto the questionnaire.

Review medication compliance with subject and/or parent/guardian.

Subjects should return all bottles and/or blister cards (if applicable) of study drug at the Early 
Termination Visit
All subjects should complete Post-Treatment assessments after early termination, as described in 
Section 6.5.
6.5.
Post-Treatment Assessments
6.5.1.
4-Week Post-Treatment Visit (± 5 days)

Vital signs, including body weight and height measurements 

Perform symptom-directed physical examination

Assessment of AEs and concomitant medications

Obtain blood samples for: 
Hematology
Chemistry
HCV RNA
Viral sequencing (archive)
HBV DNA testing for subjects HBcAb positive at Screening

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 68
08 June 2017

Obtain urine sample for:
-hCG pregnancy test for females of childbearing potential only

Pregnancy prevention counseling including partner pregnancy prevention for male 
participants (all subjects ≥ 12 years of age and subjects < 12 years of age at the discretion of 
the Investigator based on subject’s pubertal status) 
Female subjects of childbearing potential on treatment with LDV/SOF FDC + RBV should be 
provided with Urine Pregnancy Test-Kits, instructed on their use, and requested to continue to 
self-monitor for pregnancy for 6-months after their last dose of RBV. If required by local 
regulations, additional pregnancy tests beyond 6 months may be added. The subject should be 
contacted every 4 weeks and asked to report results of the urine pregnancy tests. If a positive 
urine pregnancy test is reported, the subject should return to the clinic for a serum pregnancy 
test.
6.5.2.
12-Week Post-Treatment Visit (± 5 days)

Vital signs, including body weight and height measurements

Perform symptom-directed physical examination

Assessment of SAEs

Perform Tanner Pubertal Stage assessment

Obtain blood samples for 
Hematology
Chemistry
HCV RNA
Viral sequencing (archive)
HBV DNA testing for subjects HBcAb positive at Screening

GT-3 subjects only: Obtain urine sample for -hCG pregnancy test for females of 
childbearing potential only

GT-3 subjects only: Pregnancy prevention counseling including partner pregnancy
prevention for male participants (all subjects ≥ 12 years of age and subjects < 12 years of age 
at the discretion of the Investigator based on subject’s pubertal status)

Subject completes quality of life survey: Subject is to review questionnaire with a 
parent/guardian and write/mark answers directly onto the questionnaire

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 69
08 June 2017
6.5.3.
24-Week Post-Treatment Visit (± 5 days)

Vital signs, including body weight and height measurements 

Perform symptom-directed physical examination

Assessment of SAEs

Tanner Pubertal Stage Assessment

A single X-ray of the left wrist, hand, and fingers for Bone Age Assessment

Obtain blood samples for 
HCV RNA
Viral sequencing (archive)
HBV DNA testing for subjects HBcAb positive at Screening

GT-3 subjects only: Obtain urine sample for -hCG pregnancy test for females of 
childbearing potential only

GT-3 subjects only: Pregnancy prevention counseling including partner pregnancy 
prevention for male participants (all subjects ≥ 12 years of age and subjects < 12 years of age 
at the discretion of the Investigator based on subject’s pubertal status)

Subject completes quality of life survey: Subject is to review questionnaire with a 
parent/guardian and write/mark answers directly onto the questionnaire.
All subjects (those who attain SVR24 or those who do not attain SVR24) who do not initiate 
other experimental or approved anti-HCV therapy will be followed every 6 months for the first 
2 years followed by every 12 months for assessments of growth, quality of life, and long-term 
viral suppression (if applicable) in a separate protocol (GS-US-334-1113). This follow-up will 
continue for 5 years.
6.6.
Procedures and Specifications
6.6.1.
Clinical Laboratory Analytes
Hematology: Hematocrit, Hemoglobin (Hb), Platelet count, Red blood cell count (RBC), White 
blood cell count (WBC) with differential (absolute and percentage) including Lymphocytes, 
Monocytes, Neutrophils, Eosinophils, Basophils, Reticulocyte count and MCV.
Coagulation: INR, Prothrombin time (PT), Activated partial thromboplastin time (APTT) 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 70
08 June 2017
Chemistry Alanine aminotransferase (ALT/SGPT), Aspartate aminotransferase (AST/SGOT), 
Albumin, Alkaline phosphatase, Creatinine, Total Bilirubin (reflex to Direct Bilirubin), Glucose, 
Lipase, Potassium, Sodium, Gamma-glutamyl transferase (GGT), alpha fetoprotein (AFP), 
alpha-1 anti-trypsin, creatine kinase (CK) and amylase.
Urinalysis: Appearance, Blood, Color, Glucose, Leukocyte esterase, pH, Protein, Urobilinogen. 
Reflex to microscopic urinalysis if dipstick result is abnormal.
Virological Tests: Serologies for HCV and HBV (HBsAg, HBsAb, HBcAb) and HAV; serology 
for HIV (including reflex testing as necessary). HCV RNA will be measured using the COBAS®
AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 for Use with the High Pure System. HCV GT
and subtype will be determined using the Siemens VERSANT® HCV Genotype INNO-LiPA 2.0 
Assay. Gilead reserves the right to use alternate assays for HCV RNA and HCV GT should the 
above assays become unavailable.
IL28B genotype will be determined by polymerase chain reaction (PCR) amplification of the 
SNP, rs12979860, with sequence specific forward and reverse primers and allele specific 
fluorescently labeled TaqMan® MGB probes. Gilead reserves the rights to use alternate assays 
for IL28B determination should the above assay become unavailable.
Pregnancy Tests: Serum -hCG, Urine -hCG (if positive, requires immediate confirmation with 
Serum -hCG)
Additional Tests: Urine Drug Screen (for amphetimines, cocaine, methadone, opiates), 
Hemoglobin A1c (HbA1c), TSH (reflex Free T4), Alfa fetoprotein (AFP), Alpha-1 anti-trypsin
(AAT).
6.6.2.
Medical History
Medical history including details regarding illnesses and allergies, date(s) of onset, and whether 
condition(s) is currently ongoing, and medication history will be collected on all subjects during 
screening. Parental heights will be recorded at Screening.
6.6.3.
Complete Physical Examination
A complete physical examination must include source documentation of general appearance, and 
the following body systems: Head, neck and thyroid; eyes, ears, nose, throat, mouth and tongue; 
chest (excluding breasts); respiratory; cardiovascular; lymph nodes, abdomen; skin, hair, nails; 
musculoskeletal; and neurological. 
6.6.4.
Tanner Pubertal Stage Assessment
The Tanner Stage scale is available in Appendix 4. All subjects will receive a baseline Tanner 
Pubertal Stage Assessment. If the assessment determines that the subject is at a Tanner 5 at 
Day 1, no further Tanner Pubertal Stage Assessments are to be completed. 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 71
08 June 2017
6.6.5.
Height & Weight Measurement
Height and weight measurement will be collected at each study visit. The difference in body 
weight and height measurements between Day 1 and End of Treatment, post-treatment Week 12, 
and post-treatment Week 24 will be calculated. 
6.6.6.
Bone Age Assessment
A single X-ray of the left wrist, hand, and fingers will be performed at Day 1 Visit and 
post-treatment Week 24. Local radiologist will determine bone age from x-ray.
6.6.7.
Acceptability Assessment
A LDV/SOF FDC swallowability assessment as applicable will be performed at screening up to 
Day 1. Subjects who have indicated that they can take tablets will be observed taking a placebo 
to match the 90 mg/ 400 mg LDV/SOF FDC tablet. This will confirm the swallowability of the 
90 mg/ 400 mg tablet size. If a subject is unable to swallow the 90 mg/ 400 mg LDV/SOF FDC 
tablet size, he/she will repeat the assessment with a placebo for the 22.5 mg/ 100 mg 
LDV/SOF FDC tablet. If unable to swallow the 22.5 mg/ 100 mg LDV/SOF FDC tablet, the 
subject will be dosed with the oral granule formulation.
Palatability of LDV/SOF FDC oral granules will be assessed in subjects 3 to <6 years of age, at 
Day 1, as applicable. 
6.6.8.
Vital Signs
Assessment of vital signs will include measurement of resting blood pressure, pulse, respiratory 
rate, and temperature.
Blood pressure will be measured using the following standardized process:

Subject should sit for ≥5 minutes with feet flat on the floor and measurement arm supported 
so that the midpoint of the manometer cuff is at heart level;

Use a mercury sphygmomanometer or automatic blood pressure device with an appropriately 
sized cuff with the bladder centered over the brachial artery;

Measure and record the blood pressure to the nearest 2 mmHg mark on the manometer or to 
the nearest whole number on an automatic device.
6.6.9.
Estimated Glomerular Filtration Rate (GFR)
Estimated Glomerular Filtration Rate (GFR) using Schwartz Formula (mL/min/1.73m2) = 
k × L/Scr [(k is a proportionality constant, for adolescent females ≥12 years old is 0.55; for 
adolescent males ≥12 years old is 0.70; and for female and male children 3 to < 12 years old is 
0.55); L is height in centimeters (cm); and Scr is serum creatinine (mg/dL)]

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 72
08 June 2017
6.6.10.
Viral Sequencing (Archive)
Plasma samples will be collected at Day 1 and each subsequent visit for viral sequence analysis. 
Unused samples may be archived.
6.6.11.
Pregnancy Testing
All females of childbearing potential will have urine pregnancy testing every 4 weeks during the 
dosing period and for a minimum of 6 months following the last dose of RBV or for a minimum 
of 30 days following the last dose of LDV/SOF FDC if not taking RBV. If required by local 
regulations, additional pregnancy tests beyond 6 months for RBV or 30 days for subjects not 
taking RBV may be added. In the event of a positive urine pregnancy result, subjects will be 
instructed to stop study drug immediately (if applicable) and return to the clinic as soon as 
possible for a serum pregnancy test.
GT-3 subjects only: Pregnancy test kits will be dispensed to female subjects of child bearing 
potential at the 4 Week Post-Treatment visit. The subject will be contacted by telephone monthly 
to confirm that urine pregnancy testing has been performed post-treatment and to record the 
outcome. Alternatively, if required by local regulations or preferred by the investigator or 
subject, the subject may return to the clinic for urine pregnancy tests.
6.6.12.
Quality of Life Survey (PedsQL™)
The PedsQL™Pediatric Quality of Life Inventory V4.0 Short Form (SF15) will be completed at 
Day 1, End of Treatment, Early Termination (if applicable), 12-Week Post-Treatment, and 
24-Week Post-Treatment visits.
The PedsQL™has separate survey instruments administered by age group, including the
Teen Report (ages 13-18), Child Report (ages 8-12), Young Child Report (ages 5-7), and 
Toddlers (ages 2-4). Each survey accompanied by the respective parent proxy survey will be 
administered to the subject and their parent/legal guardian (with the exception of the Toddlers 
Report which will only be completed by the parent/legal guardian) for the current age group at 
the time of survey administration.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 73
08 June 2017
7.
TOXICITY MANAGEMENT
7.1.
Modification of Dose/Schedule Due to Toxicity
Dose reduction of RBV (GT-3 subjects only) due to toxicity should be performed according to 
the product label. Information is provided in Table 7-1.
Table 7-1.
RBV Dose Reduction Guidelines
Laboratory Values
Reduce RBV Dose by 200 mg/daya if:
Discontinue RBV if:
Hemoglobin in subjects with no 
cardiac disease
<10 g/dL
<8.5 g/dL
Hemoglobin in subjects with 
history of stable cardiac disease
≥2 g/dL decrease in hemoglobin during any 
4 week period treatment
<12 g/dL despite 4 weeks at 
reduced dose
a
Dose reduction in pediatric patients taking the oral solution is accomplished by modifying the recommended RBV dose 
from original starting dose of 15 mg/kg daily in a two-step process to 12 mg/kg/day, then to 8 mg/kg/day, if needed.
7.2.
Subject Stopping Rules for LDV/SOF FDC and RBV
The Gilead Medical Monitor should be consulted prior to dose discontinuation of LDV/SOF 
FDC unless the investigator believes that immediate action is warranted to ensure the continued 
safety of the subject.
Administration of LDV/SOF FDC may be discontinued due to a clinical or laboratory event. 
There is no option for LDV/SOF FDC dose reduction. If LDV/SOF FDC is stopped for toxicity, 
it should not be restarted, RBV should be stopped (GT-3 subjects only), and the subject should 
complete an Early Termination Visit.
Subjects who meet any of the following laboratory criteria must stop treatment with LDV/SOF 
FDC:

Elevation of ALT and/or AST >5× Day 1 or nadir, confirmed by immediate repeat testing

Abnormal elevation of ALT >3× Day 1 and total bilirubin >2 × ULN, confirmed by 
immediate repeat testing

Confirmed elevation of ALT >15 × ULN, confirmed by immediate repeat testing

Any Grade 3 or greater rash associated with constitutional symptoms

Any Grade 4 event or lab abnormality assessed as related to treatment with LDV/SOF FDC

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 74
08 June 2017
8.
ADVERSE EVENTS MANAGEMENT
8.1.
Definitions of Adverse Events, Adverse Reactions, and Serious Adverse 
Events
8.1.1.
Adverse Events
An adverse event (AE) is any untoward medical occurrence in a clinical study subject 
administered a pharmaceutical product, which does not necessarily have a causal relationship 
with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or 
disease temporally associated with the use of a medicinal product, whether or not considered 
related to the medicinal product. AEs may also include pre- or post- treatment complications that 
occur as a result of protocol-mandated procedures, overdose, drug abuse/misuse reports, or 
occupational exposure. Preexisting events that increase in severity or change in nature during or 
as a consequence of participation in the clinical study will also be considered AEs.
An AE does not include the following:

Medical or surgical procedures such as surgery, endoscopy, tooth extraction, and transfusion. 
The condition that led to the procedure may be an adverse event and must be reported

Pre-existing diseases, conditions, or laboratory abnormalities present or detected before the 
screening visit that do not worsen.

Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for 
elective surgery, social and/or convenience admissions).

Overdose without clinical sequelae (see Section 8.5.1)

Any medical condition or clinically significant laboratory abnormality with an onset date 
before the consent form is signed and not related to a protocol-associated procedure is not an 
AE. It is considered to be pre-existing and should be documented on the medical history CRF
8.1.2.
Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at any dose, results in the following:

Death

Life-threatening (Note: The term “life-threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that hypothetically might have caused death if it were more severe.)

In-patient hospitalization or prolongation of existing hospitalization

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 75
08 June 2017

Persistent or significant disability/incapacity

A congenital anomaly/birth defect

A medically important event or reaction: such events may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the subject or may 
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is reportable under 
expedited reporting rules. Examples of medically important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a medically important event and subject to expedited reporting 
requirements.
8.1.3.
Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory abnormalities (e.g., clinical chemistry, hematology, and urinalysis) that 
require medical or surgical intervention or lead to IMP interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. In addition, 
laboratory or other abnormal assessments (e.g., electrocardiogram, x-rays, vital signs) that are 
associated with signs and/or symptoms must be recorded as an AE or SAE if they meet the 
definition of an AE or SAE as described in Sections 8.1.1 and 8.1.2. If the laboratory 
abnormality is part of a syndrome, record the syndrome or diagnosis (e.g., anemia), not the 
laboratory result (i.e., decreased hemoglobin).
8.2.
Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified sub-investigator is responsible for assessing AEs and SAEs for 
causality and severity, and for final review and confirmation of accuracy of event information 
and assessments.
8.2.1.
Assessment of Causality for Study Drug and Procedures
The investigator or qualified sub-investigator is responsible for assessing the relationship to 
IMP therapy using clinical judgment and the following considerations:

No: Evidence exists that the adverse event has an etiology other than the investigational 
medicinal product. For SAEs, an alternative causality must be provided (e.g., pre-existing 
condition, underlying disease, intercurrent illness, or concomitant medication).

Yes: There is reasonable possibility that the event may have been caused by the 
investigational medicinal product.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 76
08 June 2017
It should be emphasized that ineffective treatment should not be considered as causally related in 
the context of AE reporting.
The relationship to study procedures (e.g., invasive procedures such as venipuncture or biopsy) 
should be assessed using the following considerations:

No: Evidence exists that the AE has an etiology other than the study procedure.

Yes: The adverse event occurred as a result of protocol procedures (e.g.., venipuncture)
8.2.2.
Assessment of Severity
The severity grading of AEs will be assessed as Grade 1, 2, 3, or 4 using the GSI Grading Scale 
for Severity of Adverse Events and Laboratory Abnormalities (Appendix 3).
For AEs associated with laboratory abnormalities, the event should be graded on the basis of the 
clinical severity in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the laboratory abnormality.
8.3.
Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead or CRO
Requirements for collection prior to study drug initiation:
After informed consent, but prior to initiation of study medication, the following types of events 
should be reported on the case report form (CRF/eCRF): all SAEs and adverse events related to 
protocol-mandated procedures.
Adverse Events
Following initiation of study medication, collect all AEs, regardless of cause or relationship, 
until 4 weeks after last administration of study drug must be reported to the CRF/eCRF database 
as instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may request that certain AEs be followed beyond the protocol defined follow up 
period.
Serious Adverse Events
All SAEs, regardless of causal relationship, that occurs after the subject first consents to 
participate in the study (i.e., signing the informed consent) and throughout the duration of the 
study, including the protocol-required 24-week post treatment follow-up period, must be 
reported to the CRF/eCRF database and Gilead Drug Safety and Public Health (DSPH) as 
instructed. This also includes any SAEs resulting from protocol-mandated procedures performed
after informed consent is signed.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 77
08 June 2017
Any SAEs and deaths that occur after the post treatment follow-up visit but within 30 days of the 
last dose of study IMP, regardless of causality, should also be reported. Investigators are not 
obligated to actively seek SAEs after the 24 week post-treatment follow-up period. However, if 
the investigator learns of any SAEs that occur after study participation has concluded and/or if 
patient is enrolled into the long term follow-up registry study (GS-US-334-1113), and/or eCRF 
database has been locked, and the event is deemed relevant to the use of IMP, he/she should 
promptly document on paper SAE form and report the event directly to Gilead DSPH within 
24 hours of awareness. Gilead DSPH contact information is as follows: 
Email: Safety_FC@gilead.com; or
Fax: +1 (650) 522-5477
Electronic Serious Adverse Event (eSAE) Reporting Process

Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.

If for any reason it is not possible to record the SAE information electronically, i.e., the 
eCRF database is not functioning, record the SAE on the paper serious adverse event 
reporting form and submit within 24 hours to:
Gilead Sciences, Drug Safety and 
Public Health:
Fax:
E-mail:
+1 650 522-5477
Safety_FC@gilead.com

As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.

If an SAE has been reported via a paper form because the eCRF database has been locked, 
no further action is necessary.

All AEs and SAEs will be recorded in the CRF/eCRF database within the timelines outlined 
in the CRF/eCRF completion guideline.

For fatal or life-threatening events, copies of hospital case reports, autopsy reports, and other 
documents are also to be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability of a document to the subject identifiers.

Additional information may be requested to ensure the timely completion of accurate safety 
reports.

Any medications necessary for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/eCRF and the event description section of the SAE 
report form.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 78
08 June 2017
8.4.
Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and 
other country-specific legislation or regulations, Gilead may be required to expedite to 
worldwide regulatory agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide regulatory 
agencies and the relevant IEC in concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of expectedness for SAEs will be determined by Gilead using reference safety 
information specified in the investigator’s brochure or relevant local label as applicable. 
All investigators will receive a safety letter notifying them of relevant SUSAR reports associated 
with any study IMP. The investigator should notify the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required by local regulatory agencies, and in accordance with the local 
institutional policy.
8.5.
Special Situations Reports
8.5.1.
Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose, reports 
of adverse events associated with product complaints, and pregnancy reports regardless of an 
associated AE. 
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by a 
subject.
Misuse is defined as any intentional and inappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
An overdose is defined as an accidental or intentional administration of a quantity of a medicinal 
product given per administration or cumulatively which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily dose of the subject in 
question). In cases of a discrepancy in drug accountability, overdose will be established only 
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging or distribution of the medicinal product. 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 79
08 June 2017
8.5.2.
Instructions for Reporting Special Situations
8.5.2.1.
Instructions for Reporting Pregnancies
The investigator should report all pregnancies that are identified after the subject first consents to 
participate in the study (i.e., signs the informed consent) and throughout the study, including the 
post-treatment follow-up period, to Gilead DSPH using the pregnancy report form within 
24 hours of becoming aware of the pregnancy.
Refer to Section 8.3 and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of pregnancy reporting.
The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy without medical reasons.
Any premature termination of pregnancy (e.g., a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underlying medical reason for this procedure should be recorded as the AE term.
A spontaneous abortion is always considered to be an SAE and will be reported as described in 
Sections 8.1 and 8.3. Furthermore, any SAE occurring as an adverse pregnancy outcome 
post study must be reported directly to Gilead DSPH.
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy. The outcome should be reported to Gilead DSPH using the pregnancy outcome report 
form. If the end of the pregnancy occurs after the study has been completed, the outcome should 
be reported directly to Gilead DSPH. Gilead DSPH contact information is as follows: 
Email: Safety_FC@gilead.com or Fax: +1 (650) 522-5477.
Pregnancies of female partners of male study subjects exposed to Gilead or other study drug
must also be reported and relevant information should be submitted to Gilead DSPH using the 
pregnancy report form and pregnancy outcome report forms within 24 hours. Monitoring of the 
partner pregnancy should continue until the conclusion of the pregnancy. If the end of the 
pregnancy occurs after the study has been completed, the outcome should be reported directly to 
Gilead DSPH, fax number +1 (650) 522-5477 or email Safety_FC@gilead.com. 
Clinical staff should also report any pregnancies to the Ribavirin Pregnancy Registry at 
1 800-593-2214 (see also http://www.ribavirinpregnancyregistry.com).
Refer to Appendix 5 for Pregnancy Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
8.5.2.2.
Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study IMP and/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications. 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 80
08 June 2017
Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situations report form; however, for special situations that result in AEs due to a 
non-Gilead concomitant medication, the AE should be reported on the AE form. 
Any inappropriate use of concomitant medications prohibited by this protocol should not be 
reported as “misuse,” but may be more appropriately documented as a protocol deviation.
Refer to Section 8.3 and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. Details of the symptoms and 
signs, clinical management and outcome will be reported, when available.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 81
08 June 2017
9.
STATISTICAL CONSIDERATIONS
9.1.
Analysis Objectives and Endpoints
9.1.1.
Analysis Objectives
The primary objective of PK Lead-in Phase of this study is:

To evaluate the steady state pharmacokinetics (PK) and confirm the dose of LDV/SOF FDC
in chronic HCV-infected pediatric subjects
The secondary objective of PK Lead-in Phase of this study is:

To evaluate the safety, tolerability, and antiviral activity of 10 days of dosing of 
LDV/SOF FDC in chronic HCV-infected pediatric subjects
The primary objective of Treatment Phase of this study is:

To evaluate the safety and tolerability of LDV/SOF FDC +/- RBV for 12 or 24 weeks in 
chronic HCV-infected pediatric subjects
The secondary objectives of Treatment Phase of this study are:

To determine the antiviral efficacy of 12 and 24 weeks of LDV/SOF FDC +/- RBV treatment 
in chronic HCV-infected subjects (including the impact of HCV genotype, IL28B genotype, 
and prior treatment experience), as assessed by the proportion of subjects with SVR 
12 weeks after completion of treatment (SVR12)

To determine the antiviral efficacy of 12 and 24 weeks of LDV/SOF FDC +/- RBV treatment 
in chronic HCV-infected subjects, as assessed by the proportion of subjects with SVR 4 and 
24 weeks after completion of treatment (SVR4 and SVR24)

To evaluate the kinetics of circulating HCV RNA during treatment and after completion of 
treatment

To evaluate the emergence of viral resistance to LDV and SOF during treatment and after 
completion of treatment

To evaluate acceptability assessed by swallowability of tablets and palatability of granules

To evaluate the effect of growth and development on pediatric subjects during and after 
treatment

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
The explorat01y objective of this study is: 
• 
PD 
9.1.2. 
Primary Endpoints 
Final 
Amendment 6.0 
For the PK Lead-in Phase, the appropriateness of the LDV /SOF FDC dose will be assessed by 
evaluating the steady-state PK of the LDV/SOF FDC. The primruy endpoint for detennining 
steady state PK is AUCtau of GS-331 007, SOF, and LDV. Additional steady-state PK pru·ameters 
of GS-331007, SOF, and LDV (e.g., AUC!ast, Cmax, Tmax, Clast, Tlast, Ctau, 'Az, CLIF, VzJF and tv.) 
will be estimated and summru·ized as described in Section 9.4. 
For the Treatment Phase, the primruy safety endpoint is any AE leading to pennanent 
discontinuation of study dmg (s). 
9.1.3. 
Secondary Endpoints 
For the PK Lead-in Phase, the secondruy endpoint will include antiviral activity measmements, 
including assessment ofHCV RNA. AEs leading to pe1m anent discontinuation of study dmg will 
be evaluated as a secondaty safety endpoint. 
For the Treatment Phase, the key efficacy endpoint is SVR12 and secondruy efficacy endpoints 
include SVR4, SVR24, breakthrough and relapse. Additional efficacy evaluations may include 
HCV RNA change from Day 1; AL T nonnalization; and viral kinetic pru·ameters. Secondaty 
safety endpoints of growth and development measmements will be assessed (e.g. height, weight, 
and Tanner Stage Assessment). Other seconda1y endpoints include acceptability assessed by 
swallowability of tablets and palatability of granules. 
9.2. 
Analysis Conventions 
All individual subject data will be listed as measmed. All statistical summru'ies and analyses will 
be perfonned using SAS® software (SAS Institute, Cruy, North Cru·olina, USA). 
9.2.1. 
Analysis Sets 
9.2.1.1. 
Phrum acokinetics (PK) Analysis Sets 
Intensive PK Analysis Set 
The intensive PK Lead-in analysis set will include all PK Lead-in phase subjects who received at 
least one dose of study dmg and for whom at least one non-missing PK concentration data, 
dming the intensive sampling period, rep01ted by PK lab. The PK analysis set will be used for 
detailed phrum acokinetic analysis ofLDV, SOF, and metabolites. 
CONFIDENTIAL 
Page 82 
08 Jnne 2017 

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
PD 
Sparse PK Analysis Set 
Final 
Amendment 6.0 
The PK analysis set will include all enrolled subjects who received at least one dose of study 
dmg and for whom at least one observed concentration data of LDV, SOF, or GS-331 007 are 
available. The PK analysis set will be used for analysis of general PK and single sample plasma 
concentrations. 
9.2.1.2. 
Safety Analysis Set 
The prima1y analysis set for safety analyses will include subjects who have received at least one 
dose of study dmg. 
Treatment-emergent data will be analyzed and defmed as data collected from the first dose of 
study dmg through the date of last dose of study dmg plus 30 days. 
9.2.1.3. 
Efficacy Analysis Set 
The analysis set for antiviral activity analyses will be the Full Analysis Set (F AS) which includes 
HCV -infected subjects who were enrolled and have received at least one dose of study dmg. 
9.2.2. 
Data Handling Conventions 
Natural logarithm transf01m ation for key PK parameters, such as Cmax and AUCtau, will be 
applied for phannacokinetic analysis. 
The PK concentration values below the limit of quantitation (BLQ) will be treated as zero for the 
dete1mination of suminaty and order statistics. Individual values that m·e BLQ will be presented 
as "BLQ" in the concentration data listing and will be excluded in any calculation of geometric 
means or ratios. For the presentation of summmy and order statistics, if at least 1 subject has a 
concentration value BLQ for the time point, then the minimum value will be displayed as 
"BLQ". If more than 50% of the subjects have a concentration data value BLQ for the time 
point, then the minimum and median values will be displayed as "BLQ". If all subjects have 
concentration data values BLQ for the time point, then all order statistics (minimum, first 
qumi ile [Q1], median, third qumtile [Q3], maximum) will be displayed as "BLQ". 
Missing data can have an impact upon the inte1pretation of the trial data. Other than the 
endpoints discussed below, in general, values for missing data will not be imputed. 
For the analysis of post-baseline categorical efficacy endpoints, if a data point is missing and is 
preceded and followed in time by values that m·e deem successes, then the missing data point 
will be tenned a success; othe1w ise the data point will be tenned a failure. 
CONFIDENTIAL 
Page 83 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 84
08 June 2017
Any subject with missing data due to premature discontinuation of the study medication will be 
considered a failure at the time points subsequent to the date of discontinuation. If no HCV RNA 
values are obtained after the last dose of study medication, the subject will be considered a 
treatment failure for the SVR endpoints. 
Where appropriate, safety data for subjects that did not complete the study will be included in 
summary statistics. For example,

If a subject received study medication, the subject will be included in a summary of adverse 
events according to the treatment received; otherwise, if the subject is not dosed then they 
will be excluded from the summary.

If safety laboratory results for a subject are missing for any reason at a time point, the subject 
will be excluded from the calculation of summary statistics for that time point. If the subject 
is missing a pre-dose value, then the subject will be excluded from the calculation of 
summary statistics for the pre-dose value and the change from pre-dose values.
Values for missing safety laboratory data will not be imputed; however, a missing baseline result 
will be replaced with a screening result, if available. If no pre-treatment laboratory value is 
available, the baseline value will be assumed to be normal (i.e., no grade [Grade 0]) for the 
summary of graded laboratory abnormalities.
Values for missing vital signs data will not be imputed; however, a missing baseline result will 
be replaced with a screening result, if available.
HCV RNA values below the LLOQ for the assay will be set to the lower limit minus 1 for 
calculation of summary statistics for the actual HCV RNA values and the change from baseline 
values by study visit. The reported values will be provided in the HCV RNA listing.
For selected analyses of early time point data, HCV RNA data (IU/mL) may be transformed to 
the logarithmic (base 10) scale (log10 IU/mL).
9.2.3.
Interim Analysis
Interim analyses may be performed to provide treatment regimen and duration recommendations
for adolescent subjects (12 to < 18 years of age).
There will be no changes to the study design, study conduct, or the sample size as a result of the 
interim analysis.
9.3.
Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be summarized using standard descriptive 
methods by age group and overall for PK Lead-in phase and for Treatment Phase, respectively.
Demographic data will include sex, self-identified race/ethnicity, and age.

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
Final 
Amendment 6.0 
Baseline characteristic data will include body weight, height, body mass index, HCV RNA level 
(log10 ID/mL), HCV genotype, prior treatment experience, and additional endpoints as necessmy. 
9.4. 
Pharmacokinetic Analysis 
erfonned for PK Lead-in phase using the intensive PK Lead-in analysis set. 
The concentration data 
of:-;:L-;:D~V
'"';',-:S
::-:O
:::-::F~,-an
-.d._m_e-:-ta-.b·-o"l-i'~
te_
s..,.(G=
s-..
-3~3-=-
1~
00~7=-an
_,d'~G=
s--::5:-:::6-:::-
65
-;:-:0
::-:0:o::-
)-o-
v-
et-
. s-a-m~
pling time will be listed 
and summm·ized by nominal time and coh01t. Phmmacokinetic pm·ameters (e.g., AUC~au, AUC1ast, 
Cmax, Tma.x, Clast, Tlast' Ctau' 'Az, CLIF, Vz/F and tv,) will be listed and summm·ized for LDV, SOF, 
and metabolites (as applicable) using descriptive statistics (e.g., sample size, arithmetic mean, 
geometric mean and its 95% confidence interval, coefficient of vm·iation %, standai·d deviation, 
median, Q1, Q3, minimum, and maximum) by coh01t and overall. Plasma concentrations over 
time will be plotted in seinilogarithmic and linear fonnats as mean ± standai·d deviation and 
median (Q1, Q3). 
To evaluate if the steady-state PK of GS-331007, SOF, and LDV achieved in pediatric subjects 
ofthis study m·e siinilm· to the exposmes observed in adult subjects (Table 9-1), the GS-331007, 
SOF, and LDV exposme data. from this study will be compared to the integrated adult data .. The 
primmy endpoint of this analysis will be evaluated by cm1ying out an analysis of variance 
(ANOVA) for log-transf01med GS-331007, SOF, and LDV AUCtau· The 90% confidence 
intervals will be constmcted for the ratio of geometric means of each PK pm·ameters. The 
equivalence boundmy is set as 50% to 200%. 
Given that dose ranging studies for SOF established that a dose of 200 mg results in suboptimal 
exposme compared to the 400 mg dose, and the lack of clinically significant exposme-safety 
relationships observed across a broad range of GS-331007 and SOF exposme, bounds of 50% to 
200% for GS-331007 and SOF AUCtau will allow identification of a clinically relevant difference 
in exposme in the pediatric population. 
A phase 2 study evaluating LDV doses of 30 or 90 mg LDV in combination with DAAs 
VDV+TGV+RBV suggested LDV exposme may be suboptimal at the 30 mg dose based on the 
incidence of virologic breakthrough being approximately half in the 90 mg mm; as such the 
90 mg dose was selected for fmther development. In the 90 mg LDV mm of this study, the LDV 
AUCtau at the 25 percentile was 3230 hr*ng/mL. While this value is 62% lower than the mean 
LDV AUCtau (8530 hr*ng/mL) observed in adult HCV-infected subjects in the LDV/SOF FDC 
Phase 2/3 population, it provides - 99.8% of maximal viral load reduction ( exposme-response 
model established in the monotherapy proof of concept study). In the Phase 2/3 population when 
administered the LDV/SOF FDC, there was a lack of clinically significant exposure-efficacy or 
safety relationships observed across the broad range of LDV exposme. Taken together these data 
supp01t the utility ofbmmds of 50% to 200% for LDV AUCrnu to identify a clinically relevant 
difference in LDV exposme in the pediatric population. 
In all pediatric age groups, the tm·geted exposmes for GS-331007, SOF, and LDV are the adult 
equivalent for which safety and efficacy has been established. In the absence of any pediatric PK 
CONFIDENTIAL 
Page 85 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 86
08 June 2017
information (i.e., variability and exposure of GS-331007, SOF, or LDV is unknown) assuming a 
2-fold higher variability, or a 30 % difference in GS-331007, SOF, or LDV AUCtau in the 
pediatric population compared to adults, the predicted 90% CIs of the geometric mean ratio 
(GMR) will be contained within the bounds of 50% to 200%.
Individual patient management will be performed by maintaining exposures comparable to 
adults. In the event more than one subject in each cohort exhibits GS-331007, SOF, or LDV 
exposures (AUCtau) less than the 2.5th percentile of adult values, a dose assessment may be 
require for the cohort as appropriate.
The effect of age and LDV/SOF FDC dose on PK (LDV, SOF and GS-331007) will be assessed.
Table 9-1.
GS-331007, SOF, and LDV PK Parameters after Once-Daily 
Administration of LDV/SOF FDC in HCV-Infected Adults Subjects 
(Population PK Analysis from Phase 2 and 3 Studies)
Mean (%CV) PK Parametera
GS-331007 (N=2113)
SOF (N=1542)
LDV (N=2113)
AUCtau (ng•h/mL)
12,500 (29.2)
1380 (34.0)
8530 (60.8)
Cmax (ng/mL)
736 (28.2)
659 (34.0)
364 (51.4)
Ctau (ng/mL)
N/A
N/A
247 (59.2)
a
Pharmacokinetic parameters are presented as mean (%CV) and are shown to 3 significant digits.
9.5.
Safety Analysis
Safety analysis will be performed for PK Lead-in Phase and for Treatment Phase respectively. 
Safety data will be summarized by age group and overall for PK Lead-in Phase and by treatment
regimen for each age group for the Treatment Phase.
Safety will be evaluated by assessment of clinical laboratory tests, physical examinations, vital 
signs measurements, and by the documentation of AEs.
All safety data collected while on or after the first dose of study drug administration up to 
30 days after the last dose of study drug will be summarized according to the study drug 
received.
Safety endpoints will be analyzed by the number and percent of subjects with events or 
abnormalities for categorical values or 8-number summary (n, mean, standard deviation, median, 
Q1, Q3, minimum, maximum) for continuous data.
9.5.1.
Extent of Exposure
A subject’s extent of exposure to study drug will be generated from the study drug 
administration page of the CRF. Exposure data will be summarized.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 87
08 June 2017
9.5.2.
Adverse Events
Clinical and laboratory AEs will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA). System Organ Class (SOC), High-Level Group Term (HLGT), 
High-Level Term (HLT), Preferred Term (PT), and Lower-Level Term (LLT) will be attached to 
the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment-emergent 
adverse event will be defined as any adverse event with an onset date on or after the study drug 
start date and no later than 30 days after permanent discontinuation of the study drug or any 
adverse event leading to premature discontinuation of the study drug. 
Summaries (number and percentage of subjects) of treatment-emergent adverse events (by SOC 
and preferred term) will be provided by cohort:

All AEs,

All treatment-related AEs,

Combined Grade 2, 3 and 4 AEs,

Combined Grade 3 and 4 AEs,

Combined Grade 2, 3 and 4 treatment-related AEs,

Combined Grade 3 and 4 treatment-related AEs,

All AEs that caused permanent discontinuation from study drug,

All AEs that caused change in dose or temporary interruption of study drug,

All SAEs,

All treatment-related SAEs
All AEs collected during the course of the study will be presented in data listings.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 88
08 June 2017
9.5.3.
Laboratory Evaluations
Selected laboratory data will be summarized using only observed data. Absolute values and 
changes from baseline at all scheduled visits will be summarized. Graded laboratory 
abnormalities will be defined using the grading scheme in Grading of Laboratory Abnormalities 
provided in Appendix 3. Incidence of treatment-emergent laboratory abnormalities, defined as 
values that increase by at least one toxicity grade from baseline at any time post baseline up to 
and including the date of last dose of study drug plus 30 days, will be summarized by age group 
and overall. If baseline data are missing, then any graded abnormality (i.e., at least a Grade 1) 
will be considered treatment emergent.
All laboratory abnormalities will be included in the listings of laboratory data.
9.5.4.
Other Safety Evaluations
9.5.4.1.
Tanner Pubertal Stage Assessment
Tanner Stages (Appendix 4) will be summarized by baseline Tanner Stage using frequency and 
percentage. 
9.5.4.2.
Vital Signs (including Body Weight and Height)
Vital signs including body weight and height and change from baseline will be summarized at 
each visit.
9.6.
Efficacy Analysis
Efficacy will be evaluated using scheduled assessments of HCV RNA performed using COBAS®
TaqMan® HCV Test, v2.0 for use with the High Pure System.
Efficacy analysis will be performed by treatment regimen for each age group for Treatment 
Phase.
All continuous endpoints will be summarized using an 8-number summary (n, mean, standard 
deviation, median, Q1, Q3, minimum, maximum). All categorical endpoints will be summarized 
by number and percentage of subjects who meet the endpoint definition.
9.6.1.
Key Efficacy Analysis
The key efficacy endpoint is SVR12 (HCV RNA < LLOQ 12 weeks after completion of 
treatment) in the FAS population. Point estimate and its 95% confidence interval will be 
provided. 
9.6.2.
Secondary Efficacy Analysis
For the PK Lead-in Phase, serum HCV RNA actual values and change from baseline will be
summarized at each visit.

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
Final 
Amendment 6.0 
For the Treatment Phase, the proportion of subjects with HCV RNA below LLOQ over time 
(including SVR endpoints SVR4 and SVR24) will be presented in tabular and graphical f01m. In 
addition, descriptive summaries and listings will be provided for additional efficacy evaluations 
including senun HCV RNA actual values and change from baseline, prop01iion of subjects with 
virologic failmes, and other endpoints of interest including AL T n01malization. 
PD 
9.6.3. 
Subgroup Analysis 
Subgroup analysis on SVR12 will be perf01m ed by treatment experience and cinhosis status, by 
IL28B genotype, and by HCV genotype. Other clinically relevant subgroup analyses may be 
conducted as appropriate (i.e., assuming that adequate numbers of subjects in these subsets are 
available for analysis). 
Details on efficacy analyses will be described in the statistical analysis plan. 
9.7. 
Quality of Life Analysis 
The data from PedsQL TM Pediau·ic Quality of Life survey will be summarized by visit and 
age group and overall. 
9.8. 
Acceptability 
Acceptability of the study u·eatments will be sUIIllnarized using descriptive statistics by assessing 
swallowability of the solid dosage tablet f01mulations (if subject is able to swallow the tablet) 
and evaluating palatability of the granules f01mulation as applicable. 
9.9. 
Data Monitoring Committee 
An extemal multidisciplinruy data monitoring committee (DMC) will review the progress of the 
study and perf01m interim reviews of safety and provide recommendation to Gilead about 
whether the nature, frequency, and severity of adverse effects associated with study u·eatment 
wruTant the eru·ly te1mination of the study in the best interests of the pruiicipants, whether the 
study should continue as planned, or the study should continue with modifications. 
The DMC's specific activities will be defmed by a mutually agreed chruier, which will define the 
DMC's membership, conduct and meeting schedule. 
While the DMC will be asked to advise Gilead regarding futme conduct of the study, including 
possible eru·ly study tennination, Gilead retains fmal decision-making authority on all aspects of 
the study. 
CONFIDENTIAL 
Page 89 
08 Jnne 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 90
08 June 2017
9.10.
Sample Size
With approximately 100 subjects enrolled into 12 to <18 years (Group 1) of the Treatment Phase, 
a two-sided 95.0% confidence interval of the SVR12 rate will extend at most 5.9% in both 
directions from the observed SVR12 rate, assuming the expected SVR12 rate is 90%.
With approximately 120 subjects enrolled into the 3 to < 12 years (Group 2) of the Treatment 
Phase, a two-sided 95.0% confidence interval of the SVR12 rate will extend at most 5.4% in 
both directions from the observed SVR12 rate, assuming the expected SVR12 rate is 90%.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 91
08 June 2017
10.
RESPONSIBILITIES
10.1.
Investigator Responsibilities
10.1.1.
Good Clinical Practice
The investigator will ensure that this study is conducted in accordance with the principles of the 
“Declaration of Helsinki” (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and 
South Africa), International Conference on Harmonization (ICH) guidelines, or with the laws 
and regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study subject. For studies conducted under a United States IND, the investigator 
will ensure that the basic principles of “Good Clinical Practice,” as outlined in 21 CFR 312, 
subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, part 50, 1998, and 
21 CFR, part 56, 1998, are adhered to.
Since this is a “covered” clinical trial, the investigator will ensure that 21 CFR, Part 54, 1998, is 
adhered to; a “covered” clinical trial is any “study of a drug or device in humans submitted in a 
marketing application or reclassification petition subject to this part that the applicant or FDA 
relies on to establish that the product is effective (including studies that show equivalence to an 
effective product) or that make a significant contribution to the demonstration of safety.” This 
requires that investigators and all sub-investigators must provide documentation of their financial 
interest or arrangements with Gilead Sciences, or proprietary interests in the drug being studied. 
This documentation must be provided before participation of the investigator and any 
sub-investigator. The investigator and sub-investigator agree to notify Gilead Sciences of any 
change to reportable interests during the study and for one year following completion of the 
study. Study completion is defined as the date that the last subject has completed the protocol 
defined activities.
This study is also subject to and will be conducted in accordance with 21 CFR, part 320, 1993, 
“Retention of Bioavailability and Bioequivalence Testing Samples.”
10.1.2.
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Approval
This protocol and any accompanying material to be provided to the subject (such as 
advertisements, subject information sheets, or descriptions of the study used to obtain informed 
consent/assent) will be submitted by the investigator to an IRB (for studies conducted in the
United States) or IEC (for studies conducted outside of the United States). Approval from the 
IRB or IEC must be obtained before starting the study and should be documented in a letter to 
the investigator specifying the protocol number, protocol version, protocol date, documents 
reviewed, and date on which the committee met and granted the approval.
Any modifications made to the protocol after receipt of IRB or IEC approval must also be 
submitted to the IRB or IEC for approval before implementation. Additionally, modifications 
should be submitted to competent authorities, as necessary.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 92
08 June 2017
10.1.3.
Informed Consent/Assent
The investigator is responsible for obtaining written informed consent from the parent/legal 
guardian of the subject participating in this study after adequate explanation to the parent/legal 
guardian and subject of the aims, methods, objectives, and potential hazards of the study and 
before undertaking any study-related procedures. Written assent should be obtained from the 
subject as required by IRB/IEC/local requirements for this age population. The investigator must 
utilize an IRB- or IEC-approved consent/assent form for documenting written informed 
consent/assent. Each informed consent/assent will be appropriately signed and dated by the 
subject or the subject’s parent/legally authorized representative and the person obtaining 
consent/assent.
10.1.4.
Confidentiality
The investigator must assure that subjects’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, and an 
identification code (i.e., not names) should be recorded on any form or biological sample 
submitted to the Sponsor, IRB or IEC, or laboratory. The investigator must keep a screening log 
showing codes, names, and addresses for all subjects screened and for all subjects enrolled in the 
trial.
The investigator agrees that all information received from Gilead Sciences, including but not 
limited to the Investigator Brochure, this protocol, CRFs, the investigational new drug, and any 
other study information, remain the sole and exclusive property of Gilead Sciences during the 
conduct of the study and thereafter. This information is not to be disclosed to any third party 
(except employees or agents directly involved in the conduct of the study or as required by law) 
without prior written consent from Gilead Sciences. The investigator further agrees to take all 
reasonable precautions to prevent the disclosure by any employee or agent of the study site to 
any third party or otherwise into the public domain.
10.1.5.
Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study file, and 
(2) subject clinical source documents.
The investigator’s study file will contain the protocol/amendments, CRF and query forms, IRB 
or IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data are listed in the Source Data verification Plan, and should include 
sequential notes containing at least the following information for each subject:

Subject identification (name, date of birth, gender);

Documentation that subject meets eligibility criteria, i.e., history, physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 93
08 June 2017

Participation in trial (including trial number);

Trial discussed and date of informed consent;

Dates of all visits;

Documentation that protocol specific procedures were performed;

Results of efficacy parameters, as required by the protocol;

Start and end date (including dose regimen) of trial medication (preferably drug dispensing 
and return should be documented as well);

Record of all AEs and other safety parameters (start and end date, and preferably including 
causality and intensity);

Concomitant medication (including start and end date, dose if relevant; dose changes should 
be motivated);

Date of trial completion and reason for early discontinuation, if applicable.
All clinical study documents must be retained by the investigator until at least 2 years after the 
last approval of a marketing application in an ICH region (i.e., United States, Europe, or Japan) 
and until there are no pending or contemplated marketing applications in an ICH region; or, if no 
application is filed or if the application is not approved for such indication, until 2 years after the 
investigation is discontinued and regulatory authorities have been notified. Investigators may be 
required to retain documents longer if required by applicable regulatory requirements, by local 
regulations, or by an agreement with Gilead Sciences. The investigator must notify 
Gilead Sciences before destroying any clinical study records.
Should the investigator wish to assign the study records to another party or move them to another 
location, Gilead Sciences must be notified in advance.
If the investigator cannot guarantee this archiving requirement at the study site for any or all of 
the documents, special arrangements must be made between the investigator and Gilead Sciences 
to store these in sealed containers outside of the site so that they can be returned sealed to the 
investigator in case of a regulatory audit. When source documents are required for the continued 
care of the subject, appropriate copies should be made for storage outside of the site.
Biological samples at the conclusion of this study may be retained in storage by the Sponsor for 
a period up to 15 years for purposes of this study.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 94
08 June 2017
10.1.6.
Case Report Forms
For each subject enrolled, a CRF (or eCRF) must be completed and signed by the principal 
investigator or sub-investigator (as appropriate) within a reasonable time period after data 
collection. This also applies to records for those subjects who fail to complete the study 
(even during a pre-randomization screening period if a CRF was initiated). If a subject 
withdraws from the study, the reason must be noted on the CRF. If a subject is withdrawn from 
the study because of a treatment-limiting adverse event, thorough efforts should be made to
clearly document the outcome.
10.1.7.
Drug Accountability
The investigator or designee (i.e., pharmacist) is responsible for ensuring adequate accountability 
of all used and unused investigational medicinal product, and comparators. This includes 
acknowledgment of receipt of each shipment of study product (quantity and condition), subject 
dispensing records, and returned or destroyed study product. Dispensing records will document 
quantities received from Gilead Sciences and quantities dispensed to subjects, including lot 
number, date dispensed, subject identifier number, subject initials, and the initials of the person 
dispensing the medication.
At study initiation, the monitor will evaluate the site’s standard operating procedure for 
investigational medicinal product disposal/destruction in order to ensure that it complies with 
Gilead Sciences requirements. Drug may be returned or destroyed on an ongoing basis during the 
study if appropriate. At the end of the study, following final drug inventory reconciliation by the 
monitor, the study site will dispose of and/or destroy all unused investigational medicinal 
product supplies, including empty containers, according to these procedures. If the site cannot 
meet Gilead Sciences’ requirements for disposal, arrangements will be made between the site 
and Gilead Sciences or its representative for destruction or return of unused investigational 
medicinal product supplies.
All drug supplies and associated documentation will be periodically reviewed and verified by the 
study monitor over the course of the study.
10.1.8.
Inspections
The investigator should understand that source documents for this trial should be made available 
to appropriately qualified personnel from Gilead Sciences or its representatives, to IRBs or IECs, 
or to regulatory authority or health authority inspectors.
10.1.9.
Protocol Compliance
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 95
08 June 2017
10.2.
Sponsor Responsibilities
10.2.1.
Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be 
made only by Gilead Sciences. All protocol modifications must be submitted to the IRB, IEC, or 
competent authorities in accordance with local requirements. Approval must be obtained before 
changes can be implemented.
10.2.2.
Study Report and Publications
A clinical study report will be prepared and provided to the regulatory agency (ies). 
Gilead Sciences will ensure that the report meets the standards set out in the ICH Guideline for 
Structure and Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may 
be prepared in certain cases.
After conclusion of the study and without prior written approval from Gilead Sciences, 
investigators in this study may communicate, orally present, or publish in scientific journals or 
other scholarly media only after the following conditions have been met:

the results of the study in their entirety have been publicly disclosed by or with the consent of 
Gilead Sciences in an abstract, manuscript, or presentation form; or

the study has been completed at all study sites for at least 2 years.
No such communication, presentation, or publication will include Gilead Sciences’ confidential 
information (see Section 10.1.4).
The investigator will submit any proposed publication or presentation along with the respective 
scientific journal or presentation forum at least 30 days before submission of the publication or 
presentation. The investigator will comply with Gilead Sciences’ request to delete references to 
its confidential information (other than the study results) in any paper or presentation and agrees 
to withhold publication or presentation for an additional 60 days in order to obtain patent 
protection if deemed necessary.
10.3.
Joint Investigator/Sponsor Responsibilities
10.3.1.
Access to Information for Monitoring
In accordance with ICH Good Clinical Practice (ICH GCP) guidelines, the study monitor must 
have direct access to the investigator’s source documentation in order to verify the data recorded 
in the CRFs for consistency.
The monitor is responsible for routine review of the CRFs at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy of the 
data being entered on them. The monitor should have access to any subject records needed to 
verify the entries on the CRFs. The investigator agrees to cooperate with the monitor to ensure 
that any problems detected in the course of these monitoring visits are resolved.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 96
08 June 2017
10.3.2.
Access to Information for Auditing or Inspections
Representatives of regulatory authorities or of Gilead Sciences may conduct inspections or audits 
of the clinical study. If the investigator is notified of an inspection by a regulatory authority the 
investigator agrees to notify the Gilead Sciences medical monitor immediately. The investigator 
agrees to provide to representatives of a regulatory agency or Gilead Sciences access to records, 
facilities, and personnel for the effective conduct of any inspection or audit.
10.3.3.
Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the study at any time. Should 
this be necessary, both parties will arrange discontinuation procedures and notify the appropriate 
regulatory authority(ies), IRBs, and IECs. In terminating the study, Gilead Sciences and the 
investigator will assure that adequate consideration is given to the protection of the subjects’ 
interests.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 97
08 June 2017
11.
REFERENCES
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and 
sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 
2014a;370 (16):1483-93.
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for 
untreated HCV genotype 1 infection. N Engl J Med 2014b;370 (20):1889-98.
Bortolotti F, Verucchi G, Camma C, Cabibbo G, Zancan L, Indolfi G, et al. Long-term course of 
chronic hepatitis C in children: from viral clearance to end-stage liver disease. 
Gastroenterology 2008;134 (7):1900-7.
Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in 
Europe. J Hepatol 2008;48 (1):148-62.
European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use 
(CHMP). Guideline on the Investigation of Bioequivalence. 2010.
Fanta S, Jonsson S, Backman JT, Karlsson MO, Hoppu K. Developmental pharmacokinetics of 
ciclosporin--a population pharmacokinetic study in paediatric renal transplant 
candidates. Br J Clin Pharmacol 2007;64 (6):772-84.
Gane E, Hyland RH, An D, Pang PS, Symonds WT, McHutchison JG, et al. 
Ledipasvir/Sofosbuvir Fixed-Dose Combination Is Safe and Effective in Difficult-
to-Treat Populations Including GT 3 Patients, Decompensated GT 1 Patients, and 
GT 1 Patients With Prior Sofosbuvir Experience [Oral Presentation 6]. 49th 
Annual Meeting of The European Association for the Study of the Liver (EASL); 
2014 April 9-13; London, UK. 
Gilead Sciences Inc. HARVONI® (ledipasvir and sofosbuvir) tablets, for oral use. U.S. 
Prescribing Information. Foster City, CA.  Revised June.  2016:
Gilead Sciences International Ltd. HARVONI (ledipasvir/sofosbuvir) 90 mg/400 mg Film-
Coated Tablets. Summary of Product Characteristics. Cambridge, UK. Revised 
April.  2016:
Hu J, Doucette K, Hartling L, Tjosvold L, Robinson J. Treatment of hepatitis C in children: a 
systematic review. PLoS ONE 2010;5 (7):e11542.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 
Developmental pharmacology--drug disposition, action, and therapy in infants 
and children. N Engl J Med 2003;349 (12):1157-67.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 98
08 June 2017
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and 
sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 
2014;370 (20):1879-88.
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Archives of disease 
in childhood 1969;44 (235):291-303.
Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Archives of 
disease in childhood 1970;45 (239):13-23.
McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon 
alfa-2b alone or in combination with ribavirin as initial treatment for chronic 
hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339 
(21):1485-92.
Mohan N, Gonzalez-Peralta RP, Fujisawa T, Chang MH, Heller S, Jara P, et al. Chronic hepatitis 
C virus infection in children. J Pediatr Gastroenterol Nutr 2010;50 (2):123-31.
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of 
interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon 
alpha2b plus placebo for 48 weeks for treatment of chronic infection with 
hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). 
Lancet 1998;352 (9138):1426-32.
Roche Laboratories Inc. COPEGUS® (ribavirin, USP) TABLETS. US Prescribing Information. 
Nutley, NJ. Revised: January 2010.
Roche Products Limited. Copegus 200mg and 400mg Film-coated Tablets. Summary of Product 
Characteristics. Welwyn Garden City, United Kingdom. Revised: March 2010.
Serranti D, Buonsenso D, Ceccarelli M, Gargiullo L, Ranno O, Valentini P. Pediatric hepatitis C 
infection: to treat or not to treat...what's the best for the child? European review 
for medical and pharmacological sciences 2011;15 (9):1057-67.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for 
Drug Evaluation and Research (CDER). Guidance for Industry. Bioavailability 
and Bioequivalence Studies Submitted in NDAs or INDs — General 
Considerations [Draft Guidance].  March, 2014.
Wirth S. Current treatment options and response rates in children with chronic hepatitis C. World 
J Gastroenterol 2012;18 (2):99-104.
Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, et al. High sustained 
virologic response rates in children with chronic hepatitis C receiving 
peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52 (4):501-7.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 99
08 June 2017
Yang D, Pearce RE, Wang X, Gaedigk R, Wan YJ, Yan B. Human carboxylesterases HCE1 and 
HCE2: ontogenic expression, inter-individual variability and differential 
hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem 
Pharmacol 2009;77 (2):238-47.
Zhu HJ, Appel DI, Jiang Y, Markowitz JS. Age- and sex-related expression and activity of 
carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos 2009;37 
(9):1819-25.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 100
08 June 2017
12.
APPENDICES
Appendix 1.
Investigator Signature Page
Appendix 2.
Study Procedures Table
Appendix 3.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 4.
Tanner Stages*
Appendix 5.
Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements

LDV/SOFFDC 
Protocol GS-US-337-1116 
Final 
Gilead Sciences, Inc. 
Amendment 6.0 
Appendix 1. 
Investigator Signature Page 
GIT..EAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy 
ofLedipasvir/Sofosbuvir Fixed Dose Combination+/- Ribavirin in Adolescents and Children 
with Chronic HCV -infection 
GS-US-337-1116, Protocol Amendment 6.0, 08 June 2017 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
Benedetta Massetto, MD (Printed) 
Medical Monitor 
PD 
Signature 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) 
Signature 
Date 
Site Number 
CONFIDENTIAL 
Page 101 
08 June 2017 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 102
08 June 2017
Appendix 2.
Study Procedures Table
Appendix Table 1.
PK Lead-in: Screening and On-Treatment Study Visits
Screening
(-28 days)
On-treatment
Day 1b
Day 3
Day 10
(+ 3 days)
Clinical Assessments
Informed Consent / Assent
X
Determine Eligibility
X
X
Medical History
X j
Complete Physical Examination
X
X
Symptom-directed Physical Examination
X
X
Tanner Pubertal Stage Assessment
X
Vital Signsa
X
X
X
X
Bone Age Assessment
X
AEs and Concomitant Medications
X
X
X
X
Pregnancy Prevention Counselingf
X
LDV/SOF FDC Swallowability Assessment
X
Xh
Quality of Life Survey
Xi
Review of Study Medication Compliance
X
X
Study Drug Dispensingb
X
Subject Dosing Diary
X
X
X

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 103
08 June 2017
Screening
(-28 days)
On-treatment
Day 1b
Day 3
Day 10
(+ 3 days)
Laboratory Assessments
Hematology, Chemistry
X
X
X
X
Coagulation Tests
X
X
X
HCV RNA
X
X
X
X
Viral Sequencing c
X
X
X
Serum or Urine Pregnancy Testinge
X
X
X
Urinalysis
X
X
X
Urine Drug Screen
X
Intensive PK
X d
HCV Genotyping, IL28B
X
HCV antibody, HIV antibody, HBs antigen, HBs 
antibody, HBc antibody, and HAV antibody
X
HbA1c
X
TSH
X
Alpha fetoprotein
X
Alpha-1 anti-trypsin
X
HBV DNAk
X
a
Vital signs include blood pressure, pulse, respiratory rate and temperature, body weight, and height
b
Day 1 assessments must be performed prior to dosing
c
Plasma samples will be collected and stored for potential HCV sequencing and other virology studies
d
For Cohorts 1 and 2, plasma samples will be collected for PK analyses following dosing of study drug on Day 10 at the following time points: 0 (predose), 0.5, 1, 2, 3, 4, 5, 8, 
and 12 hours post-dose. For Cohort 3, plasma samples for PK analyses will be collected at the following time points: 0 (predose), 0.5, 2, 4, 8, and 12 hours post-dose.
e
Females of childbearing potential only. Serum pregnancy test performed at screening and for confirmation of positive urine pregnancy test. 
PPD

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 104
08 June 2017
f
Including partner pregnancy prevention for male participants (all subjects ≥ 12 years of age and subjects < 12 years of age at the discretion of the Investigator based on 
subject’s pubertal status). 
g
h
Swallowability, for subjects on tablet formulation, can occur at Day 1 if not completed during screening.
i
Quality of life survey will be completed by all subjects if a site is approved to use the survey. Subject is to review questionnaire with a parent/guardian and write/mark 
answers directly onto the questionnaire.
j
Parental height will be collected (if available)
k
Only subjects HBcAb positive at Screening
PPD

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 105
08 June 2017
Appendix Table 2.
Treatment Phase: Screening and On-Treatment Study Visits
Screeningc
(-28 days)
Day 1c
Visit identified by on-treatment study week
1c
2
4
8
12
16k
20k
24k
Early Termination
Clinical Assessments
Informed Consent / Assent
X
Determine Eligibility
X
X
Medical History
Xi
Complete Physical Examination
X
X
Xj
X
X
Symptom-Directed Physical Examination
X
X
X
X
Xk
X
X
Tanner Pubertal Stage Assessment
X
Xj
X
X
Vital Signsa
X
X
X
X
X
X
X
X
X
X
X
Bone Age Assessment
X
AEs and Concomitant Medications
X
X
X
X
X
X
X
X
X
X
X
Pregnancy Prevention Counseling g
X
Xj
X
X
LDV/SOF FDC Swallowability Assessment
X
Xh
Quality of Life Survey e
X
Xj
X
X
Review of Study Medication Compliance
X
X
X
X
X
X
X
Study Drug Dispensingb
X
X
X
Xk
X
X
Palatability Assessment of Oral Granules as 
applicable
X
Laboratory Assessments
Hematology, Chemistry, Coagulation
X
X
X
X
X
X
X
X
X
X
X
HCV RNA
X
X
X
X
X
X
X
X
X
X
X
Viral Sequencing d
X
X
X
X
X
X
X
X
X
X
Serum or Urine Pregnancy Testingl
X
X
X
X
X
X
X
X
X
Urinalysis
X
X
PPD

LDVISOFFDC 
Protocol GS-US-337-1116 
Gilead Sciences, Inc. 
Final 
Amendment 6.0 
Screening< 
Visit identified by on-treatment study week 
(-28 days) 
Day 1< 
l c 
2 
4 
Urine Drug Test 
X 
HCV Genotyping, IL28B 
X 
HCV antibody, HIV antibody, HBs antigen, 
X 
HBs antibody, HBc antibody, and HA V antibody 
HbAlc 
X 
TSH 
X 
Alpha fetoprotein, Alpha-! anti-trypsin 
X 
HBV DNAm 
X 
X 
Single PK collected at any time point 
X 
X 
Single PK Sample collected between 15 minutes 
X 
to 4 homs post-dosen 
rpo 
a 
b 
Vital signs include blood pressm·e, pulse, respiratory rate and temperature, and body weight and height 
The IWRS will provide dit·ection on the specifics of each subject's study drug dispensing. 
8 
12 
16k 
20k 
24k 
xi 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
c 
d 
Subjects rolling over from PK Lead-in phase will not be required to repeat screening, Day 1 or Week 1 visits dtumg the on Treatment Phase 
Plasma samples will be collected and stored for potential HCV sequencing and other virology studies 
Early Termination 
X 
X 
X 
e 
Quality of life stuvey will be completed by all subjects if a site is approved to use the stuvey. Subject is to review questionnait·e with a parent/guardian and \¥rite/mark 
f 
g 
h 
J 
k 
1 
m 
n 
0 
answers directly onto the questionnaire. 
PPD 
'Iiic!Ud·m
~~g~p~a~r~
tne~r~p~re~gn=a~n~cy=p~re~v~e~n..-h~on~for male patttctpants (aJlSUbjeCtS ~ f2 years of age and SUbjeCtS< f2 years of age at tlie'Citscrehon on lie Ifiveshgator based on 
subject's pubertal status). 
Swallowability, for subjects on tablet f01mulation, can occm· at Day 1 if not completed dtumg screening. 
Parental height will be collected (if available) 
Subjects on 12 Week Treatment regitnen only 
Subjects on 24 Week Treatment regitnen only 
Females of childbeatmg potential only. Serum pregnancy test petfonued at screening and for confumation of positive tume pregnancy test 
Only subjects with positive HBcAb at Screening 
A sin ale PK sam2le will be collected at Weeks 4 and 8 between 15 minutes to 4 hotu-s post dose as applicable, P O 
~--------------------------------~ 
1-'U 
CONFIDENTIAL 
Page 106 
08 June 2017 
I 

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 107
08 June 2017
Appendix Table 3.
Treatment Phase: Post Treatment Visits Following Primary Study
4 Weeks Post Treatment
12 Weeks Post Treatment
24 Weeks Post Treatment
Clinical Assessments
Vital Signs, Body weight and Height
X
X
X
Symptom-directed Physical Exam
X
X
X
AEs
X
Xc
Xc
Concomitant Medications
X
Quality of Life Survey a
X
X
Tanner Pubertal Stage Assessment 
X
X
Bone Age Assessment
X
Pregnancy Prevention Counselingd
X
Xf
Xf
Laboratory Assessments
Hematology, Chemistry
X
X
HCV RNA
X
X
X
Viral Sequencing b
X
X
X
Urine Pregnancy Test
X
Xe
Xe
HBV DNAg
X
X
X
a
Quality of life survey will be completed by all subjects at 12-Week and 24-Week Post Treatment visits if a site is approved to use the survey.  Subject is to review 
questionnaire with a parent/guardian and write/mark answers directly onto the questionnaire.
b
Plasma samples will be collected and stored for potential HCV sequencing and other virology studies
c
At Post Treatment Week 12 and 24, only SAEs will be captured
d
Including partner pregnancy prevention for male participants (all subjects ≥ 12 years of age and subjects < 12 years of age at the discretion of the Investigator based on 
subject’s pubertal status).
e
GT-3 subjects only: Female subjects of childbearing potential should be provided with Urine Pregnancy Test Kits, instructed on their use and requested to continue to 
self-monitor for pregnancy for 6 months after their last dose of RBV. If required by regulations, additional pregnancy tests beyond 6 months may be added. The subject 
should be contacted every 4 weeks and asked to report results of the urine pregnancy tests. If a positive urine pregnancy test is reported, the subject should return to the clinic 
for a serum pregnancy test.
f
GT-3 subjects only
g
Only subjects HBcAb positive at Screening

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 108
08 June 2017
Appendix 3.
GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1
Grade 2
Grade 3
Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days
8.5 to 10.0 g/dL 
85 to 100 g/L
7.5 to 8.5 g/dL 
75 to 85 g/L
6.5 to 7.5 g/dL 
65 to 75 g/L
6.5 g/dL
65 g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 
10.0 to 10.9 g/dL
100 to 109 g/L
OR
Any decrease from Baseline
2.5 to 3.5 g/dL
25 to 35 g/L
9.0 to 10.0 g/dL
90 to 100 g/L
OR
Any decrease from Baseline
3.5 to 4.5 g/dL
35 to 45 g/L
7.0 to 9.0 g/dL
70 to 90 g/L
OR
Any decrease from Baseline
4.5 g/dL
45 g/L
7.0 g/dL
70 g/L
Infant, 36–56 Days
(HIV POSITIVE OR
NEGATIVE)
8.5 to 9.4 g/dL
85 to 94 g/L
7.0 to 8.5 g/dL
70 to 85 g/L
6.0 to 7.0 g/dL
60 to < 70 g/L
6.0 g/dL
< 60 g/L
Infant, 22–35 Days
(HIV POSITIVE OR
NEGATIVE)
9.5 to 10.5 g/dL
95 to 105 g/L
8.0 to 9.5 g/dL
80 to 95 g/L
7.0 to 8.0 g/dL
70 to 80 g/L
7.0 g/dL
70 g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE)
12.0 to 13.0 g/dL
120 to 130 g/L
10.0 to 12.0 g/dL
100 to 120 g/L
9.0 to 10.0 g/dL
90 to 100 g/L
9.0 g/dL
90 g/L
Absolute Neutrophil Count  
(ANC)
Adult and Pediatric, 
≥ 7 Months# 
1000 to 1300/mm3
750 to 1000/mm3
500 to 750/mm3
500/mm3
1.00 to 1.30 GI/L
0.75 to 1.00 GI/L
0.50 to 0.75 GI/L
0.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
> 13 Years
300 to 400/mm3
300 to 400/μL
200 to 300/mm3
200 to 300/μL
100 to 200/mm3
100 to 200/μL
100/mm3
100/μL

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 109
08 June 2017
HEMATOLOGY
Grade 1
Grade 2
Grade 3
Grade 4
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13 Years
600 to 650/mm3
0.60 to 0.65 GI/L
500 to 600/mm3
0.50 to 0.60 GI/L
350 to 500/mm3
0.35 to 0.50 GI/L
350/mm3
0.35 GI/L
Platelets 
100,000 to < 125,000/mm3
100 to 125 GI/L
50,000 to 100,000/mm3
50 to 100 GI/L
25,000 to 50,000/mm3
25 to 50 GI/L
25,000/mm3
25 GI/L
WBCs 
2000/mm3 to 2500/mm3
1,500 to 2,000/mm3
1000 to 1,500/mm3
1000/mm3
2.00 GI/L to 2.50 GI/L
1.50 to 2.00 GI/L
1.00 to 1.50 GI/L
1.00 GI/L
Hypofibrinogenemia
100 to 200 mg/dL
75 to 100 mg/dL
50 to 75 mg/dL
50 mg/dL
1.00 to 2.00 g/L
0.75 to 1.00 g/L
0.50 to 0.75 g/L
0.50 g/L
Hyperfibrinogenemia
ULN to 600 mg/dL
600 mg/dL
—
—
ULN  to 6.0 g/L
6.0 g/L
—
—
Fibrin Split Product 
20 to 40 μg/mL
40 to 50 μg/mL
50 to 60 μg/mL
60 μg/mL
20 to 40 mg/L
40 to 50 mg/L
50 to 60 mg/L
60 mg/L
Prothrombin Time (PT)
1.00 to 1.25 ULN
1.25 to 1.50 ULN 
1.50 to 3.00 ULN 
3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)
1.1 to 1.5 x ULN
>1.5 to 2.0 x ULN
>2.0 to 3.0 x ULN
>3.0 x ULN
Activated Partial
Thromboplastin Time (APTT)
1.00 to 1.66 ULN
1.66 to 2.33 ULN
2.33 to 3.00 ULN
3.00 ULN
Methemoglobin 
5.0 to 10.0%
10.0 to 15.0%
15.0 to 20.0%
20.0% 
#
An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects.  Please follow the Gilead convention of grading 
any result within the LLN and ULN a 0.  

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 110
08 June 2017
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyponatremia 
130 to <LLN mEq/L
125 to 130 mEq/L
121 to 125 mEq/L
121 mEq/L
130 to <LLN mmol/L
125 to 130 mmol/L
121 to 125 mmol/L
121 mmol/L
Hypernatremia 
>ULN  to 150 mEq/L
150 to 154 mEq/L
154 to 159 mEq/L
159 mEq/L
>ULN  to 150 mmol/L
150 to 154 mmol/L
154 to 159 mmol/L
159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year
3.0 to  <LLN mEq/L
2.5 to 3.0 mEq/L
2.0 to 2.5 mEq/L
2.0 mEq/L
3.0 to <LLN mmol/L
2.5 to 3.0 mmol/L
2.0 to 2.5 mmol/L
2.0 mmol/L
Infant  <1 Year 
3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L
2.5 to 3.0 mEq/L                
2.5 to <3.0 mmolL
2.0 to 2.5 mEq/L                 
2.0 to <2.5 mmolL
2.0 mEq/L                         
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year
5.6 to 6.0 mEq/L
5.6 to 6.0 mmol/L
6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L
6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L
7.0 mEq/L
7.0 mmol/L
Infant  <1 Year
>ULN to 6.0 mEq/L           
>ULN to 6.0 mmol/L
> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L
6.5 to 7.0 mEq/L             
6.5 to 7.0 mmol/L
7.0 mEq/L                  
7.0 mmol/L
Hypoglycemia
Adult and Pediatric
1 Month
55 to 64 mg/dL
3.03 to 3.58 mmol/L
40 to 55 mg/dL
2.20 to 3.03 mmol/L
30 to 40 mg/dL
1.64 to 2.20 mmol/L
30 mg/dL
1.64 mmol/L
Infant, 1 Month
50 to 54 mg/dL
2.8 to 3.0 mmol/L
40 to 50 mg/dL
2.2 to 2.8 mmol/L
30 to 40 mg/dL
1.7 to 2.2 mmol/L
30 mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 
116 to 160 mg/dL
160 to 250 mg/dL
250 to 500 mg/dL
500 mg/dL
6.42 to 8.91 mmol/L
8.91 to 13.90 mmol/L
13.90 to 27.79 mmol/L
27.79 mmol/L

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 111
08 June 2017
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hyperglycemia, Fasting
110 to 125 mg/dL
6.08 to 6.96 mmol/L
>125 to 250 mg/dL
>6.96 to 13.90 mmol/L
>250 to 500 mg/dL
>13.90 to 27.79 mmol/L
>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years
7.8 <LLN mg/dL
1.94 to <LLN mmol/L
7.0 to 7.8 mg/dL
1.74 to 1.94 mmol/L
6.1 to 7.0 mg/dL
1.51 to 1.74 mmol/L
6.1 mg/dL
1.51 mmol/L
Pediatric ≥7 days -2 Years
7.8 to 8.4 mg/dL                          
1.94 to 2.10 mmol/L
7.0 to <7.8 mg/dL              
1.74 to <1.94 mmolL
6.1 to  <7.0 mg/dL                      
1.51 to < 1.74 mmolL
< 6.1 mg/dL                           
< 1.51 mmol/L
Infant, 7 Days
6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L
6.0 to 6.5 mg/dL
1.49 to < 1.61 mmol/L
5.5 to 6.0 mg/dL
1.36 to < 1.49 mmol/L 
5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia (corrected 
for albumin if appropriate*)
Adult and Pediatric 
7 Days
>ULN to 11.5 mg/dL
11.5 to 12.5 mg/dL
12.5 to 13.5 mg/dL
13.5 mg/dL
>ULN to 2.88 mmol/L
2.88 to 3.13 mmol/L
3.13 to 3.38 mmol/L
3.38 mmol/L
Infant, 7 Days
11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L
12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L
12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L
13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized)
3.0 mg/dL to LLN
2.5 to < 3.0 mg/dL
2.0 to 2.5 mg/dL
2.0 mg/dL
0.74 mmol/L to LLN
0.62 to 0.74 mmol/L
0.49 to 0.62 mmol/L
0.49 mmol/L
Hypercalcemia (ionized)
ULN to 6.0 mg/dL
6.0 to 6.5 mg/dL
6.5 to 7.0 mg/dL
7.0 mg/dL
ULN to 1.50 mmol/L
1.50 to 1.63 mmol/L
1.63 to 1.75 mmol/L
1.75 mmol/L
Hypomagnesemia
1.40 to  <LLN mg/dL
1.2 to <LLN mEq/L
1.04 to 1.40 mg/dL
0.9 to   1.2 mEq/L
0.67 to 1.04 mg/dL
0.6 to 0.9 mEq/L
0.67 mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L
0.43 to 0.58 mmol/L
0.28 to 0.43 mmol/L
0.28 mmol/L

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 112
08 June 2017
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Hypophosphatemia
Adult and Pediatric
14 Years
2.0 to < LLN mg/dL
0.63  to LLN mmol/L
1.5 to 2.0 mg/dL
0.47 to 0.63 mmol/L
1.0 to 1.5 mg/dL
0.31 to 0.47 mmol/L
1.0 mg/dL
0.31 mmol/L
Pediatric 1 Year–14 Years 
3.0 to <LLN mg/dL
0.96 to <LLN mmol/L
2.5 to 3.0 mg/dL
0.80 to < 0.96 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L
1.5 mg/dL
< 0.47 mmol/L
Pediatric 1 Year
3.5 to <LLN mg/dL
1.12 to <LLN mmol/L
2.5 to 3.5 mg/dL
0.80 to < 1.12 mmol/L
1.5 to 2.5 mg/dL
0.47 to < 0.80 mmol/L
1.5 mg/dL
< 0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
> 14 Days
1.0 to 1.5 ULN 
1.5 to 2.5 ULN
2.5 to 5.0 ULN 
5.0 ULN 
Infant, 14 Days 
(non-hemolytic)
NA
20.0 to 25.0 mg/dL
342 to 428 μmol/L
25.0 to 30.0 mg/dL
> 428 to 513 μmol/L
30.0 mg/dL
> 513 μmol/L
Infant, 14 Days
(hemolytic)
NA
NA
20.0 to 25.0 mg/dL
342 to 428 μmol/L
25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen
1.25 to 2.50 ULN 
2.50 to 5.00 ULN 
5.00 to 10.00 ULN 
10.00 ULN
Hyperuricemia
>ULN to 10.0 mg/dL 
10.0 to 12.0 mg/dL 
12.0 to 15.0 mg/dL 
15.0 mg/dL
>ULN to 597 μmol/L
597 to 716 μmol/L
716 to 895 μmol/L
895 μmol/L
Hypouricemia               
Adult and Pediatric           
≥ 1 year   
Infant  < 1 Year
1.5 mg/dL to LLN
87 μmol/L to LLN
1.0 to 1.5 mg/dL
57 to 87 μmol/L
0.5 to 1.0 mg/dL
27 to 57 μmol/L
0.5 mg/dL
27 μmol/L
N/A
1.0 mg/dl to <LLN-
57 μmol to <LLN
0.5 to 1.0 mg/dL
27 to 57 μmol/L
0.5 mg/dL
27 μmol/L
Creatinine** 
1.50 to 2.00 mg/dL
133 to 177 μmol/L
2.00 to 3.00 mg/dL
177 to 265 μmol/L
3.00 to 6.00 mg/dL 
265 to 530 μmol/L
6.00 mg/dL
530 μmol/L

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 113
08 June 2017
CHEMISTRY
Grade 1
Grade 2
Grade 3
Grade 4
Bicarbonate
Adult and Pediatric 
≥ 4 Years
16.0 mEq/L to LLN 
11.0 to 16.0 mEq/L
8.0 to 11.0 mEq/L
8.0 mEq/L
16.0 mmol/L to LLN
11.0 to 16.0 mmol/L
8.0 to 11.0 mmol/L
8.0 mmol/L
Pediatric < 4 Years
NA
11.0 mEq/L to <LLN
8.0 to 11.0 mEq/L
8.0 mEq/L
11.0 mmol/L to <LLN
8.0 to 11.0 mmol/L
8.0 mmol/L
Triglycerides
(Fasting)
NA
500 to 750 mg/dL
5.64–8.47 mmol/L
750 to 1200 mg/dL
8.47–13.55 mmol/L
1200 mg/dL
13.55 mmol/L
LDL (Fasting)
Adult
130 to 160 mg/dL
>160 to 190 mg/dL
> 190 mg/dL
NA
3.35 to 4.15 mmol/L
>4.15 to 4.92 mmol/L
>4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years
110 to 130 mg/dL
>130 to 190 mg/dL
> 190 mg/dL
NA
2.84 to 3.37 mmol/L
>3.37 to  4.92 mmol/L
>4.92 mmol/L
Hypercholesterolemia
(Fasting)
200 to 239 mg/dL
239 to 300 mg/dL
300 mg/dL
NA
5.16 to 6.19 mmol/L
6.19 to 7.77 mmol/L
7.77 mmol/L
Pediatric 18 Years
170 to 199 mg/dL
4.39 to 5.15 mmol/L
199 to 300 mg/dL
5.15 to 7.77 mmol/L
300 mg/dL
7.77 mmol/L
NA
Creatine Kinase
3.0 to 6.0 ULN
6.0 to 10.0 ULN
10.0 to 20.0 ULN
20.0 ULN
*
Calcium should be corrected for albumin if albumin is < 4.0 g/dL
** An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >70 yrs.  Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.  

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 114
08 June 2017
ENZYMES
Grade 1
Grade 2
Grade 3
Grade 4
AST (SGOT) 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
ALT (SGPT) 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
GGT
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
Alkaline Phosphatase 
1.25 to 2.50 ULN
2.50 to 5.00 ULN
5.00 to 10.00 ULN
10.00 ULN
Total Amylase
1.0 to 1.5 ULN
1.5 to 2.0 ULN
2.0 to 5.0 ULN
5.0 ULN
Pancreatic Amylase
1.0 to 1.5 ULN
1.5 to 2.0 ULN
2.0 to 5.0 ULN
5.0 ULN
Lipase 
1.0 to 1.5 ULN
1.5 to 3.0 ULN
3.0 to 5.0 ULN
5.0 ULN
Albumin
Pediatrics <16 years 
≥ 16 years
-
2.0 to LLN g/dL
20 to LLN g/L
2.0 g/dL
20 g/L
NA
3.0 g/dL to LLN
30 g/L to LLN
2.0 to 3.0 g/dL
20 to 30 g/L
2.0 g/dL
20 g/L
NA

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 115
08 June 2017
URINALYSIS
Grade 1
Grade 2
Grade 3
Grade 4
Hematuria (Dipstick) 
1
2
3-4+
NA
Hematuria (Quantitative) 
See Note below
                              Females
>ULN - 10 RBC/HPF
10-75 RBC/HPF
> 75 RBC/HPF
NA
                              Males
6-10 RBC/HPF
10-75 RBC/HPF
> 75 RBC/HPF
NA
Proteinuria (Dipstick)
1
2–3
4
NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years
200 to 999 mg/24 h
>999 to 1999 mg/24 h
>1999 to 3500 mg/24 h
3500 mg/24 h
Pediatric 3 Mo to 
< 10 Years
201 to 499 mg/m2/24 h
>499 to 799 mg/m2/24 h
>799 to 1000 mg/m2/24 h
1000 mg/ m2/24 h
Glycosuria (Dipstick)
1+
2-3
4
NA
Notes: 

Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.

With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.

If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for 
the AE.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 116
08 June 2017
CARDIOVASCULAR
Grade 1
Grade 2
Grade 3
Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)
Asymptomatic AND No 
intervention indicated
Asymptomatic AND Non-
urgent medical intervention 
indicated
Symptomatic, non-life-
threatening AND Non-
urgent medical intervention 
indicated 
Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac-ischemia/Infarction
NA
NA
Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia 
Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant acute 
blood loss)
NA
Symptomatic AND No 
transfusion indicated
Symptomatic AND 
Transfusion of 2 units 
packed RBCs (for children 
10 cc/kg) indicated 
Life-threatening hypotension 
OR Transfusion of 2 units 
packed RBCs indicated (for 
children 10 cc/kg) indicated
Hypertension (with repeat 
testing at same visit)
140–159 mmHg systolic 
OR 
90–99 mmHg diastolic
159–179 mmHg systolic 
OR 
99–109 mmHg diastolic
179 mmHg systolic 
OR 
109 mmHg diastolic
Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization (other than 
ER visit) indicated
Pediatric 17 Years (with 
repeat testing at same visit)
NA
91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)
≥95th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)
Life-threatening consequences 
(eg, malignant hypertension) 
OR Hospitalization indicated 
(other than emergency room 
visit)
Hypotension
NA
Symptomatic, corrected with 
oral fluid replacement
Symptomatic, IV fluids 
indicated
Shock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion
Asymptomatic, small 
effusion requiring no 
intervention
Asymptomatic, moderate or 
larger effusion requiring no 
intervention
Effusion with non-life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicated
Life-threatening consequences 
(eg, tamponade) OR Urgent 
intervention indicated

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 117
08 June 2017
CARDIOVASCULAR
Grade 1
Grade 2
Grade 3
Grade 4
Prolonged PR Interval
PR interval 
0.21 to 0.25 sec
PR interval
0.25 sec
Type II 2nd degree AV 
block OR Ventricular pause 
3.0 sec
Complete AV block 
Pediatric 16 Years
1st degree AV block
(PR > normal for age and 
rate)
Type I 2nd degree AV block 
Type II 2nd degree AV 
block 
Complete AV block
Prolonged QTc
Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baseline
Asymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baseline
Asymptomatic, QTc interval 
0.50 sec OR Increase in 
interval 0.06 sec above 
baseline
Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16 Years
Asymptomatic, QTc interval 
0.450 to 0.464 sec 
Asymptomatic, QTc interval 
0.465 to 0.479 sec 
Asymptomatic, QTc interval 
0.480 sec 
Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism
NA
Deep vein thrombosis AND 
No intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) 
Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) 
Embolic event (eg, pulmonary 
embolism, life-threatening 
thrombus) 
Vasovagal Episode (associated 
with a procedure of any kind)
Present without loss of 
consciousness 
Present with transient loss of 
consciousness
NA 
NA
Ventricular Dysfunction 
(congestive heart failure, 
CHF)
NA
Asymptomatic diagnostic 
finding AND intervention 
indicated
New onset with symptoms 
OR Worsening symptomatic 
CHF
Life-threatening CHF

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 118
08 June 2017
RESPIRATORY
Grade 1
Grade 2
Grade 3
Grade 4
Bronchospasm (acute)
FEV1 or peak flow reduced to 
70% to 80%
FEV1 or peak flow 50% to 69%
FEV1 or peak flow 25% to 
49% 
Cyanosis OR FEV1 or peak flow 
25% OR Intubation
Dyspnea or Respiratory 
Distress
Dyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities 
Dyspnea on exertion causing 
greater than minimal interference 
with usual social & functional 
activities 
Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years
Wheezing OR minimal 
increase in respiratory rate for 
age
Nasal flaring OR Intercostal 
retractions OR Pulse oximetry 
90% to 95%
Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%
Respiratory failure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1
Grade 2
Grade 3
Grade 4
Uveitis
Asymptomatic but detectable 
on exam
Symptomatic anterior uveitis OR 
Medical intervention indicated
Posterior or pan-uveitis OR 
Operative intervention 
indicated
Disabling visual loss in affected 
eye(s) 
Visual Changes (from 
baseline)
Visual changes causing no or 
minimal interference with 
usual social & functional 
activities
Visual changes causing greater 
than minimal interference with 
usual social & functional 
activities
Visual changes causing 
inability to perform usual 
social & functional activities
Disabling visual loss in affected 
eye(s)

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 119
08 June 2017
SKIN
Grade 1
Grade 2
Grade 3
Grade 4
Alopecia
Thinning detectable by 
study participant or  
caregiver (for disabled 
adults)
Thinning or patchy hair loss 
detectable by health care 
provider
Complete hair loss
NA
Cutaneous Reaction – Rash
Localized macular rash 
Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions 
Diffuse macular, 
maculopapular, or morbilliform 
rash with vesicles or limited 
number of bullae OR 
Superficial ulcerations of 
mucous membrane limited to 
one site
Extensive or generalized 
bullous lesions OR 
Stevens-Johnson syndrome 
OR Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation
Slight or localized
Marked or generalized
NA
NA
Hypopigmentation
Slight or localized 
Marked or generalized
NA
NA
Pruritis (itching – no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)
Itching causing no or 
minimal interference with 
usual social & functional 
activities
Itching causing greater than 
minimal interference with 
usual social & functional 
activities
Itching causing inability to 
perform usual social & 
functional activities 
NA

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 120
08 June 2017
GASTROINTESTINAL
Grade 1
Grade 2
Grade 3
Grade 4
Anorexia
Loss of appetite without 
decreased oral intake
Loss of appetite associated with 
decreased oral intake without 
significant weight loss 
Loss of appetite associated 
with significant weight loss 
Life-threatening consequences 
OR Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutrition]
Ascites
Asymptomatic
Symptomatic AND Intervention 
indicated (eg, diuretics or 
therapeutic paracentesis)
Symptomatic despite 
intervention
Life-threatening consequences
Cholecystitis
NA
Symptomatic AND Medical 
intervention indicated
Radiologic, endoscopic, or 
operative intervention 
indicated
Life-threatening consequences 
(eg, sepsis or perforation) 
Constipation 
NA
Persistent constipation requiring 
regular use of dietary 
modifications, laxatives, or 
enemas 
Obstipation with manual 
evacuation indicated
Life-threatening consequences 
(eg, obstruction)
Diarrhea 
Adult and Pediatric 
1 Year
Transient or intermittent 
episodes of unformed stools 
OR Increase of 3 stools 
over baseline/24 hr
Persistent episodes of unformed 
to watery stools OR Increase of 
4–6 stools over baseline per 
24 hrs. 
Bloody diarrhea OR Increase 
of 7 stools per 24-hour 
period OR IV fluid 
replacement indicated
Life-threatening consequences 
(eg, hypotensive shock)
Pediatric 1 Year
Liquid stools (more 
unformed than usual) but 
usual number of stools
Liquid stools with increased 
number of stools OR Mild 
dehydration
Liquid stools with moderate 
dehydration
Liquid stools resulting in 
severe dehydration with 
aggressive rehydration 
indicated OR Hypotensive 
shock
Dysphagia-Odynophagia 
Symptomatic but able to eat 
usual diet
Symptoms causing altered 
dietary intake without medical 
intervention indicated
Symptoms causing severely 
altered dietary intake with 
medical intervention indicated
Life-threatening reduction in 
oral intake

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 121
08 June 2017
GASTROINTESTINAL
Grade 1
Grade 2
Grade 3
Grade 4
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia-Odynophagia
Erythema of the mucosa
Patchy pseudomembranes or 
ulcerations 
Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor trauma
Tissue necrosis OR Diffuse 
spontaneous mucosal bleeding 
OR Life-threatening 
consequences (eg, aspiration, 
choking)
Nausea 
Transient (24 hours) or 
intermittent nausea with no 
or minimal interference with 
oral intake
Persistent nausea resulting in 
decreased oral intake for 24–48 
hours
Persistent nausea resulting in 
minimal oral intake for 48 
hours OR Aggressive 
rehydration indicated (eg, 
IV fluids)
Life-threatening consequences 
(eg, hypotensive shock)
Pancreatitis
NA
Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)
Symptomatic AND 
Hospitalization indicated 
(other than ER visit)
Life-threatening consequences 
(eg, sepsis, circulatory failure, 
hemorrhage)
Proctitis (functional-
symptomatic)
Also see Mucositis/ 
Stomatitis for Clinical 
Exam
Rectal discomfort AND No 
intervention indicated
Symptoms causing greater than 
minimal interference with usual 
social & functional activities OR 
Medical intervention indicated 
Symptoms causing inability to 
perform usual social/ 
functional activities OR 
Operative intervention 
indicated 
Life-threatening consequences 
(eg, perforation)
Vomiting
Transient or intermittent 
vomiting with no or 
minimal interference with 
oral intake
Frequent episodes of vomiting 
with no or mild dehydration
Persistent vomiting resulting 
in orthostatic hypotension OR 
Aggressive rehydration 
indicated
Life-threatening consequences 
(eg, hypotensive shock)

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 122
08 June 2017
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Alteration in Personality-
Behavior or in Mood (eg, 
agitation, anxiety, 
depression, mania, 
psychosis)
Alteration causing no or 
minimal interference with 
usual social & functional 
activities 
Alteration causing greater than 
minimal interference with 
usual social & functional 
activities 
Alteration causing inability to 
perform usual social & 
functional activities 
Behavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation or 
attempt, acute psychosis) OR 
Causing inability to perform 
basic self-care functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)
Changes causing no or 
minimal interference with 
usual social & functional 
activities
Mild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activities
Confusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activities
Delirium OR obtundation, OR 
coma
Ataxia 
Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no 
or minimal interference with 
usual social & functional 
activities
Symptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activities
Symptomatic ataxia causing 
inability to perform usual
social & functional activities 
Disabling ataxia causing 
inability to perform basic self-
care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention 
Deficit Disorder) 
Disability causing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicated
Disability causing greater than 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources on part-time basis 
indicated
Disability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicated
Disability causing inability to 
perform basic self-care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)
NA
NA
Transient ischemic attack
Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
Developmental delay –
Pediatric 16 Years
Mild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate 
for the setting 
Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting 
Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting 
Developmental regression, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 123
08 June 2017
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Headache 
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater 
than minimal interference with 
usual social & functional 
activities
Symptoms causing inability to 
perform usual social & 
functional activities
Symptoms causing inability to 
perform basic self-care 
functions OR Hospitalization 
indicated (other than ER visit) 
OR Headache with significant 
impairment of alertness or
other neurologic function 
Insomnia
NA
Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activities
Difficulty sleeping causing 
inability to perform usual 
social & functional activities
Disabling insomnia causing 
inability to perform basic self-
care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) 
Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak-
ness causing no or minimal 
interference with usual 
social & functional activities
Muscle weakness causing 
greater than minimal 
interference with usual social 
& functional activities
Muscle weakness causing 
inability to perform usual 
social & functional activities 
Disabling muscle weakness 
causing inability to perform 
basic self-care functions OR 
Respiratory muscle weakness 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)
Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social &
functional activities 
Sensory alteration or 
paresthesia causing greater 
than minimal interference with 
usual social & functional 
activities 
Sensory alteration or 
paresthesia causing inability to 
perform usual social & 
functional activities
Disabling sensory alteration or 
paresthesia causing inability to 
perform basic self-care 
functions
Seizure: (new onset) 
NA
1 seizure 
2–4 seizures 
Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 124
08 June 2017
NEUROLOGICAL
Grade 1
Grade 2
Grade 3
Grade 4
Seizure: (pre-existing) 
For Worsening of Existing 
Epilepsy the Grades Should 
Be Based on an Increase 
from Previous Level of 
Control to Any of These 
Levels
NA
Increased frequency of pre-
existing seizures (non-
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable meds 
in a previously controlled 
seizure disorder
Change in seizure character 
from baseline either in 
duration or quality (eg, 
severity or focality) 
Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or difficult 
to control (eg, refractory 
epilepsy)
Seizure 
– Pediatric 18 Years
Seizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5 minutes with < 24 hours 
post ictal state
Seizure, generalized onset 
with or without secondary 
generalization, lasting 5–20 
minutes with 
< 24 hours post ictal state
Seizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes 
Seizure, generalized onset 
with or without secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated 
with a procedure)
NA
Present
NA
NA
Vertigo
Vertigo causing no or 
minimal interference with 
usual social & functional 
activities
Vertigo causing greater than 
minimal interference with 
usual social & functional 
activities 
Vertigo causing inability to 
perform usual social & 
functional activities
Disabling vertigo causing 
inability to perform basic self-
care functions

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 125
08 June 2017
MUSCULOSKELETAL
Grade 1
Grade 2
Grade 3
Grade 4
Arthralgia
See also Arthritis
Joint pain causing no or 
minimal interference with 
usual social & functional 
activities
Joint pain causing greater than 
minimal interference with usual 
social & functional activities
Joint pain causing inability 
to perform usual social & 
functional activities
Disabling joint pain causing 
inability to perform basic self-
care functions
Arthritis
See also Arthralgia
Stiffness or joint swelling 
causing no or minimal 
interference with usual 
social & functional activities
Stiffness or joint swelling causing 
greater than minimal interference 
with usual social & functional 
activities
Stiffness or joint swelling 
causing inability to perform 
usual social & functional 
activities
Disabling joint stiffness or 
swelling causing inability to 
perform basic self-care 
functions
Bone Mineral Loss
BMD t-score or z-score
–2.5 to –1.0 
BMD t-score or z-score –2.5
Pathological fracture 
(including loss of vertebral 
height)
Pathologic fracture causing 
life-threatening consequences 
Pediatric 21 Years
BMD z-score 
–2.5 to –1.0
BMD z-score < –2.5
Pathological fracture 
(including loss of vertebral 
height)
Pathologic fracture causing 
life-threatening consequences 
Myalgia
(non-injection site)
Muscle pain causing no or 
minimal interference with 
usual social & functional 
activities
Muscle pain causing greater than 
minimal interference with usual 
social & functional activities
Muscle pain causing 
inability to perform usual 
social & functional activities
Disabling muscle pain causing 
inability to perform basic self-
care functions
Osteonecrosis
NA
Asymptomatic with radiographic 
findings AND No operative 
intervention indicated
Symptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicated
Disabling bone pain with 
radiographic findings causing 
inability to perform basic self-
care functions

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 126
08 June 2017
SYSTEMIC
Grade 1
Grade 2
Grade 3
Grade 4
Acute Systemic Allergic 
Reaction 
Localized urticaria 
(wheals) with no medical 
intervention indicated
Localized urticaria with medical 
intervention indicated OR Mild 
angioedema with no medical 
intervention indicated
Generalized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasm
Acute anaphylaxis OR Life-
threatening bronchospasm OR 
laryngeal edema
Chills
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater than 
minimal interference with usual 
social & functional activities 
Symptoms causing inability to 
perform usual social & 
functional activities
NA
Fatigue
Malaise
Symptoms causing no or 
minimal interference with 
usual social & functional 
activities
Symptoms causing greater than 
minimal interference with usual 
social & functional activities
Symptoms causing inability to 
perform usual social & 
functional activities
Incapacitating fatigue/malaise 
symptoms causing inability to 
perform basic self-care 
functions
Fever (nonaxillary)
37.7C to 38.6C
99.8F to 101.5F
38.7C to 39.3C
101.6F to 102.8F
39.4C to 40.5C
102.9F to 104.9F
40.5C 
104.9F
Pain- Indicate Body Site
See also Injection Site 
Pain, Headache, 
Arthralgia, and Myalgia
Pain causing no or 
minimal interference with 
usual social & functional 
activities
Pain causing greater than minimal 
interference with usual social & 
functional activities
Pain causing inability to 
perform usual social & 
functional activities
Disabling pain causing 
inability to perform basic self-
care functions OR 
Hospitalization (other than ER 
visit) indicated
Unintentional Weight 
Loss
NA
5% to 9% loss in body weight from 
baseline
10% to 19% loss in body 
weight from baseline
20% loss in body weight 
from baseline OR  Aggressive 
intervention indicated [eg, 
tube feeding or total parenteral 
nutrition]

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 127
08 June 2017
INJECTION SITE REACTION
Grade 1
Grade 2
Grade 3
Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when 
area is touched) 
Pain/tenderness causing no 
or minimal limitation of use 
of limb
Pain/tenderness limiting use of 
limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activities
Pain/tenderness causing 
inability to perform usual 
social & functional activities
Pain/tenderness causing inability 
to perform basic self-care 
function OR Hospitalization 
(other than ER visit) indicated 
for management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15 Years
Erythema OR Induration
of 5 5 cm to 9 9 cm (or 
2581 cm2)
Erythema OR Induration OR 
Edema 9 cm any diameter 
(or 81 cm2)
Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR Drainage
Necrosis (involving dermis and 
deeper tissue)
Pediatric 15 Years
Erythema OR Induration 
OR Edema present but 
2.5 cm diameter
Erythema OR Induration OR 
Edema > 2.5 cm diameter but 
< 50% surface area of the 
extremity segment (eg, upper 
arm/thigh)
Erythema OR Induration 
OR Edema involving 50% 
surface area of the extremity 
segment (eg, upper 
arm/thigh) OR Ulceration 
OR Secondary infection OR 
Phlebitis OR Sterile abscess 
OR Drainage
Necrosis (involving dermis and 
deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)
Itching localized to injection 
site AND Relieved 
spontaneously or with 
48 h treatment 
Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48 h treatment 
Generalized itching causing 
inability to perform usual 
social & functional activities
NA

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 128
08 June 2017
ENDOCRINE/METABOLIC
Grade 1
Grade 2
Grade 3
Grade 4
Lipodystrophy (eg, back 
of neck, breasts, 
abdomen)
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious 
changes on casual visual 
inspection
NA
Diabetes Mellitus
NA
New onset without need to initiate 
medication OR Modification of 
current meds to regain glucose 
control
New onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite treatment 
modification
Life-threatening consequences 
(eg, ketoacidosis, 
hyperosmolar non-ketotic 
coma) 
Gynecomastia
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious on 
casual visual inspection
NA
Hyperthyroidism 
Asymptomatic
Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid suppression therapy 
indicated
Symptoms causing inability to 
perform usual social &
functional activities OR 
Uncontrolled despite treatment 
modification 
Life-threatening consequences 
(eg, thyroid storm)
Hypothyroidism
Asymptomatic
Symptomatic causing greater than 
minimal interference with usual 
social & functional activities OR 
Thyroid replacement therapy 
indicated
Symptoms causing inability to 
perform usual social & 
functional activities OR 
Uncontrolled despite treatment 
modification 
Life-threatening consequences 
(eg, myxedema coma)
Lipoatrophy (eg, fat loss 
from the face, extremities, 
buttocks)
Detectable by study 
participant or caregiver 
(for young children and 
disabled adults)
Detectable on physical exam by 
health care provider
Disfiguring OR Obvious on 
casual visual inspection
NA

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 129
08 June 2017
GENITOURINARY
Grade 1
Grade 2
Grade 3
Grade 4
Intermenstrual Bleeding 
(IMB)
Spotting observed by participant 
OR Minimal blood observed 
during clinical or colposcopic 
exam
Intermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycle
Intermenstrual bleeding greater 
in duration or amount than usual 
menstrual cycle
Hemorrhage with life-
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract 
obstruction (eg, stone)
NA
Signs or symptoms of urinary 
tract obstruction without 
hydronephrosis or renal 
dysfunction
Signs or symptoms of urinary 
tract obstruction with 
hydronephrosis or renal 
dysfunction
Obstruction causing life-
threatening consequences
INFECTION
Grade 1
Grade 2
Grade 3
Grade 4
Infection (any other 
than HIV infection)
Localized, no systemic antiμbial 
treatment indicated AND 
Symptoms causing no or 
minimal interference with usual 
social & functional activities
Systemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activities
Systemic antiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than simple 
incision and drainage) indicated
Life-threatening 
consequences (eg, septic 
shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc.

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 130
08 June 2017
Appendix 4.
Tanner Stages*
1. Pubic hair (male and female)
Tanner I
no pubic hair at all (prepubertal Dominic state)
Tanner II
small amount of long, downy hair with slight pigmentation at the base of the penis and scrotum (males) or on the labia majora (females)
Tanner III
hair becomes more coarse and curly, and begins to extend laterally
Tanner IV
adult-like hair quality, extending across pubis but sparing medial thighs
Tanner V
hair extends to medial surface of the thighs
2. Genitals (male) (One standard deviation around mean age)
Tanner I
Testes, scrotum, and penis about same size and proportion as in early childhood
Tanner II
Enlargement of scrotum and testes; skin of scrotum reddens and changes in texture; little or no enlargement of penis (10.5-12.5)
Tanner III
Enlargement of penis, first mainly in length; further growth of testes and scrotum (11.5-14)
Tanner IV
Increased size of penis with growth in breadth and development of glans; further enlargement of testes and scrotum and increased darkening 
of scrotal skin (13.5-15)
Tanner V 
Genitalia adult in size and shape
3. Breasts (female)
Tanner I
no glandular tissue: areola follows the skin contours of the chest
Tanner II
breast bud forms, with small area of surrounding glandular tissue; areola begins to widen 
Tanner III
breast begins to become more elevated, and extends beyond the borders of the areola, which continues to widen but remains in contour with 
surrounding breast 
Tanner IV
increased breast size and elevation; areola and papilla form a secondary mound projecting from the contour of the surrounding breast
Tanner V 
breast reaches final adult size; areola returns to contour of the surrounding breast, with a projecting central papilla. 
*
Chart referenced from Marshall WA, Tanner JM, variations in the pattern of pubertal changes in boys and girls {Marshall 1969, Marshall 1970}

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 131
08 June 2017
Appendix 5.
Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1) Background
Ribavirin is contraindicated in pregnancy as significant teratogenic and embryocidal effects have 
been demonstrated in all animal species tested. Pregnancy must be excluded before the start of 
treatment with study drugs and prevented thereafter by reliable contraceptive methods. 
Pregnancy tests will be performed regularly throughout this study. Furthermore, RBV is known 
to accumulate intracellularly where it is cleared slowly, and is also excreted in semen. Therefore, 
extreme care must be taken to avoid pregnancy during RBV therapy and for up to 6 months 
following completion of treatment (7 months for males). Please refer to the latest version of the 
product insert for additional information.
Non-clinical toxicity studies of LDV/SOF FDC demonstrated no adverse effect on fertility or 
embryo-fetal development. However, there are no clinical studies of LDV/SOF FDC in pregnant 
women. Please refer to the latest version of the investigator’s brochure for additional 
information.
2) Definition of Female of Childbearing Potential and Contraceptive Requirements for 
Female Subjects (and their male partners)
For the purpose of this trial, all post-menarchal females will be considered to be of childbearing 
potential, unless there is documentation of irreversible ovarian failure or surgical sterilization.
Post-menarchal females must have a negative serum pregnancy test at Screening and a negative 
urine pregnancy test on the Day 1 visit prior to dosing. They must also agree to one of the 
following from 3 weeks prior to Day 1 until 6 months after last dose of RBV or 30 days after last 
dose of LDV/SOF FDC if not taking RBV:

Complete abstinence from intercourse. Abstinence is acceptable method of contraception 
only when it is in line with the subject’s preferred and usual lifestyle. Periodic abstinence 
(e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not 
acceptable methods of contraception.
Or

Consistent and correct use of 1 of the following methods of birth control listed below, in 
addition to a male partner who correctly uses a condom, from the date of Screening until 
6 months after last dose of RBV or 30 days  after the last dose of LDV/SOF FDC if not 
taking RBV:
intrauterine device (IUD) with a failure rate of < 1% per year
female barrier method: cervical cap or diaphragm with spermicidal agent
tubal sterilization

LDV/SOF FDC
Protocol GS-US-337-1116
Final
Gilead Sciences, Inc.
Amendment 6.0
CONFIDENTIAL
Page 132
08 June 2017
vasectomy in male partner
implants of levonorgestrel
injectable progesterone
oral contraceptives (either combined or progesterone only)
contraceptive vaginal ring 
transdermal contraceptive patch
3) Contraceptive Requirements for Male Subjects (and their female partners)
All male study participants must agree to consistently and correctly use a condom from Day 1
until 7 months after last dose of RBV or 90 days after the last dose of LDV/SOF FDC if not 
taking RBV. If their female partner is of childbearing potential (as defined above), their female 
partner must use 1 of the methods of birth control listed above from the date of Screening until 
7 months after last dose of RBV or 90 days after last dose of LDV/SOF FDC if not taking RBV.
Male subjects must agree to refrain from sperm donation for at least 7 months after last dose of 
RBV or 90 days after the last dose of LDV/SOF FDC if not taking RBV.
4) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify the investigator if they become pregnant at any time during 
the study, or if they become pregnant within 6 months (7 months for partners of male subjects) of 
last RBV dose or 30 days (90 days for partners of male subjects) of last LDV/SOF FDC dose if 
not taking RBV. Subjects who become pregnant or who suspect that they are pregnant must 
report the information to the investigator and discontinue study drug immediately. Subjects 
whose partner has become pregnant or suspects she is pregnant must report the information to 
the investigator. 
Instructions for reporting pregnancy, partner pregnancy, and pregnancy outcome are outlined in 
Section 8.5.2.1.